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1.1 Hematopoiesis 
Hematopoiesis (from Ancient Greek: αἷμα, “blood” and  ποιεĩν “to make”) is the 
process of formation and development of blood cells. Adult blood cell formation 
takes place in the bone marrow where 1011–1012 new blood cells are produced daily.1 
All blood cells are derived from hematopoietic stem cells (HSC), which usually reside 
in the bone marrow. HSCs are capable of self-renewal and have the unique ability to 
differentiate into all the different mature functional blood cell types, including red 
blood cells (erythrocytes), white blood cells (leukocytes) and platelets (thrombocytes). 
Most mature blood cells are short-lived and exhibit distinct functions: erythrocytes 
carry oxygen to the cells and tissues, leukocytes provide protection from infections 
(adaptive and innate immunity), and thrombocytes are implicated in blood clotting. 
The hematopoietic system is divided into two major branches: lymphoid and myeloid. 
The lymphoid lineage consists of T- and B-lymphocytes, implicated in the adaptive 
immunity, and NK-cells, involved in the innate immunity. The myeloid lineage, which 
includes erythrocytes, megakaryocytes, granulocytes, monocytes/macrophages, and 
mast cells, is involved in oxygen transport (erythrocytes), blood clotting (megakaryocytes), 
and innate immunity (granulocytes, monocytes/macrophages, mast cells). 
1.1.1 Classical model for hematopoiesis
The hematopoietic system exhibits a hierarchical organization with HSCs at the top of 
the hematopoietic hierarchy and terminally differentiated mature blood cells at the 
bottom.1 Within the hematopoietic hierarchy, HSCs are connected to mature cells by 
a complex network of increasingly committed progenitor cells (multipotent and lin-
eage-restricted). The differentiation of the multipotent HSCs into all the different 
types of mature blood cells is a strictly regulated process, whereby HSCs gradually 
lose their self-renewal capacity upon their differentiation and form increasingly 
restricted precursors which display a high proliferative capacity.2;3 In the classical 
model for hematopoiesis (figure 1), the multipotent HSCs give rise to multipotent 
progenitors (MPPs) which can differentiate into a common lymphoid progenitor 
(CLPs) or common myeloid progenitor (CMPs), resulting in a strict segregation of the 
lymphoid and myeloid lineage. CLPs give rise to mature lymphocytes (B- and 
T-lymphocytes, and NK-cells), whereas CMPs further differentiate into megakaryocyte/
erythroid progenitors (MEPs), which give rise to erythrocytes and megakaryocytes, 
and granulocyte-monocyte progenitors (GMPs), which give rise to granulocytes (i.e. 
neutrophils, basophils, and eosinophils), monocytes/macrophages, and mast cells. 
Within this model, differentiation along a particular lineage is associated with a 
progressive loss of potential to generate other lineages. Lineage decision occurs as a 
stepwise bifurcation resulting in a strict segregation of the lymphoid and myeloid 
lineage.2;3
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Figure 1  Classical model for hematopoiesis
 
In the conventional model of hematopoiesis multipotent hematopoietic stem cells (HSCs) give 
rise to multipotent progenitors (MPPs) which can differentiate into common lymphoid 
progenitors (CLPs) or common myeloid progenitors (CMPs), resulting in a strict segregation of 
the lymphoid and myeloid lineage. CLPs give rise to mature lymphocytes (B- and T-lymphocytes, 
and NK-cells). CMPs further differentiate into megakaryocyte/erythroid progenitors (MEPs), 
which give rise to erythrocytes and megakaryocytes, and granulocyte-monocyte progenitors 
(GMPs), which give rise to mature granulocytes (i.e. neutrophils, basophils, and eosinophils), 
and monocytes/macrophages. Mast cells can arise from the CMPs or GMPs.
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1.1.2 Pairwise model for hematopoiesis
Recent studies suggest that hematopoiesis does not follow a rigid model of strict 
myeloid and lymphoid segregation. The identification of early progenitors with lymphoid 
and myeloid potential (EPLM) and lymphoid-primed multi-potent progenitors 
(LMPPs) suggests that progenitors are more versatile.4;5 EPLMs can differentiate into 
1
Figure 2  Pairwise model for hematopoiesis
 
In this model, hematopoiesis is depicted as a fate-choice continuum (outer circle) with a 
pairwise relationship between the different hematopoietic cell fates. The inner circles represent 
intermediate progenitor populations with various lineage potential. The pairwise model for 
hematopoiesis does not display a strict lymphoid and myeloid segregation. Within this model a 
final cell fate may be reached through more than one type of intermediate progenitor and 
several different intermediate progenitors have the potential to become mature blood cells 
that are contiguous in the sequence. HSC = hematopoietic stem cell; MPP = multipotent 
progenitor; CLP = common lymphoid progenitor; CMP = common myeloid progenitor; LMPP = 
lymphoid-primed multipotent progenitor; ELMP = early progenitor with lymphoid and myeloid 
potential; GMP = granulocyte-monocyte progenitor; MEP = megakaryocyte/erythroid progenitor. 
Figure 2 is adapted from Ceredig et al.7
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myeloid cells (macrophages, dendritic cells) and lymphoid cells (NK cells, B- and 
T-lymphocytes), whereas LMPPs display a granulocytic, monocytic and lymphoid 
potential, but little potential for megakaryocytic and erythroid development. 
Identification of hematopoietic progenitors that can differentiate into both lymphoid 
and myeloid lineages resulted in revision of the classical hematopoietic model into a 
pairwise model for hematopoiesis (figure 2) which does not display a strict lymphoid 
and myeloid segregation.6;7 In this model, progenitors cells retain other lineage 
potential until quite late in their development along a specific pathway. The final 
cell-fate may be reached through more than one type of intermediate progenitor, 
indicating the existence of multiple routes towards development of one mature 
blood cell type without a fixed pattern of underlying decision points.6;7
1.2 Leukemia
Hematopoiesis is a highly efficient and strictly regulated process, resulting in the 
production of  1011–1012 new blood cells daily. The cells of the hematopoietic system 
are renewed continuously. Abnormalities in the normal developmental program for 
blood cell formation result in the development of hematological diseases. Leukemia 
(from the Ancient Greek λευκός “white”, and αἷμα “blood”) is a type of cancer of the 
blood characterized by the uncontrolled proliferation of immature white blood cells 
in the bone marrow leading to very high white blood cell counts. The discovery of 
leukemia is largely credited to John Hughes Bennett and Rudolf Virchow as they were 
the first to observe the disease in the 1840s. More than three decades passed before 
leukemia was identified as a disease of the bone marrow by Franz Ernst Christian 
Neumann who observed that leukemic cells originated in the bone marrow in 1872. 
As leukemic cells are characterized by a maturation arrest, they are less functional 
than normal blood cells. The accumulation of leukemic cells in the bone marrow 
results in suppression of the normal hematopoiesis with disturbance of the formation 
of normal mature blood cells. Clinical features may include pallor and fatigue due to 
anemia, infections due to leukopenia, and spontaneous bleeding or bruising due to 
thrombocytopenia. Leukemia is subdivided into acute and chronic forms. Acute 
leukemia is characterized by the clonal expansion of immature white blood cells due 
to enhanced proliferation in combination with an arrest in differentiation, resulting in 
a rapid increase and accumulation of immature white blood cells. Chronic leukemia 
typically takes months or years to progress and is characterized by enhanced proliferation 
and accumulation of abnormally differentiated white blood cells. Leukemia can also 
be subdivided according to which kind of blood cell is affected. Depending on the 
lineage that is affected, leukemia is classified as lymphoblastic or myeloid. In the 
current thesis we focus on acute myeloid leukemia (AML).
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1.3 Acute myeloid leukemia
AML is a disease which is most common in elderly people. From 2005-2009, 53.6% of 
the patients diagnosed with AML in the Unites States of America (USA) was aged over 
65 years. The incidence rate was 3.6 per 100,000 individuals per year. These rates are 
based on cases diagnosed in 2005-2009 from 18 Surveillance Epidemiology and End 
Results (SEER) geographic areas in the Unites States of America.8 After a peak incidence 
in infants (1.5 per 100,000 individuals < 1 year of age), the incidence decreases to 0.4 
per 100,000 individuals aged 4-9 years and continuously increases during adolescence 
and adulthood up to 16.2 per 100,000 individuals aged over 65 years each year. In 
Europe, the incidence rate of AML is 3.7 per 100,000 individuals per year, which is 
similar to reported rates in the USA.9 In the Netherlands, 500-700 patients are 
diagnosed with AML each year (Integral Cancer Centre the Netherlands; Dutch Cancer 
Registry, 2000-2010). In children, leukemia is the most frequently occurring malignancy 
which accounts for 25% of all childhood cancers. In the Netherlands, around 150 
children are diagnosed with leukemia each year, of which approximately 20-25 
children suffer from AML. The fast majority of children with leukemia are diagnosed 
with acute lymphoid leukemia (around 120 children per year). 
1.3.1 Classification of AML
AML is a heterogeneous disease which can be subdivided into multiple subgroups 
with distinct differences in morphology and underlying genetic aberrations. Clinical 
history, morphology and immunophenotyping play an important role in diagnostic 
classification of AML. The two most commonly used classification schemes for AML 
are the older French-American-British (FAB) system and the newer World Health 
Organization (WHO) system.10;11 The French-American-British (FAB) classification 
system divides AML into eight subtypes, M0 through M7, based on the type of cell 
from which the leukemia developed and its degree of maturation, as determined by 
the morphologic, cytochemical and immunophenotypic features of the leukemic 
cells (Table 1).10 Increasing evidence suggests that underlying genetic defects are 
essential for the classification of AML. In the classification scheme of the WHO, genetic 
information is incorporated with morphologic, cytochemical, immunophenotypic, 
and clinical information into a diagnostic algorithm. Recurrent genetic aberrations 
incorporated in the WHO-classification include balanced chromosomal translocations/
inversions and gene mutations (Table 2).11
1.3.2 Genetic aberrations in AML
In AML, multiple underlying genetic defects have been identified that carry diagnostic 
and prognostic information, suggesting that these acquired genetic abnormalities 
play an essential role in leukemogenesis. Genetic aberrations lead to irreversible 
1
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structural DNA changes and often involve signal transduction molecules (such as 
FLT3, KIT, RAS) and transcription factors (such as CEBPA, WT1, CBF, RARA, TP53) that play 
an important role in proliferation, survival, and differentiation of hematopoietic 
cells.12;13 Over the last decade, aberrations of various genes involved in epigenetic 
regulation (such as TET2, IDH1/2, DNMT3A, ASXL1) have been detected in AML.12;14 The 
identification of underlying genetic defects and their prognostic value is essential for 
better understanding of the disease. This knowledge will enhance diagnostic 
classification and improve risk-stratification which contributes to the development of 
individualized risk-adapted therapeutic approaches. Identification of patients at high 
risk of relapse can guide the use of intensive chemotherapeutic regimens and 
allogeneic stem cell transplantation. Moreover, genetic aberrations can serve as 
therapeutic targets and therefore contribute to the development of targeted therapy 
in AML.
Cytogenetic aberrations
Cytogenetic aberrations are recurrent numerical variations including chromosomal 
gain or loss, and recurrent structural variations including balanced chromosomal 
translocations, deletions, duplications, inversions, and rearrangements. Cytogenetic 
analysis is performed in the standardized diagnostic work-up of AML patients. Using 
standard banding techniques, 50%-60% of adult patients with de novo AML have 
abnormal karyotypes, whereas in 75%-80% of the de novo pediatric AML patients 
chromosomal abnormalities are detected.15-17 In AML, various cytogenetic aberrations 
have been detected (Table 3) that are associated with morphologically and clinically 
distinct subsets of AML. Many cytogenetic aberrations result in alteration of the 
function of transcription factors critical for normal hematopoiesis. Chromosomal 
translocations often involve transcription factors resulting in the formation of chimeric 
fusion genes such as PML-RARA (t(15;17)(q22;q21)), RUNX1-ETO (t(8;21)(q22;q22)), and 
Table 1  FAB classification of AML10
Type Name
M0 Minimally differentiated AML
M1 AML without maturation
M2 AML with maturation
M3 Acute promyelocytic leukemia
M4 Acute myelomonocytic leukemia
M5 Acute monoblastic or monocytic leukemia
M6 Acute erythroid leukemia
M7 Acute megakaryoblastic leukemia
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CBFB-MYH11 (inv(16)(p13;q22) or t(16;16)(p13;q22)). Chimeric fusion proteins can serve 
as aberrant transcription factors leading to genome-wide dysregulation of gene 
expression and impaired differentiation of the leukemic cells.18
In the 1990s, recurrent cytogenetic aberrations appeared to be effective as prognostic 
marker and predictor for response to therapy, relapse risk and survival, resulting in 
risk-classification of patients based on cytogenetic aberrations and risk-adapted 
therapy. The presence of a t(8;21)(q22;q22), inv(16)(p13;q22), t(16;16)(p13;q22), or t(15;17) 
1
Table 2  The WHO classification of AML and related neoplasms 200811
Type Subcategories
AML with recurrent genetic abnormalities AML with t(8;21)(q22;q22)
AML with inv(16)(p13;q22) or t(16;16)(p13;q22)
AML with t(15;17)(q22;q21)
AML with t(9;11)(p22;q23)
AML with t(6;9)(p23;q34)
AML with inv(3)(q21;q26) or t(3;3)(q21;q26)
AML (megakaryoblastic) with t(1;22)(p13;q13)
AML with mutated NPM1  
AML with mutated CEBPA
AML with myelodysplasia-related changes
AML, not otherwise specified AML with minimal differentiation (M0)
AML without maturation (M1)
AML with maturation (M2)
Acute myelomonocytic leukemia (M4)
Acute monoblastic/monocytic leukemia (M5)
Acute erythroid leukemia (M6)
Acute megakaryocytic leukemia (M7)
Acute basophilic leukemia
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma
Myeloid proliferations related to Down 
Syndrome
Transient abnormal myelopoiesis
Myeloid leukemia associated with Down 
Syndrome
Blastic plasmacytoid dendritic cell 
neoplasm
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(q22;q21) confers a relatively favorable prognosis, whereas various cytogenetic 
aberrations including monosomy 7, t(6;9)(p23;q34), or t(7;12)(q36;p13), are associated 
with an adverse outcome. The frequency and prognostic impact of cytogenetic 
aberrations differs between pediatric and adult AML as well as between studies. A 
significant group of AML patients lack chromosomal aberrations and is referred to as 
cytogenetically normal AML (CN-AML), representing 40%-50% of adult AML patients 
and 20%-25% of pediatric AML patients.15-17 
Molecular aberrations
Molecular aberrations include aberrantly expressed genes and single gene mutations 
(Table 4). Recent advances in genomics technologies led to the identification of a 
myriad of molecular aberrations in leukemic cells, that correlate with clinical outcome 
and further improved diagnostic classification and prognostic stratification of AML 
patients. Co-occurrence of distinct mutations is frequently observed, indicating that 
mutations can cooperate in the process of malignant transformation. However, 
somatic mutations can be mutually exclusive as well.13 
Gene mutations
In the WHO classification, NPM1 and CEBPA mutations are defined as distinct disease 
entities. NPM1 encodes for a ubiquitously expressed chaperone protein that shuttles 
between the nucleus and cytoplasm, but predominantly resides in the nucleus. NPM1 
plays a key role in many basic cellular processes, including cell cycle progression and 
Table 3  Recurrent cytogenetic aberrations in AML
Cytogenetic 
aberration
Fusion gene % in  
adult16;37
% in 
pediatric17;38-40
Prognostic value
Normal karyotype 40-47 22-25 Intermediate
t(8;21)(q22;q22) AML1-ETO 4-8 11-16 Favorable
inv(16)(p13;q22) or 
t(16;16)(p13;q22)
CBFB-MYH11 2-9 6-9 Favorable
t(15;17)(q22;q21) PML-RARA 4-13 6-10 Favorable
11q23 rearrangements MLL-diverse 
partner genes
2-7 16-23 Depending on 
partner gene 
and additional 
aberrations
Complex karyotype 
(≥3 aberrations)
5-12 8-18 Unfavorable
Other cytogenetics 22-25 20-32 Unfavorable/
Intermediate
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genomic stability.19 NPM1 mutations represent one of the most frequently identified 
genetic alteration in adult AML, which is found in 11%-34% of all adult AML cases. In 
children NPM1 mutations are less frequent, occurring in 6%-8% of all pediatric AML 
cases (Table 4). NPM1 mutations are associated with a relatively favorable prognosis in 
the absence of FLT3-ITD.12;15;20 CEBPA is an important myeloid transcription factor, 
which is mutated in 8%-13% of adult AML and 4%-8% of pediatric AML (Table 4). The 
presence of biallelic CEBPA mutations (also called double mutations) predicts a 
favorable outcome.12;21 Other hematopoietic transcription factors involved in genetic 
mutations in AML include WT1 and RUNX1.12
Activating mutations in the receptor tyrosine kinases FLT3 and KIT or downstream 
mediators such as NRAS and KRAS result in uncontrolled proliferation of leukemic cells 
due to constitutive activation of the signal transduction pathway.22;23 FLT3 mutations 
represent one of the most frequently identified genetic alterations in AML associated 
with an increased risk of relapse and worse overall survival. FLT3-ITD involves a 
duplication of the internal juxtamembrane domain of the tyrosine kinase receptor 
FLT3, resulting in constitutive receptor activation. FLT3-ITD has been detected in 
approximately 16%-30% of adult AML cases and 10%-18% of pediatric AML cases 
(Table 4). This mutation represents a poor prognostic marker, especially in patients 
with a high ratio of mutated versus wild-type FLT3 allele.12;15;24 Although FLT3-ITD is not 
considered to define a distinct entity in the WHO classification, identification of 
FLT3-ITD is essential as these mutations are associated with a poor response to therapy 
and high risk of relapse.22 Therefore, hematopoietic stem cell transplantation is usually 
recommended in adult patients with FLT3-ITD. Moreover, FLT3 has emerged as a 
potential molecular target in therapy of AML using specific tyrosine kinase inhibitors.25 
Over the last decade, mutations have been detected in multiple genes involved in 
epigenetic regulation (such as TET2, IDH1/2, DNMT3A, ASXL1) in a significant amount of 
AML patients (Table 4).12;14 Large differences have been observed in the prevalence of 
these mutations between pediatric and adult AML (Table 4). Overall, mutations in 
epigenetic regulators are detected more frequently in adult AML. Mutations in ASXL1, 
DNMT3A, and TET2 are associated with poor prognosis.14;26-30 The role of mutations in 
other epigenetic regulators as predictors of prognosis in AML has not been established 
clearly. The high frequency of mutations in epigenetic regulators suggests that these 
aberrations play an important role in the pathogenesis of AML.
 
Aberrant gene expression
In AML, overexpression of various genes including EVI1, MN1, BAALC, ERG and WT1,  has 
been linked to poor prognosis.12;24;31-34 The molecular basis of overexpression of these 
genes remains poorly understood and the clinical utility of expression levels of genes 
1
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in risk-stratification is limited. In addition to the expression levels of single genes, 
the potential of genome-wide gene expression profiling for enhanced diagnostic 
classification has been extensively studied. Specific gene expression signatures 
have been identified that correlate with distinct cytogenetic and molecular AML 
subgroups.12;35;36 The role of gene expression profiling in clinical diagnosis is under 
investigation.36
1.3.3 Initiating and cooperating events in AML
For the development of leukemia, multiple genetic aberrations are required. Recent 
studies regarding the origin and evolution of mutations in AML,  suggested that 
mutations can be subdivided into initiating and cooperating events.74 The initiating 
event transforms the hematopoietic stem/progenitor cells and provides an advantage 
for the affected cells resulting in clonal expansion. Initiating events, which can be 
Table 4  Recurrent molecular aberrations in AML
Gene 
mutation
Adult (%) reference Pediatric (%) reference Prognostic value
NPM1 11-34 26;27;41-45 6-8 46-48 Favorable in FLT3 wild-type 
patients
FLT3-ITD 16-30 27;41-45 10-18 48-50 Unfavorable
KIT 3-7 26;41;45;51 8 49;50 Unfavorable in CBF-AML
NRAS 7-14 26;41;43-45 7-16 49;50;52 None
KRAS 1-8 30;43;45 1-9 49;50;52 None
PTPN11 4 45 2-4 50;53 None
CEBPA 8-13 26;27;41-43;45 4-8 21;48;54 Biallelic: Favorable
WT1 4-9 26;41;45;51;55-57 8-12 48;58;59 Unfavorable55;56;58
RUNX1 5-18 27;41;42;45 3-6 60;61 Unfavorable27;62
IDH1 6-13 26;27;41;43-45;57;63 0-2 64-66 Controversial 
(unfavorable or none)
IDH2 6-14 26;27;41;43-45;57 2 64;67 Controversial
TET2 7-29 26-30;41;42;45;57;68 4-6 67;69 Unfavorable28-30
DNMT3A 7-27 26;27;41;44;51 0-2 67;70 Unfavorable26;44;51
ASXL1 3-15 26;27;45;71 UD Unfavorable27;71
MLL-PTD 5-6 27;41;45;72 3-13 49;73 Controversial  
(unfavorable27 or none)
TP53 2-12 27;41 UD Unfavorable27
UD = undetermined
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associated with specific AML subtypes, require cooperating events to cause leukemia. 
The PML-RARA fusion gene, which is associated with acute promyelocytic leukemia 
(APL), is one of the best characterized initiating mutations. Additional cooperating 
mutations are needed for disease progression and generation of the malignant clone. 
These additional mutations can cooperate with a variety of initiating mutations and 
are shared between different AML subtypes.74
1.3.4 Leukemia initiating cells
AML is characterized by the clonal expansion of hematopoietic stem/progenitors cells 
due to enhanced proliferation and an arrest in differentiation. Increasing evidence 
suggests that leukemic cells display an hierarchical organization as well.75;76 Bonnet 
and Dick described that in a immunodeficient mouse transplant assay, only a subset 
of primary AML cells can induce leukemia.77 These cells are referred to as the leuke-
mia-initiating cells (LICs) or leukemic stem cells (LSCs). LICs are characterized by their 
marked self-renewing capacity which enables them to initiate leukemia and generate 
progeny that lack tumor-initiating ability, which form the bulk of the leukemic cells. 
LICs are multipotent, largely-quiescent cells, which are located at the top of the 
cellular hierarchy, whereas the bulk of leukemic cells, located on the bottom of the 
cellular hierarchy, are highly proliferative. 
Initially, it was thought that LICs were solely present in the immature CD34+CD38- cell 
fraction, which closely resembles the normal HSC compartment, suggesting that LICs 
are derived from HSCs.77 However, more recently, it was shown that LICs can also be 
found in the less primitive CD34+CD38+ cell fractions, suggesting that LICs can also 
arise from hematopoietic progenitors.78-80 In a large group of primary AML patients 
two different progenitor-like LIC populations were detected: an immature population 
which closely resembles normal LMPPs, and a more mature population which closely 
resembles normal GMPs.78 Both populations were hierarchically organized, whereby 
the more immature LICs gave rise to the more mature LICs, and not the other way 
around.  The  immature as well as the more mature LICs possessed self-renewing and 
leukemia-initiating capacity as illustrated by their ability to serially transplant leukemia 
in immunodeficient mice. In normal hematopoiesis, self-renewal is restricted to HSCs 
and is not a property of normal hematopoietic progenitors. LICs represent a 
heterogeneous population of malignant progenitor cells that acquired an abnormal 
self-renewal potential. The acquisition of self-renewal ability in progenitor-like LICs is 
an aberrant event resulting from genetic and/or epigenetic changes. 78-81
LICs play an important role in initiating leukemia and driving disease progression. 
In order to eradicate leukemia and cure the patients, all LICs must be eliminated. 
Currently, chemotherapy is mainly directed at the bulk of leukemic cells which are highly 
1
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proliferative. The more quiescent state of LICs may protect them from elimination by 
traditional chemotherapy, eventually resulting in relapse. To cure AML, eradication of 
LICs is thought to be a prerequisite. The identification and characterization of LICs is 
essential for the development of novel curative therapeutic strategies in AML that 
target LICs. However, identification of LICs remains challenging, as LICs display an 
heterogeneous immunophenotype. In addition to immunophenotypes, analysis of 
cell surface molecules, signal transductions pathways and epigenetic regulators 
which allow LICs to self-renew, may contribute to better characterization of LICs.80;82
1.3.5 Minimal residual disease detection in AML
Morphologic response to induction chemotherapy is a classical parameter for 
outcome in AML and is used to determine intensity of subsequent therapy and select 
candidates for allogeneic stem cell transplantation. Traditionally, residual leukemic 
cells are identified morphologically. However, in morphological remission (defined as 
less than 5% blast cells in the bone marrow in combination with normal peripheral 
blood cell counts) a substantial amount of residual leukemic cells (up to 109 cells) can 
be present that cannot be identified by conventional morphologic evaluation.83 
The presence of submicroscopic disease is called minimal residual disease (MRD). As 
residual disease is the major predictor of relapse in leukemia, detection methods with 
improved sensitivity compared to conventional morphologic analysis are essential for 
determination of the residual leukemia burden after treatment. 
Detection of specific disease markers may contribute to improved estimation of the 
leukemic burden and provide a more precise measurement of disease response. 
Longitudinal monitoring may provide a tool to detect relapse early and direct pre- 
emptive therapy. Current MRD-detection methods include real-time quantitative PCR 
(RQ-PCR) for leukemia specific targets such as abnormal fusion transcripts or mutated 
genes and RQ-PCR for genes known to be overexpressed in AML such as WT1, EVI1 
and BAALC. Moreover, leukemic cells express abnormal patterns of cellular markers 
including myeloid as well as non-myeloid markers. Multiparameter flow cytometry 
can be used to detect these leukemia-associated aberrant immunophenotypes.84;85 
These methods have a superior sensitivity and accuracy, and allow recognition of 
leukemic cells at levels below those detectable by morphology. In acute lymphoblastic 
leukemia, MRD-detection has been incorporated in the treatment protocols and has 
proven to be superior to established prognostic factors in risk stratification.86 In AML, 
MRD-detection remains challenging and is not part of standard care yet. MRD 
measurement based on genetic aberrations is limited to specific AML subtypes. The 
assessment of leukemia-associated aberrant immunophenotypes using flow cytometry 
is potentially applicable to a broader range of AML patients.85;87 Only in acute 
promyelocytic leukemia (APL), MRD-based risk-stratification has been incorporated in 
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the treatment protocols so far.88 The role of MRD-based risk-stratification in other 
AML-subtypes is under investigation.
1.3.6 Treatment and outcome in AML
The era of chemotherapy begun in the 1940s with the discovery of aminopterin, a 
folic acid related compound that prevents DNA replication, which was used in the 
treatment of acute childhood leukemia. In the 1970s, patients were cured from 
leukemia for the first time by multidrug chemotherapy. The development of bone 
marrow transplantation as a treatment for leukemia by Edward Donnall Thomas 
contributed to an increase in cure rates for leukemia. Since the 1970s, treatment 
outcome has improved substantially due to improved supportive care and better 
understanding of the molecular pathogenesis of the disease resulting in enhanced 
diagnostic classification and development of risk-adapted treatment.15;89;90 The current 
treatment of AML is divided into two phases: induction and consolidation therapy. 
The goal of induction therapy is to decrease the number of leukemic cells to an 
undetectable level and to restore the production of normal blood cells.  Complete 
remission is defined as the presence less than 5% leukemic cells in the bone marrow 
in combination with normal peripheral blood cell counts. The most common remission 
induction regimens include cytarabine and anthracyclins. Consolidation or post- 
remission therapy is administered to kill the remaining leukemic cells and is necessary 
to reduce the risk of relapse. Consolidation therapy includes additional chemotherapy, 
followed by stem cell transplantation in selected patients with a high risk of relapse.89
The response to treatment and overall survival of patients with AML is heterogeneous. 
Prognosis is dependent on patient and tumor characteristics such as age, genetic 
aberrations, and response to induction therapy. Currently available chemotherapy 
schedules achieve complete remission in 80%-95% of pediatric AML patients, with a 
5-year overall survival between 60% and 70%.15;38;91 Complete remission is induced in 
70%-85% of adult AML patients below the age of 60 years, with a 5-year probability of 
overall survival between 40% and 50%.92;93 In the elderly population (aged > 60 years), 
outcome is extremely poor, with a complete remission rate of 45%-65% and a 5-year 
overall survival of approximately 10%.89;94;95 The poor outcome in the elderly population 
is thought to be associated with unfavorable cytogenetics, poor performance status, 
increased chemotherapy toxicity leading to dose reduction, and increased chemotherapy 
resistance.89
With the current chemotherapy regimens, a substantial amount of AML patients die 
from their disease. To improve survival rates in AML, other therapeutic options are 
needed. Treatment modalities targeted to underlying oncogenic abnormalities 
contribute to better survival in specific leukemia subtypes. Two well-established 
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examples of targeted therapy include the use of all-trans retinoic acid (ATRA) and/or 
arsenic trioxide (ATO) in APL and tyrosine kinase inhibitors in chronic myeloid leukemia 
(CML).96;97 The introduction of ATRA in the treatment of APL represents the first 
paradigm of molecularly targeted therapy in human cancer which has resulted in 
dramatic improvement of the survival for patients with APL from 35% to 80%.96 The 
availability of molecularly targeted therapy with tyrosine kinase inhibitors such as 
imatinib for the treatment of BCR-ABL positive CML significantly improved survival 
from 30% to 90%.97 The use of tyrosine kinase inhibitors in AML patients with FLT3-ITD 
is currently under investigation.25 To improve outcome in other AML subtypes, 
development of targeted therapies against molecular aberrations that contribute to 
the malignant transformation is necessary. 
1.4 Acute Promyelocytic Leukemia
APL is a distinct subtype of AML that accounts for 4%-13% of adult AML cases and 
6%-10% of pediatric AML cases.16;37-39 APL is characterized by the proliferation of 
leukemic cells blocked at the promyelocytic stage of granulocytic differentiation.98;99 
In the majority of APL patients, oncogenic transformation originates from a chromosomal 
translocation t(15;17), fusing the retinoic acid receptor-alpha (RARA) gene on chromosome 
17 with the promyelocytic leukemia (PML) gene on chromosome 15. 
1.4.1 Differentiation therapy in APL
PML-RARA is a potent transcriptional repressor which binds DNA via its RARA-domain. 
The PML-RARA complex recruits various co-repressors, resulting in transcriptional 
repression of RARA target genes and many other genes.100 As RARA is implicated in 
the control of myeloid differentiation, repression of RARA signaling results in a block 
in differentiation.101 In addition to the differentiation arrest, the PML-RARA fusion 
protein increases the self-renewal capacity and growth properties of the transformed 
progenitors.102 Treatment with high dosage of the RARA ligand ATRA  induces the 
release of co-repressors and recruitment of co-activators, resulting in transcriptional 
activation of PML-RARA repressed target genes which triggers differentiation of APL 
cells (figure 3), referred to as differentiation therapy. The introduction of ATRA in the 
treatment of APL, changed APL from a deadly into a highly curable disease. Treatment 
with ATRA as a single agent generally results in transient remission of the disease. 
ATRA treatment cannot induce long-term remission unless ATRA is combined with 
myelosuppressive chemotherapy. Conventional treatment regimens for patients with 
newly diagnosed APL consist of a combination of ATRA and anthracycline-based 
chemotherapy which results in the induction of a complete remission in more than 
90% of the patients, and 5-year overall survival rates of more than 80%.96;103-110 
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Treatment with ATO was also shown to be highly effective as a single agent or in 
combination with ATRA in newly diagnosed and relapsed APL patients.111-121 The 
therapeutic efficacy of ATO largely relies on the induction of apoptosis and eradication 
of APL cells without massive induction of terminal differentiation. ATO is unable to 
directly reactivate PML-RARA dependent transcription.122  
1.4.2 Degradation of PML-RARA is essential for eradication of LICs in APL
To achieve long-term complete remission, clearance of the leukemia initiating cells 
(LICs) is essential. In APL, LICs represent a population of committed myeloid progenitors 
that have acquired enhanced self-renewal capacity.123;124 PML-RARA increases the 
self-renewal capacity and growth properties of the transformed progenitors.102 
1
Figure 3  Differentiation model of acute promyelocytic leukemia
 
In APL cells, PML-RARA binds as a heterodimer to DNA via its RARA moiety. The PML-RARA 
complex recruits various co-repressors (Co-R), resulting in transcriptional repression of RARA 
target genes and many other genes. Repression of RARA signaling results in a block in differen-
tiation. Treatment with pharmacological doses of all-trans retinoic acid (ATRA) induces the 
release of co-repressors and recruitment of co-activators, resulting in transcriptional activation 
of PML-RARA repressed target genes which triggers differentiation of APL cells.
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α α
Chapter 1
24
Recently, degradation of PML-RARA was shown to be essential for the eradication of 
LICs and long-term disease remission.102;125 Degradation of PML-RARA can be triggered 
by ATRA via recruitment of proteasomes and caspases by the RARA moiety of the 
fusion protein.125;126 For PML-RARA degradation, much higher ATRA concentrations are 
required than for transcriptional activation and differentiation induction.125 ATO can 
induce PML-RARA degradation via its PML moiety through sumoylation. Degradation 
of PML-RARA results in loss of self-renewal capacity and thereby reduction of LICs. As 
ATRA and ATO target the fusion protein in two distinct ways, the combination of ATRA 
and ATO is highly effective in PML-RARA degradation and has a synergistic effect on 
LIC clearance.115;117;127 
Figure 4  Clearance of leukemia initiating cells by PML-RARA degradation
 
In APL, low dose all-trans retinoic acid (ATRA) induces differentiation of the bulk of leukemic 
cells without clearance of leukemia initiating cells (LICs), leading to transient remission. 
Treatment with arsenic trioxide (ATO) induces partial differentiation of APL cells. By degradation 
of PML-RARA, ATO treatment results in a substantial reduction of LICs. The combination of ATRA 
with ATO or chemotherapy, induces both induction of full differentiation of leukemic cells and 
eradication of LICs by PML-RARA degradation, resulting in long-term remission. Figure 4 is adapted 
from Ablain and de The.122
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The importance of PML-RARA degradation for successful APL treatment, resulted in 
revision of the differentiation therapy model. Transcriptional activation of PML-RARA 
by ATRA triggers differentiation of the bulk of leukemic cells and induces transient 
complete remission, whereas  degradation of PML-RARA by the combination of ATRA 
with ATO or chemotherapy triggers LIC eradication and induces long-term remission. 
The therapeutic efficacy of ATRA and ATO in APL largely relies on targeting and 
degradation of the oncoprotein in combination with differentiation induction. 
Treatment of APL with ATRA and ATO could therefore be characterized as oncoprotein- 
targeting therapy. 
1.4.3 Differentiation Syndrome
Mortality during induction chemotherapy remains an important cause for treatment 
failure in APL. In large series of APL patients, mortality during induction chemotherapy 
ranges from 5% to 17%.128-130 The most common causes of death are hemorrhage, 
infection, and the differentiation syndrome (DS), formerly known as retinoic acid 
syndrome.103;128;129;131 The reported incidence of DS during induction therapy with 
ATRA and/or ATO in APL varies between studies from 2.5% to 31%. DS is not observed 
during consolidation or maintenance therapy with ATRA and/or ATO.132 In addition, in 
non-APL malignancies,  ATRA- and/or ATO-treatment do not induce DS, suggesting 
that APL cells play a crucial role in the development of DS.132
DS is characterized by an excessive systemic inflammatory response resulting in massive 
tissue infiltration of differentiating APL cells, especially in the lungs. The clinical signs and/
or symptoms of DS include respiratory distress, unexplained fever, weight gain, interstitial 
pulmonary infiltrates, pleural or pericardial effusions, hypotension and acute renal 
failure. The diagnosis DS is made on clinical grounds by the presence of at least three of 
the aforementioned signs and/or symptoms, in the absence of alternative explanations.131 
DS is a life-threatening complication which can induce respiratory insufficiency, capillary- 
leak syndrome, and multi-organ failure. Moreover, the development of DS is associated 
with an increased morbidity (e.g. increased risk of hemorrhage, higher incidence of 
thrombosis, increased rate of grade 3-4 hepatotoxicity), and may be associated with a 
higher risk of relapse.109;128;131;133-137 As the symptoms of DS can also be due to other medical 
problems such as bacteremia, sepsis, pneumonia, pulmonary hemorrhage, or congestive 
heart failure, the diagnosis DS might be difficult.138;139 The pathogenesis of DS is not fully 
understood yet. Induction of chemokines, inflammatory cytokines and adhesion 
molecules during ATRA therapy may  contribute to the hyperinflammatory cascade in 
DS.139-152 Current treatment of DS mainly consists of steroids. Steroid prophylaxis during 
induction therapy in APL has reduced the incidence of DS.129 Although corticosteroids are 
effective in prevention and treatment of DS when administered at early stages, treatment 
of full blown DS remains difficult.
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1.5 Regulation of hematopoiesis
In the hematopoietic system, the maturation of hematopoietic progenitors is dependent 
on two fundamental processes: reduction of self-renewal and induction of differentiation. 
If progenitors are triggered to differentiate, genes that maintain self-renewal are switched 
off, whereas genes that enforce differentiation are switched on. The transcription of 
lineage-specific genes required for cellular differentiation can be turned on/off by 
transcription factors, indicating that transcription factors function as drivers of cell 
fate by controlling gene expression. However, transcription factors are not the only 
key regulators of lineage-specific gene expression.  Epigenetic mechanisms (such as 
DNA methylation and histone modifications) and post-transcriptional regulators (such as 
microRNAs) also contribute to the modulation of gene expression and determination 
of cell fate.
1.5.1 Transcriptional regulation: myeloid transcription factors
Transcription factors play an essential role in driving the expression of lineage specific 
target-genes in the hematopoietic system. The expression of transcription factors 
displays a cell-lineage and cell-stage-restricted pattern. The formation of myeloid 
cells is controlled by a relatively small number of transcription factors which regulate 
Figure 5  Transcription factors in myeloid differentiation
 
Granulopoiesis is characterized by the differentiation of myeloblasts into mature neutrophils. 
Terminal granulopoiesis is a step-wise process. The first step is differentiation of myeloblasts 
into promyelocytes. The next step is development of promyelocytes into myelocytes, 
metamyelocytes and neutrophils. In the metamyelocyte, the nucleus is flattened and the 
chromatin is further condensed. In the band-neutrophil, the nucleus is horseshoe-shaped. In 
the segmented neutrophil, the nucleus is segmented into lobes. The last step is the development 
of a segmented into a mature neutrophil. Transcription factors important for the regulation of 
differentiation at different stages of the terminal granulopoiesis are depicted. The expression 
pattern of these transcription factors in indicated by the gray triangles. Figure 5 is adapted from 
Fiedler and Brunner.155
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the expression of essential myeloid genes, including growth factors (such as M-CFS, 
G-CSF, GM-CSF) and their receptors, enzymes, adhesion molecules, and other transcription 
factors. Moreover, lineage-specific transcription factors actively suppress the transcription 
of genes that are normally expressed in other lineages.153 In early stages of the myelopoiesis, 
transcription factors such as  C/EBPα, PU.1, RARα, Gfi-1, CBF, WT1 and GATA2 play an 
important regulatory role, whereas regulation of later stages requires transcription 
factors such as C/EBPε and PU.1.154 In AML, these transcription factors are often 
involved in chromosomal translocations, such as PML-RARA and RUNX1-ETO fusion 
genes, and mutations such as CEBPA, WT1, and GATA2 mutations. Transcription factors 
involved in normal and malignant myelopoiesis will be discussed in more detail. 
CCAAT/Enhancer Binding Proteins
CCAAT/Enhancer binding proteins (C/EBPs) are a family of leucine-zipper transcription 
factors implicated in myeloid differentiation. The C/EBP transcription factor family 
consists of six different members: C/EBPα, C/EBPβ, C/EBPδ, C/EBPε, C/EBPγ and CHOP. 
In granulopoiesis, C/EBPα plays an important regulatory role in immature myeloid 
cells, whereas C/EBPε is predominantly associated with more mature granulocytes.
 
In  the hematopoietic system, C/EBPα is expressed by HSCs, myeloid progenitors and 
granulocytes, but not by macrophages. C/EBPα plays a critical role in the proliferation 
and differentiation of myeloid cells. During granulocytic differentiation, C/EBPα is 
highly expressed, whereas rapid downregulation is observed during monocytic dif-
ferentiation.156 C/EBPα-deficient mice lack neutrophils and eosinophils, but retain 
monocytes, lymphocytes and erythroid cells.157 C/EBPα is essential for the generation 
of GMPs from CMPs, but C/EBPα is not required for granulocytic differentiation 
beyond the GMP stage, as illustrated by the fact that C/EBPα deficient mice have 
normal numbers of CMPs but lack GMPs and all subsequent granulocytic stages due 
to an early and specific differentiation block in the granulocytic lineage.157;158 Moreover, 
C/EBPα is implicated in inhibition of cell cycle progression which is critical for the 
induction of terminal granulocytic differentiation.159 In addition to its role in myeloid 
differentiation, C/EBPα is also involved in the regulation of stem-cell self-renewal as 
illustrated by an increased competitive repopulation activity of C/EBPα deficient HSCs 
in mouse transplant models.158 In myelopoiesis, C/EBPα is implicated in the regulation 
of expression of myeloid specific genes including the G-CSF and GM-CSF receptor, 
myeloperoxidase, lysozyme, and late granulocytic genes such as lactoferrin en C/
EBPε.160 In addition, C/EBPα can activate the expression of PU.1, which is an important 
myeloid transcription factor.161 In AML, mutations of the CEBPA gene have been 
detected with a frequency of 8%-13% in adults and 4%-8% in pediatric patients (Table 4). 
The presence of biallelic CEBPA mutations (also called double mutations) predicts a 
favorable outcome.12;21 
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C/EBPε functions as an important regulator of terminal granulopoiesis. The expression 
of C/EBPε is restricted to myeloid cells and is regulated by C/EBPα.160;162 Granulocytic 
differentiation is associated with upregulation of  C/EBPε expression, with a peak at 
the myelocyte/metamyelocyte stage.162-165 During granulopoiesis, C/EBPε interacts 
with cell cycle regulators and induces terminal differentiation of granulocytes.163 C/
EBPε is involved in the formation of secondary granules and functional maturation of 
neutrophils and macrophages. In the absence of C/EBPε, mice develop normally, but 
fail to generate functional neutrophils due to a lack of secondary granules.166 Mutations 
in CEBPE have been associated with a rare congenital disorder called neutrophil-spe-
cific secondary granule defiency.167
PU.1
The transcription factor PU.1, encoded by the SPI1 gene, is a member of the large 
family of ETS transcription factors. PU.1 functions as a transcriptional master regulator 
of myeloid as well as lymphoid cells. Expression of PU.1 is restricted to blood cells. PU.1 
is expressed at low levels in HSCs, CMPs, and CLPs, whereas PU.1 is highly expressed in 
B-cells and myelomonocytic cells.168;169 Expression of PU.1 gradually increases as 
immature myeloid cells differentiate into mature granulocytes and monocytes.165;170 
PU.1 disruption causes embryonic lethality between days 16.5 and 18.5 of gestation 
due to a fatal defect in hematopoiesis. The complete absence of myelocytes and 
lymphocytes in these mice implicates an early differentiation block on both 
lymphopoiesis and myelopoiesis.171 The absence of PU.1 also impairs HSC repopulation 
capacity and blocks differentiation of HSCs into CMPs and CLPs, suggesting a role for 
PU.1 in HSC self-renewal and in commitment/maturation of myeloid and lymphoid 
lineages.172 While PU.1 is required for the generation of CMPs from stem cells, the 
subsequent transition of CMPs to GMPs is regulated by C/EBPα. In GMPs, PU.1 is 
thought to be involved in lineage commitment:  high levels of PU.1 support monocytic 
differentiation whereas low levels of PU.1 favor granulocytic differentiation.173 PU.1 is 
also required for terminal myeloid differentiation.174 PU.1 target genes include genes 
associated with terminal myeloid differentiation such as myeloid cell surface antigens 
CD11b and CD18, growth factor receptors for M-CSF, G-CSF, and GM-CSF, and 
neutrophil elastase.160 In addition, PU.1 regulates the expression of the hematopoietic 
transcription factor GATA2, which is implicated in the regulation of myeloid lineage 
determination.175;176 Several studies have indicated that PU.1 function is suppressed in 
subsets of AML patients, such as in the presence of the leukemic fusion proteins 
PML-RARA or AML1-ETO.177;178 Conflicting results have been found regarding the 
presence of genomic mutations of PU.1 in AML patients.179-181 
Growth factor independence 1
Growth factor independence 1 (Gfi-1) is a zinc-finger transcription factor which is 
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expressed in thymus, spleen, testis, and the hematopoietic system.182 Gfi-1 expression 
is expressed in HSCs, myeloid progenitors and granulocytes. In addition, Gfi-1  is 
expressed in CLPs and early B and T cells. Gfi-1 is required for HSC self-renewal and 
granulocytic differentiation.182;183 In HSCs, Gfi-1 maintains quiescence, whereas in 
myeloid cells, Gfi-1 controls proliferation and differentiation of myeloid progenitors. 
Gfi-1 -deficient mice show defects in lymphocyte progenitor differentiation and lack 
normal neutrophilic granulocytes.182 The development of early myeloid progenitors 
including GMPs is not disturbed in Gfi-1-deficient mice. In myeloid progenitors cells, 
Gfi-1 enhances granulocytic differentiation via regulation of G-CSF/G-CSF receptor 
signaling, whereas Gfi-1  suppresses monocytic differentiation.182;184 Gfi-1  cooperates 
with C/EBPε to control the expression of genes implicated in terminal differentiation 
of granulocytes.185 The important role of Gfi-1  in myeloid differentiation is illustrated 
by the presence of heterozygous GFI1 mutations in patients with severe congenital 
neutropenia.186 Moreover, a polymorphism in GFI1 has been described that predisposes 
to development of AML.187
Retinoic Acid Receptors
Retinoids play an important role in myeloid differentiation. Activity of retinoids is 
mediated via two different families of nuclear receptors: the retinoic acid receptors 
(RAR) and the retinoid X receptors (RXR).188 RARs are zinc finger transcription factors 
that control the expression of retinoic acid target genes via binding to specific retinoic 
acid response elements (RAREs) present in the promoters of their target genes. RARs 
require heterodimerisation with RXR for DNA binding. The RAR-family consists of 
three different members which are broadly expressed: RARα, RARβ, and RARγ.188 RARα 
is preferentially expressed in myeloid cells and is involved in controlling the 
proliferation of promyelocytes and their differentiation into neutrophils.101;189 RARα 
can modulate granulopoiesis bidirectionally. RARα stimulates differentiation in 
response to retinoic acid, whereas RARα limits differentiation in the absence of 
retinoic acid.101 Dominant inhibition of RARα arrests granulocytic differentiation at the 
promyelocytic stage.190 RARα target genes include genes associated with terminal 
myeloid differentiation such as C/EBPε, which is involved in terminal differentiation of 
granulocytes.163;191  In APL, RARα is targeted by chromosomal translocations, resulting 
in a block in differentiation at the promyelocytic stage.98;99
Core binding factors
Core binding factor (CBF) is a family of heterodimeric transcription factors composed 
of a DNA-binding CBFα subunit bound to a non-DNA binding CBFβ subunit. The CBF 
family consist of three distinct DNA-binding CBFα subunits (RUNX1, RUNX2, and 
RUNX3) and a common non-DNA-binding CBFβ subunit that is encoded by CBFB. 
CBFα2 (RUNX1) en CBFβ are key regulators of hematopoiesis.192 Homozygous disruption 
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of CBFα2 or CBFβ in mice results in midgestation embryonic lethality between embryonic 
day 12.5-13.5 and a profound block in definitive hematopoiesis. These mice lack all 
lineages of definitive hematopoiesis due a defect in the generation of definitive 
hematopoietic progenitors and stem cells.193-196 CBFs can function as both activators 
and repressors of transcription and CBF targets include genes associated with terminal 
myeloid differentiation such as C/EBPα and PU.1.197 Moreover, CBFs are frequent 
targets of chromosomal translocations and mutations associated with AML. The most 
common translocations include t(8;21)(q22;q22) creating the RUNX1-ETO fusion gene, 
and inv(16)(p13;q22) resulting in formation of the CBFB-MYH11 fusion gene.198 Both 
chromosomal aberrations disrupt the function of CBFs and prevent expression of CBF 
target genes that are crucial for hematopoietic development resulting in impaired 
hematopoietic differentiation.192 These AML-subtypes, also known as CBF-AML, 
account for 6%-17% of adult AML and 17%-25% of pediatric AML cases, and are 
associated with a favorable prognosis (Table 4). Moreover, RUNX1 (CBFα2) point 
mutations have been detected with a frequency of 5%-18% in adults and 3%-6% in 
pediatric patients (Table 4). The presence of RUNX1 mutations has been recently been 
associated with poor outcome in (CN-)AML.27;62
Wilms’ Tumor 1
Wilms’ Tumor 1 (WT1) is a zinc finger transcription factor which is involved in urogenital 
development and hematopoiesis. The expression and function of WT1 in hematopoietic 
cells largely depends on the differentiation status and is tightly regulated. WT1 is 
expressed in multipotent uncommitted and committed hematopoietic progenitors. 
During early myeloid differentiation (CMPs, GMPs and MEPs), WT1 expression is 
upregulated, whereas WT1 expression is downregulated during later stages of 
myeloid differentiation, resulting in low WT1 expression in fully differentiated myeloid 
cells.199 WT1 deficiency is embryonically lethal at day 13.5 to 15.5 of gestation. In WT1 
knock-out mice, the hematopoietic system is grossly normal, whereas abnormal 
development of the kidney, gonads, mesothelium, heart, and lungs is observed.200-202 
Although embryonic hematopoietic cells lacking WT1 can reconstitute the 
hematopoietic system and are capable of full range of proliferation and differentiation, 
they show functional defects in growth potential, indicating that WT1 plays a role in 
maintenance of self-renewal of early hematopoietic cells.203 In myeloid progenitors, 
WT1 is involved in the regulation of proliferation, differentiation, and apoptosis.204-208 
WT1 target genes include genes associated with myeloid differentiation such as RARA 
and apoptotic genes such as BCL2.209;210 In AML, WT1 mutations have been detected 
with a frequency of 4%-9% in adults and 8-12% in pediatric patients (Table 4). The 
presence of WT1 mutations has been associated with poor outcome.58;211;212 Moreover, 
WT1 is overexpressed in the majority of AML-patients and has been identified as a 
marker for MRD-detection and as a target for immunotherapy.211 The prognostic 
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importance of WT1 expression levels in AML is still a matter of debate. At diagnosis, 
WT1 expression has not consistently been predictive for outcome. The use of WT1 as 
a marker for MRD-detection is more promising as failure to normalize WT1 expression 
after induction or consolidation therapy was shown to be predictive for relapse in 
pediatric and adult AML.84;213  Studies of WT1 immunotherapy in AML patients 
demonstrated the induction of WT1-specific cytotoxic T-cells and tumor regression, 
suggesting potential efficacy of WT1 immunotherapy.214-217
GATA transcription factors
The GATA binding protein transcription factors are a family of six zinc finger transcription 
factors (GATA1-6) which bind to specific GATA motifs in the DNA. GATA1, GATA2 and 
GATA3 are involved in hematopoiesis. GATA1 plays an important role in erythrocyte, 
megakaryocyte, mast cell, and eosinophil development.218 Germline deletion of 
GATA1 in mice is embryonically lethal due to an arrest of erythroid development at the 
proerythroblast stage indicating that GATA1 essential for erythropoiesis.219 GATA1 
mutations are present in transient myeloproliferative disorder and acute megakaryo-
blastic leukemia (AML-M7) associated with trisomy 21.220 Moreover, inherited GATA1 
mutations have been associated with X-linked thrombocytopenia, congenital 
erytrophoietic porphyria, and Diamond Blackfan anemia.221;222
GATA2 plays an essential role in the regulation of hematopoietic stem and progenitors 
cell development as well as in myeloid differentiation.223 The expression and function 
of GATA2 in hematopoietic cells largely depends on their differentiation status and is 
tightly regulated.224 GATA2 is broadly expressed in hematopoietic cells, with 
particularly high expression in hematopoietic stem and progenitor cells as well as 
early erythroid cells, megakaryocytic cells, and mast cells.164;225-233 GATA2 knock-out 
mice have profound defects in definitive hematopoiesis resulting in embryonic 
lethality at day 10-11 of gestation due to a pan-hematopoietic deficit.234 In hematopoietic 
stem and progenitors cells, GATA2 functions as a regulator of proliferation, differentiation 
and survival, and acts as a regulator of stem cell quiescence.224;230;235-237 During myeloid 
differentiation, GATA2 plays an important role in the regulation of lineage 
determination.175 GATA2 blocks terminal erythroid, monocytic and granulocytic 
 differentiation, while it promotes erythroblast proliferation, megakaryopoiesis and 
mast cell formation.237-239 GATA2 target genes include the crucial myeloid transcription 
factors PU.1 and C/EBPα, which are implicated in terminal granulocytic and monocytic 
differentiation.229;236;238;240 In myeloid progenitors, GATA2 induces downregulation of 
PU.1 and C/EBPα, and inhibits the ability of PU.1 to transactivate critical myeloid target 
genes and thereby prevents the induction of a myeloid gene expression program.241 
In addition, GATA2 can induce expression of the hematopoietic transcription factor 
WT1 via binding to the 3’ enhancer of WT1.242  In (familial) AML and syndromes with a 
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predisposition to development of AML, inherited GATA2 mutations have been 
detected, whereas acquired GATA2 mutations were recently described in adult AML 
and during blast crisis in chronic myeloid leukemia (CML).243-253 
GATA3 is implicated in T-cell development.218 GATA3 null mice display gross abnormalities 
in fetal liver hematopoiesis and die due to internal bleeding.254 GATA3 mutations have 
been detected in early T-cell precursor acute lymphoblastic leukaemia.255 
1.5.2 Epigenetic regulation
Epigenetic mechanisms play an important role in the regulation of gene expression. 
Epigenetic modifications include DNA methylation and histone modifications.256 
Histones are the chief protein components of chromatin, acting as spools around 
which the DNA is wound. Histones undergo posttranslational modifications that 
alter their interaction with DNA and nuclear proteins. Posttranslational modifications 
of histones (such as acetylation, methylation, ubiquitination, phosphorylation, 
sumoylation) are associated with a transcriptionally active or silent chromatin state 
(euchromatic versus heterochromatic).256 Epigenetic modifications of the DNA refer to 
functionally relevant modifications to the genome without altering its primary 
nucleotide sequence. DNA methylation, which often occurs in the promoter region of 
genes, is associated with repression of gene transcription, whereas demethylation is 
associated with transcriptional activation. 
In hematopoieisis, epigenetic mechanisms are involved in regulating the expression 
of hematopoietic transcription factors and thereby affect transcription.14 In AML, 
epigenetic dysregulation plays an important role. Specific DNA methylation signatures 
have been identified distinct from the methylation patterns of normal hematopoietic 
cells.257  Moreover, epigenetic regulators are often targeted by mutations in AML.14;256 
The mixed lineage leukemia (MLL) gene, which functions as a histone methyltransferase, 
is frequently involved in chromosomal translocations or intragenic partial tandem 
duplications. Fusion of MLL to one of over 50 different translocation partners converts 
it into a potent leukemogenic oncoprotein, which is associated with a dismal 
prognosis, depending on the MLL-translocation partner.258 Moreover, recurrent 
genetic mutations in epigenetic regulators including TET2, IDH1/2, DNMT3A, and 
ASXL1, were described recently in a substantial amount of adult AML patients (Table 
4).12;14 In pediatric AML patients, these aberrations are detected less frequently. 
Mutations in ASXL1, DNMT3A and TET2 are associated with poor prognosis.26-30 The role 
of mutations in other epigenetic regulators as predictors of prognosis in AML is not 
clearly established yet. Epigenetic regulators are regarded as potential molecular 
targets for tailored therapies. Epigenetic therapeutic agents include DNA methyl-
transferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors.256 
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1.5.3 Post-transcriptional regulation: microRNAs
MicroRNAs are small, non-coding RNA molecules of approximately 22 nucleotides 
that have been identified as a distinct class of gene expression regulators with 
conserved functions in the early 2000s. The human genome encodes more than 1000 
microRNAs, located in introns, exons, or intergenic regions. Mature microRNAs are 
generated by sequential processing of primary microRNA transcripts (pri-microRNA) 
by the ribonucleases Drosha and Dicer (figure 6).259;260 MicroRNAs show a tissue and 
cell-type specific expression and are involved in the regulation of critical cell processes 
1
Figure 6  MicroRNA processing
 
In the nucleus microRNAs are expressed as primary microRNAs (pri-miRNAs) transcribed by 
RNA polymerase II. The ribonuclease Drosha digests the pri-miRNA in the nucleus into the 
hairpin precursor miRNA (pre-miRNA). Exportin-5 is responsible for the export of the pre-miRNA 
from the nucleus to the cytoplasm. Dicer cleaves the pre-miRNA into a double-stranded RNA of 
approximately 22 base pairs containing a leading strand and a lagging strand. Only one of the 
two strands is the mature miRNA. To control the translation of target mRNAs, the double-
stranded RNA produced by Dicer must be separated. The single-stranded mature miRNA 
associates with the RISC complex and binds to the target mRNA. MicroRNA mediated cleavage 
of the target mRNA is induced in case of complete complementarity between the mature 
microRNA and the target mRNA. Translational repression of the target mRNA is induced in case 
of incomplete complementarity.
3’ III III 5’ 
AAAAAAA 
RISC 
AAAAAAA 
5’ 3’ 
3’ 
5’ 
3’ 
5’ 
RISC 
3’ 
5’ 
Chapter 1
34
including cell growth, differentiation, and apoptosis.261;262 MicroRNAs function as key 
regulators of gene expression at the post-transcriptional level through inhibition of 
protein translation or degradation of messenger RNA (mRNA) of target genes via 
recognition of complementary sites, generally located in the 3’ untranslated region 
(UTR, figure 6).262-264 One microRNA may regulate the expression of multiple genes and 
one gene may be targeted by several microRNAs.265 MicroRNA mediated cleavage of 
the target mRNA is induced in case of complete complementarity between the 
mature microRNA and the target mRNA. Translational repression of the target mRNA 
is induced in case of incomplete complementarity. The seed region, located at the 2nd 
to 7th nucleotide at the 5’ end of the mature microRNA, is essential for target gene 
recognition. 
MicroRNAs play a crucial role in the regulation of hematopoiesis by modulating the 
expression of target genes such as transcription factors and genes involved in cell 
cycle regulation and proliferation.266 In myelopoiesis, miR-223 was one of the first 
microRNAs that was shown to play an important regulatory role. MiR-223 is specifically 
expressed in myeloid cells of the granulocytic lineage and its expression is upregulated 
during terminal granulocytic differentiation.267;268 The expression of miR-223 is driven 
by myeloid transcription factors such as PU.1, CEBPA, NFIA.269-271 MiR-223 targets 
cell-cycle regulators (E2F1) and crucial myeloid transcription factors (such as NFIA, 
CEBPB, LMO2, MEF2C), resulting in a block of cell cycle progression and induction of 
granulocytic differentiation.270;272-274 Recently, various other microRNAs (e.g. miR-29a/b, 
miR-34a, miR-107, miR-124a, miR-125b, miR-142, miR-328, and miR-342) were shown to 
be involved in the regulation of myeloid progenitor proliferation and differentiation 
via interaction with crucial myeloid transcription factors, cell cycle regulators, and 
DNA methyltransferases.275-283 In AML, the expression of various microRNAs is deregulated 
and distinctive microRNA expression signatures have been associated with 
cytogenetics, molecular aberrations, and prognosis, suggesting that dysregulated 
expression of microRNAs may contribute to leukemogenesis.284;285 Increasing evidence 
suggests a role for microRNA-based therapeutic approaches in leukemia.286 MicroRNAs 
can function both as tumor suppressors by targeting of oncogenes, or display an 
oncogenic role through targeting of tumor suppressor genes.287;288 Oncogenic microRNAs 
may be used as therapeutic targets, whereas tumor-suppressive microRNAs may be 
used as therapeutic agents. 
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1.6 Thesis Outline
Although treatment outcome of AML patients has improved substantially with the 
use of risk-directed treatment and improved supportive care, a substantial amount of 
AML patients still die from their disease. Multi-drug chemotherapy is the standard of 
care in AML. As intensification of the current chemotherapy regimens is not feasible, 
other therapeutic options are needed to improve survival rates. Deciphering of the 
molecular pathogenesis of the disease is necessary for improvement of prognostic 
classification and development of individualized treatment strategies and targeted 
therapy. One of the hallmarks of AML is deregulated gene expression. The objective 
of this thesis is to extend our knowledge on the (post-) transcriptional regulation of 
gene expression in myelopoiesis to improve prognostic classification and identify 
novel targets for therapy in AML.
MicroRNAs are an important class of gene expression regulators that play a crucial 
role in the regulation of hematopoiesis. Dysregulated expression of microRNAs may 
contribute to leukemogenesis. Although various microRNAs have been implicated in 
the regulation of normal and malignant myelopoiesis, information on relevant target 
genes is still scarce. In chapters 2 and 3, the expression of microRNAs during myeloid 
differentiation was investigated using microRNA expression profiling. The aim was to 
identify differentially expressed microRNAs and determine whether these microRNAs 
may target genes involved in myeloid differentiation. We demonstrated that miR-132 
is highly upregulated during granulocytic differentiation in cell-line models as well as 
in primary cells. In chapter 2, we identified the hematopoietic transcription factors 
WT1 as a direct target of miR-132. We demonstrate that miR-132 functions as a 
translational repressor of the WT1 oncoprotein in myeloid cells. These findings may 
be relevant because WT1 is involved in the regulation of proliferation, differentiation 
and apoptosis in myeloid progenitors. Moreover, aberrant WT1 expression is 
associated with disturbed hematopoietic differentiation and the development of 
AML. In chapter 3, we demonstrate that messenger RNA of the hematopoietic 
transcription factors GATA2 is also targeted by miR-132. GATA2 plays an essential role 
in the regulation of myeloid differentiation and hematopoietic stem and progenitors 
cell development. The role of GATA2 in leukemia is addressed in chapter 4, where the 
prognostic relevance of GATA2 expression and GATA2 mutations in a large pediatric 
AML cohort is described. We identified GATA2 as a novel marker for poor prognosis in 
pediatric AML, especially in specific AML subgroups, which might contribute to better 
risk-group stratification and risk-adapted therapy in the future.
With the current chemotherapy regimens, the outcome of AML patients is generally 
poor. The most prominent exceptions to this general statement is APL, which 
1
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comprises 4%-13% of adult AML cases and 6%-10% of pediatric AML cases.16;37-39 In 
APL, the majority of patients is cured using a combination of anthracycline-based 
chemotherapy and targeted therapy with ATRA and/or ATO. Mortality during 
induction chemotherapy remains an important cause for treatment failure in APL. The 
differentiation syndrome (DS) is an important life-threatening complication of 
induction therapy with ATRA in APL. Chapters 5 and 6 focus on the pathogenesis of 
DS, which is characterized by massive pulmonary infiltration of differentiating 
leukemic cells. Chapter 5 describes massive induction of chemokines during APL 
treatment with ATRA in a cell-line model as well as in primary APL cells, which is not 
influenced by corticosteroid treatment. Because chemokines are implicated in 
migration and extravasation of leukemic cells, induction of chemokines may 
contribute to the development of the uncontrolled hyperinflammatory reaction in 
DS. In chapter 6, we postulate a model on the pathogenesis of DS in which induction 
of integrins, adhesion molecules, and chemokines plays a central role. We hypothesize 
that application of chemokine-(receptor) antagonists might be more effective than 
corticosteroids as treatment of DS. Finally, chapter 7 provides an overview and 
discussion with future perspectives of the research described in this thesis.
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Abstract
Wilms’ Tumor 1 (WT1) is a zinc finger transcription factor which plays a crucial role 
during hematopoiesis. WT1 is involved in the regulation of proliferation, differentiation 
and apoptosis in myeloid progenitor cells. Aberrancies in WT1 function may contribute 
to leukemogenesis, as somatic mutations in the WT1 gene are present in 5%-15% of 
cases with acute myeloid leukemia (AML). In addition, overexpression of WT1 is 
found in the vast majority of AML cases. How WT1 expression is controlled in normal 
and leukemic cells is largely unknown. Here, we identify microRNA-132 as a regulator 
of WT1 protein expression. To identify microRNAs and target genes implicated in 
myelopoiesis, we studied differential expression of microRNAs during myeloid 
 differentiation and showed that miR-132 was strongly upregulated (up to 500-fold). 
Computational target prediction identified the WT1 gene as a putative target gene of 
miR-132, based on the presence of a conserved recognition element for miR-132 in the 
3’UTR of WT1. To validate the putative targeting of WT1 by miR-132, luciferase reporter 
assays were performed. Co-expression of miR-132 with a luciferase construct 
containing the 3’UTR of WT1 resulted in downregulation of the luciferase levels. When 
the complementarity between miR-132 and the 3’UTR of WT1 was disrupted by 
mutations, repression of the luciferase signal by miR-132 was lost. Further studies 
indicated that miR-132 did not destabilize the WT1 mRNA transcript, but rather inhibited 
protein translation. When miR-132 was overexpressed in myeloid cells, the endogenous 
WT1 protein levels were significantly downregulated. We conclude that miR-132 is a 
novel post-transcriptional regulator of the WT1 oncoprotein. Targeting of WT1 by 
miR-132 may be an interesting therapeutic approach to downregulate WT1 protein 
levels in target cells. 
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Introduction
Hematopoiesis is a complex process that is tightly regulated. MicroRNAs are embedded 
in complex regulatory networks and play a crucial role in the regulation of hematopoiesis 
by modulating the expression of target genes. MicroRNAs negatively regulate gene 
expression by inhibiting protein translation or degrading target messenger RNA 
(mRNA) via the recognition of complementary sites, generally located in the 3‘ 
untranslated region (UTR) of target genes. Individual microRNAs have been implicated 
in the regulation of hematopoiesis by targeting genes involved in proliferation, dif-
ferentiation, and cell cycle regulation.1 In myelopoiesis, miR-223 was one of the first 
microRNAs that was shown to play an important regulatory role. MiR-223 is specifically 
expressed in myeloid cells of the granulocytic lineage and its expression is upregulated 
during terminal granulocytic differentiation.2;3 In acute myeloid leukemia (AML), 
suppression of miR-223 is observed.4;5 The expression of miR-223 is driven by myeloid 
transcription factors such as PU.1, CEBPA and NFIA.2;5;6 MiR-223 targets cell-cycle 
regulators (E2F1) and crucial myeloid transcription factors (such as NFIA, CEBPB, LMO2, 
MEF2C), resulting in a block of cell cycle progression and induction of granulocytic 
differentiation.2;5;7;8 Recently, various other microRNAs (e.g. miR-29a/b, miR-34a, 
miR-107, miR-124a, miR-125b, miR-142, miR-328, and miR-342) were shown to be 
involved in the regulation of myeloid progenitor proliferation and differentiation via 
interaction with crucial myeloid transcription factors, cell cycle regulators and DNA 
methyltransferases.9-17 
The tight control of normal hematopoiesis can be disturbed by deregulated expression 
of microRNAs which may contribute to leukemogenesis. In AML, the expression of 
various microRNAs is deregulated and distinctive microRNA expression signatures 
have been associated with cytogenetics, molecular aberrations and prognosis.18;19 
MicroRNAs can function both as tumor suppressors via targeting of oncogenes, or 
display an oncogenic role through targeting of tumor suppressor genes. MiR-34a acts 
as a tumor suppressor by targeting the oncogenic transcription factor E2F3, which is 
involved in cell cycle progression. The miR-17-92 cluster functions as an oncomiR via 
targeting the tumor suppressor PTEN, which mediates cell growth and apoptosis.12;20 
In AML, miR-34a is frequently downregulated whereas the miR-17-92 cluster is 
frequently overexpressed.12;21 Increasing evidence suggests that anti-leukemic effects 
can be achieved by modulating microRNA expression, which may lead to the 
development of microRNA-based therapeutic approaches in leukemia.22 
Although various microRNAs have been implicated in the regulation of normal and 
malignant myelopoiesis, information on relevant target genes is still scarce. To identify 
microRNAs and target genes that may contribute to the regulation of myelopoiesis, 
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we performed microRNA expression profiling during myeloid differentiation and 
focused on identification of target genes regulated by differentially expressed 
microRNAs. During granulocytic differentiation, miR-132 was most highly upregulated. 
We identified Wilms’ Tumor 1 (WT1), a crucial transcription factor in normal and 
malignant myelopoiesis, as a direct target of miR-132, resulting in repression of WT1 
protein expression by miR-132 in myeloid cells. Targeting of WT1 by miR-132 may be 
an interesting tool to downregulate WT1 protein levels in target cells. 
Materials and Methods
Cell culture
NB423 and HL6024;25 cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 
culture medium (Invitrogen, Paisley, UK), supplemented with 10% heat-inactivated 
Fetal Bovine Serum (FBS; Invitrogen) and 1% Penicillin/Streptomycin (MP Biomedicals, 
Illkirch Cedex, France). Primary acute promyelocytic leukemia (APL) cells were isolated 
from bone marrow or peripheral blood of eight patients at diagnosis after informed 
consent in accordance with the Declaration of Helsinki and after Institutional Review 
Board approval according to local laws and regulations. Mononuclear cells were 
isolated after 1077 Ficoll density gradient centrifugation (GE Healthcare, Buckinghamshire, 
UK) and stored in liquid nitrogen. After thawing, leukemic cells were cultured in 
RPMI-1640 medium, supplemented with 20% FBS  and 1% penicillin/streptomycin. 
All-trans retinoic acid (ATRA) (Sigma, St Louis, MO, USA) was used to induce differen-
tiation in NB4 cells,  HL60 cells, and primary APL cells at a final concentration of 10-6 M. 
HeLa cells26 were cultured in Dulbecco modified Eagle medium (DMEM, Invitrogen), 
supplemented with 10% heat-inactivated FBS and 1% Penicillin/Streptomycin. HEK293FT 
cells (Invitrogen), which were used for production of lentivirus, were cultured according 
to manufacturer’s protocol. Cultures were incubated at 37 0C in a 5% CO2 completely 
humified atmosphere. 
Reverse transcriptase reaction and Quantitative Polymerase Chain 
Reaction (PCR)
Granulocytes were isolated from peripheral blood of healthy donors (N=5) after 1077 
Ficoll density gradient centrifugation (GE Healthcare, Buckinghamshire, UK) and 
subsequent magnetic cell sorting (MACS) using anti-CD15 microbeads (Miltenyi 
Biotec, Leiden, The Netherlands). CD34-positive progenitor cells were isolated from 
bone marrow of healthy donors (N=5) by FACS sorting using monoclonal antibodies 
to CD34 (Beckman Coulter, Miami, Florida, USA). Informed consent was obtained in 
accordance with the Declaration of Helsinki and after Institutional Review Board approval 
according to local laws and regulations. Total RNA from cell lines, granulocytes and 
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CD34-positive progenitors was isolated using RNA-Bee (Iso-Tex Diagnostics, Friendswood, 
TX, USA). For complementary DNA (c-DNA) synthesis 1 mg of total RNA was reverse 
transcribed into cDNA. Reverse transcriptase (RT) reactions for microRNAs were 
carried out using 10 ng of total RNA, 50 nM stem-loop RT primer in combination with 
the TaqMan® MicroRNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, 
USA), according to manufacturer's protocol.  MicroRNA expression was measured 
using stem-loop RT-PCR TaqMan® MicroRNA Assays (Applied Biosystems) which are 
designed to detect and accurately quantify mature microRNAs. Significant expression 
of a microRNA was defined as Ct value ≤ 35. For measurement of WT1 mRNA expression 
we used the European LeukemiaNet (ELN) WT1 assay, which was previously developed 
by our lab.27;28 As a reference gene we used a premixed assay for GAPDH (4326317E, 
Applied Biosystems).  Quantitative PCR reactions for WT1 and GAPDH contained 2,5 µl 
cDNA (10 ng/µl), 1x TaqMan® Universal PCR Master Mix (58003365-01, Applied 
Biosystems), 1.25 µl premixed assay, or 0.75 µl forward primer, 0.75 µl reverse primer, 
and 0.5 µl probe. The reactions were incubated in a 96-well plate for 10 minutes at 95 
0C, followed by 45 cycles of 15 seconds at 95 0C and 1 minute at 60 0C. Quantitative PCR 
reactions were performed on the ABI/PRISM 7500 or 7700 Sequence Detection system 
(ABI/PE, Foster City, CA, USA). 
Plasmids
The pre-miR-132 sequence (101 base pairs (bp)) with 250-300 bp flanking sequences 
on either side (total fragment of 669 bp), which are required for the transcription and 
processing of the pre-miRNA into a functional mature microRNA, was amplified from 
human genomic DNA. This fragment was subcloned into the entry vector pDONR201 
(Invitrogen) and subsequently into the lentiviral destination vector pLenti6.2/V5 DEST 
(Invitrogen) using the Gateway cloning technology (Invitrogen). The pLenti6.2/V5 
DEST vector contains a blasticidine selection marker, under the control of a murine 
phosphoglycerate kinase-1 (PGK) promoter. The PGK-EM7-blasticidine cassette was 
replaced by a PGK-DNGFR-WPRE cassette derived from the RRL-GFP-PGK-DNGFR-
WPRE-GATA1 vector29 (kindly provided by Prof. G. Ferrari, H. San Raffaele, Milan, Italy) 
using Kpn I digestion (New England Biolabs, Ipswich, MA, USA), resulting in formation 
of a pLenti-miR-132-PGK-DNGFR-WPRE vector. The pre-miR-132 fragment with 
flanking sequences was subcloned from the pLenti6.2/V5 DEST vector into the 
pcDNA3.1 vector (Invitrogen), using Apa I digestion (New England Biolabs). Mutations 
of three adjacent nucleotides in the seed sequence of miR-132 were introduced with 
the QuickChangeXL kit (Promega, Madison, WI, USA), according to manufacturer’s 
protocol.
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Lentiviral transduction of miR-132
miR-132 lentivirus was produced by co-transfection of the HEK293 FT producer cell 
line (Invitrogen) with the pLenti-miR-132 expression construct and the ViraPower 
packaging mix (Invitrogen) using Polyethylenimine (PEI) (Polysciences, Warrington, 
PA, USA). NB4 cells were lentivirally transduced by plating cells onto retronectin-coat-
ed culture dishes (Takara, Cambrex Bio Science, Heerhugowaard, The Netherlands), 
and subsequent incubation of the cells with the viral supernatant. Transduction 
efficiency was 1%-10%, as determined by the expression the expression of DNGFR 
(microRNA expression vector), measured by flow cytometry on a Beckman Coulter 
Cytomics FC 500 (Beckman Coulter). DNGFR expression was detected by using the 
supernatant of the 20.4 hybridoma cells (HB8737, American Type Culture Collection, 
Rockville, MD, USA) producing anti-human NGFR antibody. pLenti-transduced NB4 
cells were isolated by MACS on the basis of DNGFR positivity, according to 
manufacturer’s protocol (Militenyi Biotec). After two rounds of MACS sorting, a purity 
of more than 90% was obtained. 
Western blot analysis
Cells were lysed in RIPA buffer (phosphate buffered saline with 1% Igepal CA-63 
(Sigma), 0.5% Sodium Deoxycholate (Sigma), 0.1% Sodium Dodecyl Sulphate 
(Invitrogen), 1.5M Magnesium Chloride (Sigma), and 0.1 M Zinc Chloride (Sigma)), 
supplemented with Benzonase Nuclease (Novagen, EMD Chemicals, San Diego, CA, 
USA) and complete protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). 
Total protein (100 µg) was separated on 10% SDS-poly-acrylamide gels and transferred 
onto polyvinylidenefluoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA). Blots 
were stained with the anti-WT1-H2 antibody (Dako Cytomation, Glostrup, Denmark). 
As a control for equal loading blots were stained with antibodies to β-Actin (A5441, 
Sigma).
Luciferase reporter assay
The full-length WT1 3’UTR (position 33-1371, downstream of WT1 coding sequence 
(CDS)) was amplified from human genomic DNA and subcloned into the PGL3-control 
vector (Promega) downstream of the firefly luciferase, using the Xba I restriction 
enzyme (New England Biolabs). The miR-132 recognition element (MRE) in the WT1 
3’UTR is located near its 3’ end (position 925-930 downstream of WT1 coding 
sequence). Mutation of three adjacent nucleotides in the miR-132 MRE or 3’UTR of 
WT1 were introduced using the QuickChangeXL kit (Promega), according to 
manufacturer’s protocol. Luciferase reporter assays were performed in HeLa cells as 
these cells do not endogenously express WT1. The WT1 3’UTR reporter construct 
(wild-type or mutated) was co-transfected with the pcDNA empty vector or 
pcDNA-miR-132 vector (wild-type or mutated) and a Renilla vector (pRL-CMV, 
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Promega) in HeLa cells using PEI (Polysciences). To determine non-specific effects of 
miR-132 on the firefly luciferase expression, we co-transfected miR-132 (wild-type or 
mutant) with the backbone firefly luciferase construct PGL3-control, which lacks the 
3’UTR of WT1. Cells were harvested 48 hours after transfection using 100 µl Passive 
Lysis Buffer (Promega). Firefly and Renilla luciferase activities were measured 
consecutively on a luminometer (Lumat LB 9507, Perkin-Elmer/Applied Biosystems, 
CA, USA) using the Dual-Luciferase Reporter Assay System (Promega), according the 
manufacturer's protocol. Renilla activity was used to normalize the firefly luciferase 
activity. The normalized firefly luciferase signal in the presence of miR-132 (wild-type 
or mutant) is plotted relative to the normalized firefly luciferase signal in the presence 
of empty vector.
Results
Differential expression of microRNAs during granulocytic differentiation
We evaluated the expression of 157 mature microRNAs during granulocytic differen-
tiation in the acute promyelocytic leukemia (APL) cell line NB4 using stem-loop 
RT-PCR microRNA assays, designed to specifically quantify mature microRNAs. 
Terminal granulocytic differentiation of the immature promyelocytic NB4 cells was 
induced by all-trans retinoic acid (ATRA). In untreated NB4 cells, expression of 97 
microRNAs (62%) was detected (Supplemental Table S1). During ATRA-induced 
granulocytic differentiation, 52 microRNAs were differentially expressed (e.g. ≥ 3-fold 
upregulation (N=51) or downregulation (N=1)). We confirmed previously reported 
induction of miR-223 (15-fold), miR-342 (11-fold), miR-107 (8-fold), miR-29a (4-fold), 
and miR-29b (3-fold) during granulocytic differentiation of NB4 cells.2;5;9;11;13;30
miR-132 expression is highly upregulated during granulocytic differentiation
In terminally differentiated NB4 cells, the expression of nine microRNAs was highly 
upregulated (≥ 15-fold, figure 1). We identified miR-132 as the most strongly induced 
microRNA during ATRA-induced differentiation in NB4 cells (491-fold at 96 hours, 
figure 2A). Induction of miR-132 was also observed during ATRA-induced granulocytic 
differentiation of the myeloblastic leukemia cell line HL60 (31-fold at 96 hours, figure 
2B). Upregulation of miR-132 expression during granulocytic differentiation was 
confirmed in normal as well as leukemic primary cells. In vitro ATRA-mediated 
granulocytic differentiation of primary APL patient cells (N=8) was associated with 
induction of miR-132 expression (9-fold at 72 hours, figure 2C). In healthy donors, 
miR-132 expression was 15-fold higher in granulocytes (N=5) compared to 
CD34-positive progenitors (N=5) (figure 2D). These results indicate that granulocytic 
differentiation is associated with induction of miR-132.   
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WT1 is a putative target of miR-132
As miR-132 is highly upregulated during granulocytic differentiation, we studied 
whether miR-132 modulates the expression of genes implicated in myelopoiesis. To 
identify candidate miR-132 target genes, we used four microRNA target prediction 
programs (DIANA-microT, miRanda, PicTar, TargetScanS) and selected genes that were 
predicted to be targeted by miR-132 according to at least two prediction programs. 
Within this selection, several miR-132 target genes were present that have previously 
been validated in neuronal and immunological systems (e.g. GATA2, EP300, MECP2, 
BTG2, PAIP2A, SIRT1, ACHE, and HBEGF).31-37 In the hematopoietic system, miR-132 target 
genes have not been studied yet. We identified the Wilms’ Tumor 1 gene (WT1), which 
encodes for a zinc-finger transcription factor implicated in normal and malignant 
myelopoiesis, as a novel putative miR-132 target.38;39 In the 3’UTR of WT1 an 
Figure 1  Induction of microRNA expression during granulocytic differentiation
The expression of 157 mature microRNAs was determined during granulocytic differentiation 
using stem-loop RT-PCR Taqman® microRNA assays, designed to specifically quantify mature 
microRNAs. ATRA-induced differentiation of NB4 cells was used as a model system for granulocytic 
differentiation. NB4 cells were cultured in the presence of ATRA for 96 hours. MicroRNA 
expression relative to GAPDH was determined and the fold-induction of expression in ATRA-
stimulated NB4 cells compared to non-stimulated NB4 cells is plotted. Only microRNAs which 
are more than 15-fold upregulated after ATRA-stimulation for 96 hours are shown.
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evolutionary conserved potential miR-132 recognition element (MRE) is present which 
is fully complementary to the seed region of miR-132, defined as the 2nd to 7th nucleotides 
from the 5’end of a mature microRNA (Figure 3A). Complementarity between the target 
and the seed region of a microRNAs is known to be essential for target recognition.
miR-132 targets the 3’UTR of WT1
Although WT1 has emerged as a crucial transcription factor in myelopoieis, the 
mechanisms by which WT1 expression is regulated in normal and leukemic cells 
remain largely unclear. Therefore we investigated whether WT1 expression is 
2
Figure 2  Induction of miR-132 expression during granulocytic differentiation
Expression of miR-132 in (A) NB4 cells (N=3, mean + SD), (B) HL60 cells (N=3, mean + SD), (C) 
primary APL cells (N=8, mean + SD), and in (D) nontransformed CD34-positive bone marrow 
progenitor cells and mature granulocyte samples from healthy donors (N=5, mean + SD). 
MicroRNA expression relative to GAPDH was determined. Granulocytic differentiation was 
induced with ATRA (10-6M) for 72-96 hours in NB4, HL60, and primary APL cells, and fold-induction 
of miR-132 expression in ATRA-stimulated cells compared to non-stimulated cells is plotted.
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Figure 3  miR-132 targets the 3’UTR of WT1
(A) Alignment of human (hsa-)miR-132 with the 3’UTR of WT1. Complementary nucleotides are 
marked bold. The predicted miR-132 recognition element (MRE) is fully complementary to the 
seed region (SEED) of miR-132, consisting of the 2nd to 7th position at the 5’ end of miR-132 (both 
underlined). (B) Schematic representation of the luciferase reporter construct containing the 
full-length 3’UTR of WT1 including the predicted miR-132 MRE. Reciprocal mutations were created 
in the putative miR-132 MRE in the 3’UTR of WT1 (3’UTR WT1-mutant) or in the seed sequence of 
miR-132 (miR-132-mutant). Mutated nucleotides are marked gray. Complementarity between 
MRE (wild-type or mutant) and seed region (wild-type or mutant) is depicted. (C) Effect of miR-132 
on firefly luciferase expression in the presence of the WT1 3’UTR. The WT1 3’UTR reporter construct 
(wild-type or mutant) was co-transfected with the pcDNA empty vector or pcDNA-miR-132 vector 
(wild-type or mutant), and a Renilla vector in HeLa cells (no endogenous WT1 expression). Renilla 
activity was used to normalize the firefly luciferase activity. To determine non-specific effects of 
miR-132 on the firefly luciferase expression, miR-132 (wild-type or mutant) was co-expressed with 
the backbone firefly luciferase reporter construct, which lacks the WT1 3’UTR. The normalized 
firefly luciferase signal in the presence of miR-132 (wild-type or mutant) is plotted relative to the 
normalized firefly luciferase signal in the presence of empty vector. Significance of differences in 
the normalized relative firefly luciferase signal in the presence of miR-132 versus miR-132-mutant 
was determined using an unpaired t-test. * indicates P-value < .01.
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regulated by miR-132. To test the predicted targeting of WT1 by miR-132, we performed 
luciferase reporter assays. The full-length 3’UTR of human WT1 gene (position 33 
–1371, downstream of WT1 CDS) was cloned downstream of the firefly luciferase gene 
(figure 3B) and co-transfected with a miR-132 expression vector or empty vector in 
HeLa cells, which do not endogenously express WT1. If the wild-type 3’UTR of WT1 
was present downstream of the firefly luciferase gene, co-transfection of miR-132 
resulted in a significant reduction of the firefly luciferase signal compared to empty 
vector (mean reduction: 33±3%, N=3; figure 3C, middle panel). 
Targeting of WT1 by miR-132 is disrupted by mutations
To show that repression of the luciferase signal was dependent on complementarity 
between the seed region and MRE, we tested whether compromising the comple-
mentarity by the mutation of three adjacent nucleotides in either the seed region or 
the MRE, could abolish the repressive effect of miR-132 on the luciferase signal. If the 
seed region of miR-132 was mutated (miR-132-mutant), repression of the firefly 
luciferase signal by miR-132 was lost (P < .01, figure 3C, middle panel). In addition, if 
the miR-132 MRE in the 3’UTR of WT1 was mutated (3’UTR WT1-mutant), repression of 
the firefly luciferase signal by miR-132 (wild-type) was lost as well (figure 3C, right 
panel). Since the seed sequence of the miR-132-mutant was fully complementary to 
the mutated miR-132 MRE in the 3’UTR of WT1, co-transfection of both mutants 
showed a similar repression of the firefly luciferase signal as observed when the 
wild-type WT1 3'UTR and miR-132 were co-transfected (mean reduction: 30±2%, N=3, 
P < .01; figure 3C). These results point out that miR-132 can directly target WT1 through 
interaction with a recognition element in the 3’UTR of WT1 and that full complemen-
tarity between the seed region of and MRE is essential for the targeting of WT1 by 
miR-132.
miR-132 downregulates WT1 protein expression in myeloid cells
To determine whether WT1 is regulated by miR-132 in myeloid cells, the effect of 
ectopic miR-132 expression on WT1 expression was studied in NB4 cells. NB4 cells, 
which endogenously express miR-132 and WT1, were transduced with miR-132 
lentivirus. Transduced cells were isolated by magnetic cell sorting (MACS), resulting in 
a purity of more than 90%. A 10-fold upregulation of miR-132 expression was observed 
in miR-132 transduced NB4 cells compared to empty vector transduced NB4 cells 
(N=3, figure 4A). Endogenous WT1 expression was not affected by overexpression of 
miR-132 at the mRNA level, as determined by quantitative RT-PCR (figure 4B). However, 
significantly lower endogeneous WT1 protein levels were detected by Western blot 
analysis in miR-132 transduced NB4 cells compared to empty vector transduced NB4 
cells (figure 4C), indicating that miR-132 functions as a translational repressor of WT1 
in myeloid cells. 
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Discussion
In the current study we show that miR-132 is differentially expressed during 
granulocytic differentiation and demonstrate a role for miR-132 in the regulation of 
WT1 protein expression in myeloid cells. Using microRNA expression profiling, we 
show that granulocytic differentiation is associated with differential expression of 
multiple microRNAs, including a significant induction of miR-132 expression, which 
has not been described so far. We confirmed previously reported induction of 
miR-29a/b, miR-107, miR-223, and miR-342.2;5;9;11;13;30 In myelopoiesis, the expression of 
various microRNAs including miR-29b, miR-34a, miR-142, and miR-223 is known to be 
driven by myeloid transcription factors such as PU.1, CEBPA, LMO2, NFI-A, and 
Figure 4  WT1 protein expression is repressed by miR-132
Effect of ectopic miR-132 expression on endogenous WT1 expression in NB4 cells. (A) Lentiviral 
transduction of miR-132 in NB4 cells (N=3) resulted in a 10-fold upregulation of miR-132 
expression compared to empty vector transduced cells. (B) WT1 mRNA expression was 
determined in miR-132 transduced and empty vector transduced NB4 cells. MiR-132 and WT1 
mRNA expression relative to GAPDH was determined and the fold-induction in miR-132 
transduced cells compared to empty vector transduced cells is shown. (C) WT1 protein 
expression in miR-132 transduced and empty vector transduced NB4 cells. β-Actin was used as 
a control for equal loading.
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MYC.2;7;11;12;17 In neuronal tissues, REST and CREB have been implicated in the transcrip-
tional control of miR-132.40;41 Transcriptional control of miR-132 in myelopoiesis has 
not been studied yet. Besides its regulatory role in neuronal tissues, CREB is a leucine 
zipper transcription factor which is known to be critical for normal myelopoiesis as 
well, suggesting that CREB might also be involved in the regulation of miR-132 
expression during myelopoiesis.42 
We identified WT1 as a novel direct target of miR-132. The WT1 gene, located at 
chromosome 11p13, encodes for a zinc-finger transcription factor which is implicated 
in both normal and malignant hematopoiesis.38;39 The expression and function of WT1 
in hematopoietic cells largely depend on their differentiation status. In normal 
hematopoiesis, WT1 is highly expressed in immature hematopoietic progenitor cells 
and downregulated during later stages of myeloid differentiation.43 Expression of 
WT1 is tightly regulated in the hematopoietic system. Aberrant WT1 expression is 
associated with disturbed hematopoietic differentiation and the development of 
hematopoietic malignancies.27 In myeloid malignancies, an oncogenic role for WT1 is 
described. In acute myeloid leukemia, somatic WT1 mutations are detected in 5%-15% 
of the patients.44 Moreover, in the fast majority of AML patients, overexpression of 
WT1 is observed.28
Strict regulation of WT1 expression is known to be essential in hematopoietic differ-
entiation. However, the mechanisms by which WT1 expression is regulated in normal 
and leukemic cells remain largely unclear. So far, the regulation of WT1 expression has 
mainly been studied at the transcriptional level. Transcription factors implicated in 
the regulation of WT1 expression include GATA1, GATA2, NFKB, SP1, PAX2, PAX8 and 
MYB.45-54 The mechanisms of post-transcriptional regulation of WT1 expression are 
largely unknown. Recently, miR-15a and miR-16-1 were shown to inhibit proliferation 
of leukemic cells by downregulation of WT1 protein levels, but both microRNAs did 
not directly target WT1 through microRNA-mRNA base pairing, indicating that WT1 is 
regulated by downstream targets of the miR-15a/16-1 cluster.55 No microRNAs have 
been identified yet that directly target WT1. In the current study we show that protein 
translation of WT1 is repressed by miR-132 via direct targeting of a specific miR-132 
recognition element located in the 3’UTR of WT1. This indicates that miR-132 functions 
as a negative regulator of WT1 protein expression.  
So far, miR-132 has mainly been involved in neuronal and immune functions.56 A role 
for miR-132 in hematopoiesis has not been reported previously. In neuronal tissue, 
miR-132 targets various genes including GATA2, EP300 and MECP2, which are known to 
be implicated in the regulation of hematopoiesis as well.31;36 In the hematopoietic 
system, GATA2 is an essential transcription factor for the regulation of myeloid lineage 
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determination and has recently been identified as a poor prognostic factor in AML.57;58 
EP300 is a transcriptional co-activator that interacts with important myeloid 
transcription factors (RUNX1 and CEBPs) and is involved in leukemia associated 
chromosomal translocations.59-62 MECP2 is a transcriptional repressor that acts as a 
co-repressor of the crucial myeloid transcription factors PU.1 and CEBPD, and thereby 
may prevent the induction of a myeloid gene expression program.63;64 Future studies 
should determine whether GATA2, EP300, and MECP2 are regulated by miR-132 in the 
hematopoietic system. The current study identified WT1 as a miR-132 target in myeloid 
cells. By targeting WT1 in myeloid cells, miR-132 may fulfill an important regulatory 
role in myelopoiesis. 
We conclude that miR-132 is a novel post-transcriptional regulator of the WT1 
oncoprotein, which functions as a crucial transcription factor in myelopoiesis. As WT1 
is frequently overexpressed in myeloid leukemias, targeting of WT1 by miR-132 might 
be an interesting therapeutic tool against WT1 expressing leukemic cells. 
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Supplemental Table S1  microRNA expression during granulocytic differentiation
microRNA t=0 t=8
ATRA (hrs)
t=24 t=48 t=96
hsa-miR-9 28.68 28.30 28.19 27.27 26.90
hsa-miR-9* 31.19 31.53 31.09 31.16 30.09
hsa-miR-10a ND ND ND ND 37.09
hsa-miR-15a 24.61 24.64 24.76 24.58 23.07
hsa-miR-15b 24.06 24.44 23.97 23.60 23.48
hsa-miR-16 21.59 21.86 21.34 20.81 20.50
hsa-miR-17-3p 28.01 28.78 29.95 28.53 28.62
hsa-miR-17-5p 22.39 22.78 22.68 23.00 24.09
hsa-miR-19a 22.25 22.28 22.69 22.00 22.89
hsa-miR-20 23.27 23.19 23.53 23.92 24.17
hsa-miR-21 25.05 25.79 25.63 25.94 23.38
hsa-miR-23a 25.73 25.51 25.54 25.23 24.42
hsa-miR-23b 28.50 28.76 28.16 27.85 27.81
hsa-miR-25 23.22 23.59 23.62 23.32 23.21
hsa-miR-26a 26.09 26.04 25.90 24.34 23.52
hsa-miR-26b 24.96 25.23 25.21 25.08 24.51
hsa-miR-27a 27.43 26.99 27.53 27.95 27.20
hsa-miR-27b 28.68 28.23 28.79 28.66 28.13
hsa-miR-28 30.66 29.84 29.77 29.70 28.24
hsa-miR-29a 24.62 25.25 24.51 24.41 23.14
hsa-miR-29b 25.58 26.22 26.09 26.23 24.49
hsa-miR-29c 24.40 24.57 23.83 24.01 23.04
hsa-miR-30a-3p 30.49 30.95 30.44 30.50 29.67
hsa-miR-30b 24.85 25.02 24.96 24.77 23.68
hsa-miR-30c 24.43 24.48 24.49 24.05 23.32
hsa-miR-30d 27.77 27.88 27.68 26.94 26.23
hsa-miR-30e 28.91 30.12 29.06 28.41 25.13
hsa-miR-31 ND ND ND ND ND
hsa-miR-34a 36.05 34.62 35.23 35.38 36.71
hsa-miR-34b ND ND ND ND ND
hsa-miR-34c ND ND ND ND ND
hsa-miR-92 20.65 21.56 20.72 21.31 22.19
hsa-miR-95 ND ND ND 37.54 34.69
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microRNA t=0 t=8
ATRA (hrs)
t=24 t=48 t=96
hsa-miR-96 30.31 32.02 32.02 32.65 33.27
hsa-miR-98 29.68 29.92 29.56 28.82 27.63
hsa-miR-99a 31.51 31.02 30.10 28.47 28.09
hsa-miR-100 33.20 32.14 30.68 29.51 27.41
hsa-miR-103 23.92 23.92 23.41 23.46 21.89
hsa-miR-104 37.48 38.82 ND 39.10 38.61
hsa-miR-105 36.08 39.78 ND 37.99 38.84
hsa-miR-106a 23.59 24.07 23.23 23.83 24.08
hsa-miR-107 29.54 31.80 28.68 29.83 27.12
hsa-miR-122a ND ND ND ND ND
hsa-miR-124a 28.58 29.06 27.97 27.01 25.64
hsa-miR-124b 31.73 31.12 30.35 30.33 28.67
hsa-miR-125a 30.72 30.19 30.01 30.26 28.30
hsa-miR-125b 32.90 31.84 31.13 29.65 28.45
hsa-miR-126 ND ND ND 36.83 36.58
hsa-miR-127 38.35 37.72 38.74 39.62 38.69
hsa-miR-128a 30.97 31.25 30.86 31.86 30.53
hsa-miR-128b 32.57 32.80 32.65 33.37 32.29
hsa-miR-129 30.70 31.07 30.56 30.20 29.50
hsa-miR-130a 33.49 33.43 33.23 34.27 34.42
hsa-miR-130b 25.37 25.69 25.78 25.79 25.53
hsa-miR-132 32.53 31.23 29.26 27.30 23.91
hsa-miR-133a 36.24 36.06 34.52 34.74 36.42
hsa-miR-133b 37.55 33.50 34.84 36.16 35.38
hsa-miR-134 35.07 36.15 36.18 36.20 38.94
hsa-miR-135a 36.54 33.05 32.55 32.47 30.24
hsa-miR-135b ND ND ND ND ND
hsa-miR-137 37.67 ND ND ND 38.08
hsa-miR-138 ND ND 38.37 39.21 37.70
hsa-miR-139 35.17 35.31 34.05 35.13 34.52
hsa-miR-140 26.07 26.35 25.48 25.57 24.62
hsa-miR-141 34.02 33.55 32.59 32.35 31.19
hsa-miR-142-3p 21.11 21.10 22.25 21.25 21.07
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microRNA t=0 t=8
ATRA (hrs)
t=24 t=48 t=96
hsa-miR-142-5p 25.50 25.89 25.01 26.92 25.08
hsa-miR-144 37.57 ND ND 37.27 38.73
hsa-miR-145 29.56 28.09 27.97 27.26 27.19
hsa-miR-146 26.81 27.17 27.43 26.03 23.09
hsa-miR-147 35.73 38.11 37.53 37.54 39.32
hsa-miR-148a 27.01 31.12 27.01 29.14 26.53
hsa-miR-149 ND ND ND ND ND
hsa-miR-150 33.38 32.60 31.93 33.28 33.73
hsa-miR-151 ND ND ND ND ND
hsa-miR-152 34.18 34.20 32.85 32.53 31.46
hsa-miR-154 ND ND ND ND ND
hsa-miR-154* ND ND ND ND ND
hsa-miR-155 27.37 27.72 28.19 29.39 28.80
hsa-miR-181a 25.06 24.38 24.43 24.17 23.50
hsa-miR-181b 24.39 25.43 25.01 24.29 24.48
hsa-miR-181c 29.50 30.48 30.21 30.30 29.36
hsa-miR-182 28.51 28.45 29.11 29.93 30.16
hsa-miR-182* 35.51 36.10 35.12 36.11 36.69
hsa-miR-183 32.13 33.44 34.02 33.40 33.19
hsa-miR-184 37.66 ND ND 35.94 ND
hsa-miR-185 31.85 30.87 31.34 31.12 29.67
hsa-miR-186 27.75 26.67 27.14 26.19 26.58
hsa-miR-187 38.78 36.20 34.45 36.71 33.03
hsa-miR-189 35.88 ND 38.38 35.98 36.13
hsa-miR-190 36.65 35.68 36.84 35.43 35.01
hsa-miR-191 23.13 23.19 22.60 22.49 21.97
hsa-miR-193 29.18 30.37 30.37 30.89 30.23
hsa-miR-194 31.36 30.41 29.08 28.14 27.76
hsa-miR-195 26.84 27.35 27.50 27.28 26.24
hsa-miR-197 27.98 27.39 27.39 26.69 26.26
hsa-miR-198 ND ND ND ND ND
hsa-miR-199a 35.65 35.48 35.72 36.35 36.39
hsa-miR-199a* 26.02 26.26 26.09 25.81 25.84
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microRNA t=0 t=8
ATRA (hrs)
t=24 t=48 t=96
hsa-miR-199b 26.41 26.99 27.18 27.05 27.15
hsa-miR-199-s 32.90 33.44 32.17 32.39 32.35
hsa-miR-200a ND 36.90 37.00 35.25 35.88
hsa-miR-200b ND ND 39.00 35.84 35.16
hsa-miR-200c 32.13 31.66 31.23 31.04 30.61
hsa-miR-203 ND ND 37.34 ND 36.09
hsa-miR-204 26.75 26.80 27.39 27.23 27.59
hsa-miR-205 ND ND ND ND ND
hsa-miR-210 29.54 29.53 29.83 28.45 25.92
hsa-miR-211 ND ND ND ND ND
hsa-miR-213 28.65 28.86 28.79 28.55 28.23
hsa-miR-214 32.49 32.67 33.03 33.23 32.19
hsa-miR-215 32.40 33.00 32.64 31.43 29.92
hsa-miR-216 38.09 39.43 ND ND 38.04
hsa-miR-218 37.08 38.16 38.44 35.47 31.78
hsa-miR-219 36.72 36.40 40.00 36.53 35.33
hsa-miR-220 ND ND ND ND ND
hsa-miR-221 24.26 25.19 23.97 23.29 23.36
hsa-miR-222 24.39 24.58 24.23 23.44 23.35
hsa-miR-223 22.42 22.54 20.90 19.78 19.02
hsa-miR-224 ND ND ND ND ND
hsa-miR-296 34.96 ND 35.43 33.81 33.94
hsa-miR-299 ND ND ND ND ND
hsa-miR-301 26.61 26.34 25.63 24.97 24.24
hsa-miR-302a ND ND ND ND ND
hsa-miR-302b ND ND ND ND ND
hsa-miR-302b* ND ND ND ND ND
hsa-miR-302c ND ND ND ND ND
hsa-miR-302c* ND ND ND ND ND
hsa-miR-302d ND ND ND ND ND
hsa-miR-320 25.18 25.52 25.37 24.51 24.36
hsa-miR-323 ND ND ND ND ND
hsa-miR-324-5p 27.77 27.42 27.12 26.84 26.01
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microRNA t=0 t=8
ATRA (hrs)
t=24 t=48 t=96
hsa-miR-325 37.18 38.13 39.04 38.02 37.01
hsa-miR-326 33.01 32.00 31.64 30.76 29.66
hsa-miR-328 30.72 30.34 29.55 28.57 27.40
hsa-miR-330 32.12 32.66 32.32 32.37 31.44
hsa-miR-331 27.58 27.27 26.61 26.78 25.83
hsa-miR-335 28.22 28.49 28.29 28.11 28.19
hsa-miR-337 ND ND ND ND ND
hsa-miR-338 37.37 38.07 37.39 35.24 34.39
hsa-miR-339 25.37 25.68 26.03 24.92 25.24
hsa-miR-340 32.07 32.49 32.94 33.08 31.13
hsa-miR-342 26.08 26.06 25.22 24.75 23.16
hsa-miR-367 ND ND ND ND ND
hsa-miR-368 ND ND ND ND ND
hsa-miR-370 ND ND ND ND ND
hsa-miR-371 ND ND ND ND ND
hsa-miR-372 ND ND ND ND ND
hsa-miR-373 36.64 37.52 38.22 39.84 35.94
hsa-miR-373* ND ND ND ND ND
hsa-miR-374 27.78 27.37 27.74 27.56 25.94
hsa-let-7a 24.61 24.62 24.77 23.93 23.65
hsa-let-7b 28.19 27.99 28.61 27.90 27.67
hsa-let-7d 25.14 25.03 25.30 25.13 24.20
hsa-let-7e 34.54 34.97 34.29 35.01 32.75
hsa-let-7g 25.86 26.22 25.62 25.39 24.28
hsa-let-7i 29.54 30.07 29.16 28.11 26.63
The expression of 157 mature microRNAs was determined during ATRA-induced granulocytic 
differentiation in the acute promyelocytic leukemia (APL) cell line NB4, using stem-loop RT-PCR 
Taqman® microRNA assays, designed to specifically quantify mature microRNAs. ATRA-induced 
differentiation of NB4 cells was used as a model system for granulocytic differentiation. NB4 
cells were cultured in the presence of ATRA (10-6M) for 96 hours. Cycle threshold values (Ct) are 
shown. Significant expression of a microRNA was defined as Ct value ≤ 35. ATRA = all-trans 
retinoic acid. ND = not detectable.
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Abstract
MicroRNAs are implicated in hematopoiesis by targeting genes involved in differen-
tiation, proliferation, and cell cycle regulation. We showed that miR-132 is highly 
upregulated during granulocytic differentiation. To determine whether miR-132 
targets genes implicated in myelopoiesis, we performed computational target 
prediction and identified the hematopoietic transcription factor GATA binding protein 
2 (GATA2) as a putative target of miR-132. GATA2 plays a crucial role in normal and 
malignant hematopoiesis. In the 3’UTR of GATA2 a conserved microRNA recognition 
element for miR-132 is present. Luciferase reporter assays have been performed to 
validate the putative targeting of GATA2 by miR-132. Co-expression of miR-132 with a 
luciferase construct containing the 3’UTR of GATA2 resulted in downregulation of the 
luciferase levels. Repression of the luciferase signal by miR-132 was lost if full comple-
mentarity between the seed region of miR-132 and the 3’UTR of GATA2 was disrupted 
by mutations. We conclude that the 3’UTR of the hematopoietic transcription factor 
GATA2 is targeted by miR-132. Induction of miR-132 expression during granulocytic 
differentiation, may contribute to the regulation of GATA2 expression in myelopoiesis.
.
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Introduction
The GATA binding protein-2 (GATA2) gene encodes for a zinc-finger transcription 
factor which is broadly expressed in the hematopoietic system.1;2 The expression and 
function of GATA2 in hematopoietic cells largely depends on their differentiation 
status. GATA2 expression is particularly high in hematopoietic stem and progenitor 
cells as well as in early erythroid cells, megakaryocytes, and mast cells.3-7 In GATA2 
knock-out mice, profound defects in definitive hematopoiesis have been observed, 
resulting in embryonic lethality at day 10-11 of gestation due to a pan-hematopoietic 
deficit.8 In hematopoietic stem and progenitor cells, GATA2 is an important regulator 
of proliferation, differentiation and survival. In addition, GATA2 acts as a regulator of 
stem cell quiescence.1;9-13 GATA2 is also implicated in the regulation of myeloid lineage 
determination. GATA2 blocks terminal erythroid, monocytic and granulocytic differ-
entiation, while it promotes erythroblast proliferation, megakaryopoiesis and mast 
cell formation.13-16 In myeloid progenitors, knockdown of GATA2 results in significant 
upregulation of the crucial myeloid transcription factors PU.1 and C/EBPα, which 
allows terminal granulocytic and monocytic differentiation to proceed.13-15 Enforced 
expression of GATA2 in myeloid progenitors induces downregulation PU.1 and C/
EBPα, which prevents the induction of a myeloid gene expression program by 
inhibiting the ability of PU.1 to transactivate critical myeloid target genes.11;15;17-19 
Aberrant GATA2 expression is associated with disturbed hematopoietic differentiation 
and the development of hematopoietic malignancies.20;21 In acute myeloid leukemia 
(AML), high GATA2 expression has recently been identified as a poor prognostic 
factor.20;21 In addition, GATA2 mutations have been detected in AML.20;22-24
In the hematopoietic system, the expression of GATA2 is tightly regulated by several 
transcription factors such as GATA1, NOTCH1, PU.1, EVI1, BMP4 and ETS1.1 Moreover, GATA2 
can enhance its own transcription by binding its promoter.1;25 The activity of GATA2 
is also modulated by post-translational modifications including phosphorylation, 
acetylation, sumoylation, and ubiquitination.1 MicroRNAs have recently been implicated 
in the regulation of GATA2 expression.26-29 We showed that the expression of miR-132 is 
highly upregulated during granulocytic differentiation and demonstrate that the 3’UTR 
of GATA2 is targeted by miR-132, indicating that GATA2 is a direct  target of miR-132. 
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Material and methods
Cell culture
HeLa cells were cultured in Dulbecco’s modified Eagle medium (DMEM; Invitrogen, 
Paisley, UK), supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS; 
Invitrogen) and 1% Penicillin/Streptomycin (MP Biomedicals, Illkirch Cedex, France). 
Cultures were incubated at 37 0C in a 5% CO2 completely humified atmosphere. 
Plasmids
The pre-miR-132 sequence (101 base pairs (bp)) with 250-300 bp flanking sequences 
on either side (total fragment of 669 bp), which are required for the transcription and 
processing of the pre-miRNA into a functional mature microRNA, was amplified from 
human genomic DNA as previously described.30 This fragment was subcloned into 
the pcDNA3.1 vector (Invitrogen), using Apa I digestion (New England Biolabs). 
Mutations of three adjacent nucleotides in the seed sequence of miR-132 were 
introduced with the QuickChangeXL kit (Promega, Madison, WI, USA), according to 
manufacturer’s protocol. The full-length GATA2 3’UTR (position 282 to 1847, 
downstream of GATA2 coding sequence (CDS)) was amplified from human genomic 
DNA and subcloned into the PGL3-control vector (Promega) downstream of the firefly 
luciferase reporter gene, using Xba I (New England Biolabs). The miR-132 recognition 
element (MRE) in the GATA2 3’UTR is located near its 3’ end (position 1561-1566 
downstream of GATA2 CDS). Mutation of three adjacent nucleotides in the miR-132 
MRE and the 3’UTR of GATA2 were introduced using the QuickChangeXL kit (Promega), 
according to manufacturer’s protocol.
Luciferase reporter assay
The GATA2 3’UTR reporter construct (wild-type or mutated) was co-transfected with 
the pcDNA empty vector or pcDNA-miR-132 vector (wild-type or mutated) and a 
Renilla vector (pRL-CMV, Promega) in HeLa cells using PEI (Polysciences). To determine 
non-specific effects of miR-132 on the firefly luciferase expression, we co-transfected 
miR-132 (wild-type or mutant) with the backbone firefly luciferase construct 
PGL3-control, which lacks the 3’UTR of GATA2. Cells were harvested 48 hours after 
transfection using 100 µl Passive Lysis Buffer (Promega). Firefly luciferase and Renilla 
luciferase activities were measured consecutively on a luminometer (Lumat LB 9507, 
Perkin-Elmer/Applied Biosystems, CA, USA) using the Dual-Luciferase Reporter Assay 
System (Promega), according the manufacturer's protocol. Renilla activity was used to 
normalize the firefly luciferase activity. Firefly luciferase signal in the presence of 
miR-132 (wild-type or mutant) are presented relative to  the firefly luciferase signal in 
the presence of empty vector. 
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Results
miR-132 directly targets GATA2 messenger RNA
We showed that miR-132 is highly upregulated during granulocytic differentiation in 
myeloid cell-line models as well as in primary myeloid cells.30 To determine whether 
miR-132 targets genes implicated in myelopoiesis, we performed computational 
target prediction. We used four microRNA target prediction programs (DIANA-microT, 
miRanda, PicTar, TargetScanS) and selected genes that were predicted to be targeted 
by miR-132 according to at least two prediction programs. Within this selection, 
several miR-132 target genes were present that have previously been validated in 
neuronal, immunological and hematopoietic systems (e.g. WT1, EP300, MECP2, BTG2, 
PAIP2A, SIRT1, ACHE and HBEGF).26;30-36 We identified GATA2 as a novel putative miR-132 
target. In the 3’UTR of GATA2 an evolutionary conserved potential miR-132 recognition 
element (MRE) is present which is fully complementary to the seed region of miR-132, 
defined as the 2nd to 7th nucleotides from the 5’end of a mature microRNA (figure 1A). 
Complementarity between the target messenger RNA (mRNA) and the seed region of 
a microRNA is known to be essential for the recognition of target genes. To validate 
the putative targeting of GATA2 by miR-132, luciferase reporter assays have been 
performed. The full-length 3’UTR of human GATA2 gene (position 282 to 1847, 
downstream of the GATA2 CDS) was cloned downstream of the firefly luciferase gene 
(figure 1B) and co-transfected with a miR-132 expression vector or empty vector in 
HeLa cells. If the wild-type 3’UTR of GATA2 was present downstream of the firefly 
luciferase gene, co-transfection of miR-132 resulted in a reduction of the firefly 
luciferase signal compared to empty vector (mean reduction: 16±11%, N=4; figure 1C, 
middle panel). 
Targeting of the 3’UTR of GATA2 by miR-132 is disrupted by mutations
To show that repression of the luciferase signal was dependent on complementarity 
between the seed region and MRE sequence, we tested whether mutations of three 
adjacent nucleotides in either sequences, could abolish the repressive effect of 
miR-132 on the luciferase signal (figure 1B). If the seed region of miR-132 was mutated 
(miR-132-mutant), repression of the firefly luciferase signal by miR-132 was lost (figure 
1C, middle panel). In addition, if the miR-132 MRE in the 3’UTR of GATA2 was mutated 
(3’UTR GATA2-mutant), repression of the firefly luciferase signal by miR-132 (wild-type) 
was lost as well (figure 1C, right panel). The seed sequence of the miR-132-mutant was 
fully complementary to the mutated miR-132 MRE in the 3’UTR of GATA2 (figure 1B). 
Co-transfection of both mutants also resulted in repression of the firefly luciferase 
signal (mean reduction: 36±14%, N=3; figure 1C, right panel). These results point out 
that miR-132 targets the 3’UTR of GATA2 and that full complementarity between the 
seed region and MRE is essential for targeting of the 3’UTR of GATA2 by miR-132.
3
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Figure 1  miR-132 targets the 3’UTR of GATA2
(A) Alignment of human (hsa-)miR-132 with the 3’UTR of GATA2. Complementary nucleotides are 
marked bold. The predicted miR-132 recognition element (MRE) is fully complementary to the 
seed region (SEED) of miR-132, consisting of the 2nd to 7th position at the 5’ end of miR-132 (both 
underlined). (B) Schematic representation of the luciferase reporter construct containing the 
full-length 3’UTR of GATA2 including the predicted miR-132 MRE. Reciprocal mutations were 
created in the putative miR-132 MRE in the 3’UTR of GATA2 (3’UTR GATA2-mutant) or in the seed 
sequence of miR-132 (miR-132-mutant). Mutated nucleotides are marked gray. Complementarity 
between MRE (wild-type or mutant) and seed region (wild-type or mutant) is depicted. (C) Effect 
of miR-132 on firefly luciferase expression in the presence of the GATA2 3’UTR. The GATA2 3’UTR 
reporter construct (wild-type or mutant) was co-transfected with the pcDNA empty vector or 
pcDNA-miR-132 vector (wild-type or mutant), and a Renilla vector in HeLa cells. Renilla activity 
was used to normalize the firefly luciferase activity. To determine non-specific effects of miR-132 
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Discussion
In the current study we demonstrate that the hematopoietic transcription factor 
GATA2 is targeted by miR-132 via a specific miR-132 recognition element located in the 
3’UTR of GATA2, suggesting that miR-132 may negatively regulate GATA2 expression. 
GATA2 plays an important role in the regulation of normal and malignant hematopoiesis. 
In normal hematopoiesis, GATA2 is essential for controlling proliferation and differentiation 
of hematopoietic cells. Aberrant GATA2 expression is associated with disturbed 
hematopoietic differentiation and the development of hematopoieticmalignan-
cies.20;21 The expression of GATA2 is tightly regulated by several transcription factors 
and post-translational modifications.1 MicroRNAs have recently been implicated in 
the regulation of GATA2 expression.26-29 Targeting of GATA2 by miR-24 and miR-200b is 
involved in angiogenesis27;29, whereas targeting of GATA2 by miR-451 was shown to 
play a crucial role in erythroid maturation.28 During the preparation of this manuscript, 
Miller et al. described dysregulation of miR-132 in prefrontal cortical tissue from 
schizophrenic patients.26 They showed that miR-132 directly targets GATA2 in neuro-
development, confirming our results. 
So far, miR-132 has been implicated in neuronal and immune functions.37 A role for 
miR-132 in hematopoiesis was suggested by our previous findings that miR-132 
functions as a translational repressor of the hematopoietic transcription factor Wilms’ 
Tumor 1 (WT1) in myeloid cells.30 Previously identified miR-132 targets in non-hemato-
poietic tissues include genes that are also implicated in the regulation of myelopoieis 
such as MECP2 and EP300.26;31-36 MECP2 is a transcriptional repressor that acts as a 
co-repressor of the crucial myeloid transcription factors PU.1 and CEBPD, and thereby 
may prevent the induction of a myeloid gene expression program.38;39 EP300 is a 
 transcriptional co-activator that interacts with important myeloid transcription 
factors (RUNX1 and CEBPs) and is involved in leukemia associated chromosomal 
translocations.40-43 By targeting multiple myeloid transcriptional regulators including 
WT1 and GATA2, miR-132 may fulfill an important regulatory role in myelopoiesis 
which should be studied in more detail.
3
on the firefly luciferase expression, miR-132 (wild-type or mutant) was co-expressed with the 
backbone firefly luciferase reporter construct, which lacks the GATA2 3’UTR. The normalized firefly 
luciferase signal in the presence of miR-132 (wild-type or mutant) is plotted relative to the 
normalized firefly luciferase signal in the presence of empty vector. 
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Abstract
In acute myeloid leukemia (AML), aberrant expression and mutations of transcription 
factors have been correlated with disease outcome. In the present study, we 
performed expression and mutation screening of GATA2, which is an essential 
transcription factor for regulation of myeloid lineage determination, in de novo 
pediatric AML patients. GATA2 mutations were detected in 5 of 230 patients, 
representing a frequency of 2.2% overall, and 9.8% in cytogenetically normal AML. 
GATA2 expression analysis demonstrated that in 155 of 237 diagnostic samples (65%), 
GATA2 expression was higher than in normal bone marrow. In complete remission, 
normalization of GATA2 expression was observed, whereas GATA2 expression levels 
stayed high in patients with resistant disease. High GATA2 expression at diagnosis was 
an independent poor prognostic factor for overall survival (hazard ratio [HR] = 1.7, P = 
.045), event-free survival (HR = 2.1, P = .002), and disease-free survival (HR = 2.3, P = 
.004). The prognostic impact of GATA2 was particularly evident in specific AML 
subgroups. In patients with French-American-British M5 morphology, inv(16), or high 
WT1 expression, significant differences in survival were observed between patients 
with high versus normal GATA2 expression. We conclude that high GATA2 expression 
is a novel marker for poor prognosis in pediatric AML, which may contribute to better 
risk-group stratification and risk-adapted therapy in the future. 
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Introduction
Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease 
that accounts for 15%-20% of childhood leukemia. Over the past decades, the 
prognosis for children with AML has improved considerably as a result of better 
(risk-adapted) therapeutic strategies. Nowadays approximately 60%-70% of the 
pediatric AML patients experience long-term survival.1;2 Current risk-group classification is 
based mainly on cytogenetic aberrations and response to induction chemotherapy.1 In 
addition, several molecular aberrations (acquired gene mutations and altered gene 
expression) that are correlated with clinical outcome have been identified in pediatric 
and adult AML. For various molecular aberrations, differences have been observed in 
the prevalence and prognostic significance between pediatric and adult AML.1;3;4 For 
the assessment of treatment response and early detection of relapse, monitoring of 
minimal residual disease (MRD) is important.5;6 Specific gene rearrangements and 
mutations can be used for MRD monitoring, but suitable MRD markers are lacking in 
the majority of AML patients.6
Genes that have been implicated in leukemogenesis are usually involved in the 
regulation of cellular survival, proliferation and hematopoietic differentiation.7 These 
processes are tightly regulated by various transcription factors. The GATA-binding 
protein 2 (GATA2) gene, located at chromosome 3q21, encodes for a zinc-finger 
transcription factor that plays an essential role during development and differentiation 
of hematopoietic cells. GATA2 knockout mice have profound defects in definitive 
hematopoiesis resulting in embryonic lethality at day 10-11 of gestation due to a 
 pan-hematopoietic deficit.8 The expression and function of GATA2 in hematopoietic 
cells depends largely on their differentiation status and is tightly regulated. GATA2 is 
expressed broadly in hematopoietic cells, with particularly high expression in 
hematopoietic stem and progenitor cells and early erythroid cells, megakaryocytic 
cells, and mast cells.9-14 In hematopoietic stem and progenitor cells, GATA2 functions 
as an important regulator of proliferation, differentiation and survival and acts as a 
regulator of stem cell quiescence.15-19 During myeloid differentiation, GATA2 plays an 
important role in the regulation of lineage determination. GATA2 blocks terminal 
erythroid, monocytic and granulocytic differentiation, and also promotes erythroblast 
proliferation, megakaryopoiesis and mast cell formation.19-22 Tight regulation of GATA2 
expression is essential in the process of myeloid lineage determination. Enforced 
expression of GATA2 in myeloid progenitors induces down-regulation of the crucial 
myeloid transcription factors PU.1 and CEBPA, which are implicated in terminal 
granulocytic and monocytic differentiation.17;21;23;24 Moreover, GATA2 inhibits the 
ability of PU.1 to transactivate critical myeloid target genes and thereby prevents the 
induction of a myeloid gene expression program.25 Conversely, knockdown of GATA2 
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in myeloid progenitors results in significant up-regulation of the expression of PU.1 
and CEBPA,20;21 which allows terminal granulocytic and monocytic differentiation to 
proceed.19 
In sporadic and familial myeloid malignancies, acquired and inherited mutations in 
the highly conserved zinc-finger domains of the GATA2 gene have been described 
recently (figure 1).14;26-35 These two zinc fingers play an essential role in DNA-binding 
and protein-protein interactions of GATA2 with target genes. During blast crisis in 
chronic myeloid leukemia (CML), two acquired GATA2 mutations were found in 9 of 85 
(10%) patients.27 In adult monocytic AML (French-American-British M5 [FAB-M5]), 
three acquired GATA2 mutations were detected in 4 of 112 (3.6%) patients.26 In three 
other adult AML cohorts (N=50, N=225, and N=268), no acquired mutations in the 
GATA2 coding sequence were found.14;28;29 So far, GATA2 mutations have not been 
reported in pediatric AML. In the present study, we investigated the relevance and 
prognostic value of GATA2 expression and mutations in a large cohort of pediatric 
AML patients.
Methods
Patient samples
Viable frozen bone marrow (BM) or peripheral blood (PB) samples taken at diagnosis 
from 261 children with de novo AML were provided by the Dutch Childhood Oncology 
Group (DCOG; The Hague, The Netherlands), the AML-Berlin-Frankfurt-Münster (BFM) 
Study Group (Hannover, Germany, and Prague, Czech Republic), and the Saint-Louis 
Hôpital (Paris, France). As controls, 18 BM samples form healthy donors and 62 BM 
samples from patients with AML (N=42) or acute lymphoblastic leukemia (N=20) in 
long-term complete remission (CR) were included. For a subgroup of 38 patients, 
follow up BM samples were provided by the DCOG on the basis of available material 
for MRD analysis, including ten paired diagnostic-relapse samples. The majority of the 
processed diagnosis samples (248 of 261) contained more than 80% leukemic cells, as 
assessed morphologically on May-Grünwald-Giemsa-stained cytospin slides. 
Mononuclear cells were isolated from BM or PB and contaminating nonleukemic cells 
were eliminated as described previously.36 Genomic DNA and total cellular RNA were 
extracted from at least 5 X 106 leukemic cells using TRIzol reagent (Invitrogen), 
RNA-Bee (Iso-Tex Diagnostics), or the GeneElute Mammalian Total RNA isolation kit 
(Sigma-Aldrich). Informed consent was obtained after Institutional Review Board 
approval according to local laws and regulations and in accordance with the 
Declaration of Helsinki. Each national study group performed central review of the 
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morphologic classification according to the FAB classification system, cytogenetic 
classification, and clinical follow-up. 
Survival analysis was restricted to a subset of 205 pediatric AML patients who were 
treated according to the BFM and Dutch pediatric AML protocols (studies AML-BFM 
98, AML-BFM 04, DCOG-BFM 87, DCOG 92/94 and DCOG 97). The median follow up 
time for survivors was 4.6 years (range 0.4-22.7 years). In the total cohort, 4-year 
probability for overall survival (pOS; time between diagnosis and death from any 
cause) was 60% ± 4%, probability for event-free survival (pEFS; time between diagnosis 
and first event) was 41% ± 4%, and probability for disease-free survival (pDFS; time 
between achieving CR and relapse) was 53% ± 4%. 
Cytogenetic and molecular analysis
Leukemic samples were routinely investigated for cytogenetic aberrations using standard 
chromosome banding analysis by the national study groups. Leukemic samples were 
further analyzed for recurrent nonrandom genetic aberrations characteristic of AML 
as described by the World Health Organization classification of myeloid neoplasms 
and acute leukemia 2008,37 including t(15;17)(q22;q21), inv(16)(p13;q22), t(8;21)(q22;q22), 
and 11q23 translocations, using fluorescent in situ hybridization (FISH) and/or reverse 
transcription polymerase chain reaction (RT-PCR). 11q23 translocations were confirmed 
by RT-PCR or long-distance inverse PCR.38 
Detection of molecular aberrations included mutation analysis of WT1, NPM1, CEBPA, 
FLT3-ITD, NRAS, KRAS, PTPN11, KIT and MLL-PTD as described previously.4 If positive for 
MLL-PTD, this was confirmed by a multiplex ligation-dependent probe amplification 
(MLPA) analysis.39 High expression of EVI1 was established previously by gene-expres-
sion profiling and real-time quantitative PCR.40 
Sequence analysis of GATA2
Sequence analysis of GATA2 was performed in 230 de novo pediatric AML patients 
with more than 80% blasts in their bone marrow and for whom genomic DNA was 
available. Because all acquired GATA2 mutations in myeloid malignancies so far were 
present within the DNA-binding zinc-finger domains encoded by exon 4, 5 and 6 
(Figure 1), we performed Sanger sequencing of the coding region of these exons and 
their associated splice sites. Genomic DNA was PCR amplified and direct sequencing 
of the purified PCR products was performed unidirectionally using the described 
primers (Supplemental Table S1). The sequence data were analyzed using Variant 
Reporter (Applied Biosystems). Mutations were confirmed by an independent 
amplification of the fragment and direct sequencing of both strands. 
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Microarray-based gene-expression profiling 
Gene-expression profiling data (Affymetrix HGU133 Plus 2.0 microarray) were available 
from 237 patients.41 The data files are available in the Gene Expression Omnibus 
Repository (accession number GSE17855). Probeset intensities were normalized using 
the variance stabilization normalization (VSN) procedure (Bioconductor Package 
‘VSN’). Details regarding RNA quality, microarray processing, data acquisition, and 
data normalization have been described previously.41 
Three probe sets on the Affymetrix Human Genome U133 Plus 2.0 Array were 
annotated to the GATA2 gene (209710_at , 210358_x_at, and 207954_at). All probesets 
are located within the 3’ untranslated region of exon 6 in regions common for all 
isoforms of GATA2. VSN-normalized expression values of GATA2 obtained by microarray 
were validated with real-time quantitative PCR in a subset of patients (N=44). 
VSN-normalized expression values of probeset 209710_at showed a good correlation 
with GATA2 expression values obtained by real-time quantitative PCR (Spearman 
correlation coefficient = 0.73, P < .00001) which enabled us to define a conversion 
factor (VSN-normalized expression = 1222.3*Q-PCR expression0.2955). GATA2 expression 
was considered to be high when the expression was two standard deviations (SDs) 
above median GATA2 expression obtained in normal BM as determined by microarray 
(N=6) or real-time quantitative PCR (N=74). Real-time quantitative GATA2 expression 
values obtained in normal BM were converted into VSN-normalized expression values 
using the conversion factor described in this section. The cutoff value for high GATA2 
expression was determined to be 320 arbitrary units (AU). 
Expression of WT1 was analyzed using VSN-normalized expression values of probeset 
206067_s_at on the Affymetrix Human Genome U133 Plus 2.0 Array, which is 
annotated to the WT1 gene. Previously, we showed a good correlation with WT1 
expression values obtained by real-time quantitative PCR.42 In the present study, we 
could define a conversion factor (VSN-normalized expression = 523.86*Q-PCR 
expression0.1613). WT1 expression was considered to be high when the expression was 
two SDs above the median WT1 expression obtained in normal BM as determined by 
microarray (N=6) or real-time quantitative PCR (N=69). Real-time quantitative WT1 
expression values were converted into VSN-normalized expression values using the 
conversion factor described in this section. The cutoff value for high WT1 expression 
was determined to be 143 AU.
Real-time quantitative PCR
For quantification of GATA2 expression, a TaqMan® Gene Expression Assay (Hs_00231119_
m1, Applied Biosystems) was used. For quantification of WT1 expression, we used the 
European LeukemiaNet (ELN) WT1 assay that was developed previously in our 
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laboratory43 and was recently evaluated in normal control and AML patient samples 
by the ELN.44 For quantification of EVI1 expression we used a forward primer (5’-GGT-
CAACAAACCAATTTAGACAGACA-3’), reverse primer (5’-TTCAGAATGAGGCGACGAT-
GT-3’), and probe (5’-ATGGGAACATGTCCGGTAC-3’). For quantification of the AML1-ETO 
fusion-gene expression we used a forward primer (5’-CCACAGAGCCATCAAAATCA-
CA-3’), reverse primer (5’CAGCCTAGATTGCGTCTTCACAT-3’), and probe (5’-TGAGA-
AGCACTCCACAAT-3’). As a reference gene we used GAPDH (premixed assay 4326317E, 
Applied Biosystems) or PBGD (forward primer: 5’-GCGGAGCCATGTCTGGTAA-3’; reverse 
primer: 5’-GGGTACCCAACGCGAATCAC-3’; probe: 5’-CTCATCTTTGGGCTGTTTTCTTCC-
GCC-3’). Samples were considered eligible for testing only when the threshold cycle 
value (Ct) of the reference gene GAPDH was lower than 26. Quantitative PCR reactions 
contained 2.5-5.0 µl cDNA (10 ng/µl), 1.25 µl premixed assay, or 0.75 µl forward primer 
(10 pmol/µl), 0.75 µl reverse primer (10 pmol/µl), and 0.35-0.5 µl probe (10 pmol/µl). 
The 25 µl reactions were incubated in a 96-well plate for 2 minutes at 50 0C, 10 minutes 
at 95 0C, followed by 45 cycles of 15 seconds at 95 0C, and 1 minute at 60 0C. Quantitative 
PCR reactions were performed on the ABI/PRISM 7900 Sequence Detection system. 
Statistical methods and Analysis
To compare categorical variables, c2 analysis and Fisher exact test for small patients 
numbers were used. The nonparametric Mann-Whitney U test was applied for continuous 
variables. Correlations between continuous variables were calculated using Spearman 
correlation coefficient. 
Analysis of the FAB-subgroup AML-M3 was restricted to patients harboring a 
translocation t(15;17)(q22;q21). Patients with rare recurrent cytogenetic aberrations, 
such as t(7;12)(q36;p16), t(6;9)(p23;q34), t(16;21)(p11;q22), t(8;16)(p11;p13), monosomy 7, 
trisomy 8, and complex karyotype, were classified as one cytogenetic subgroup 
entitled “rare cytogenetics”. 
To assess outcome, the following parameters were used: CR-rate, resistant disease 
(RD; defined as failure to achieve complete remission after ≤ 2 cycles of chemotherapy, 
excluding patients with early death), pOS (defined as time between diagnosis and 
death from any cause), pEFS (defined as time between diagnosis and first event, 
including relapse, death by any cause, second malignancy, or failure to achieve 
complete remission after ≤ 2 cycles of chemotherapy (included as an event on day 0)), 
and pDFS (defined as time between achieving CR and relapse; only patients who 
achieved CR were included). pOS, pEFS and pDFS were estimated by the Kaplan-Meier 
method and compared using log-rank test. Two different analyses were performed 
according to the selected population: on the overall population and on the different 
morphological, cytogenetic and molecular subgroups. The independence of prognostic 
4
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factors was examined by multivariate Cox regression analysis, including in pediatric 
AML-established prognostic factors such as age, WBC count at diagnosis, favorable 
karyotype, NPM1 mutation,  biallelic CEBPA mutation (CEBPA-DM (double mutation)), 
and FLT3-ITD.45 Age and WBC count were included as continuous variables. Favorable 
karyotypes was defined as patients harboring t(15;17)(q22;q21), inv(16)(p13;q22), or 
t(8;21)(q22;q22). The results of univariate Cox regression analysis of the established 
prognostic factors are included in Supplemental Table S4. P < .05 was considered 
statistically significant (2-tailed testing). All analysis were performed with SPSS  16.0 or 
18.0 software.
Results
Genomic variations in the zinc-finger domains of the GATA2 gene 
Sequence analysis of GATA2 was performed in 230 de novo pediatric AML patient 
samples. In nine patients a synonymous alteration (conversion of GCG to GCA) was 
observed within codon 411 of the coding sequence of exon 6, which is a known 
polymorphism (dbSNP release 132). A novel synonymous alteration was observed in 
codon 471 of exon 6 (Supplemental Table S2). Nonsynonymous GATA2 variations were 
found in 5 of 230 (2.2%) pediatric AML patients (Table 1 and Figure 1B). No correlation 
was observed between the presence of these variations and the expression levels of 
GATA2. The sequence abnormalities included four distinct heterozygous missense variants 
and one heterozygous single nucleotide deletion. In one patient, a heterozygous 
missense variant was detected in exon 4 leading to a A318V substitution. Neither this 
variant nor the affected codon has been described previously. The other three 
heterozygous missense variants and the single nucleotide deletion were present 
within codon 362 of exon 5. The three heterozygous missense variants resulted in three 
distinct amino acid substitutions (R362Q, R362G and R362P). The single nucleotide 
deletion resulted in a frameshift with premature termination. Because neither germline 
nor remission material was available, the origin of the variations (acquired or inherited) 
could not be determined in the present study. 
Patients who harbored nonsynonymous GATA2 variations were classified morpho-
logically as FAB-M1 (N=1), FAB-M2 (N=1), or FAB-M4 AML (N=3; Table 1). The non -
synonymous GATA2 variants were mainly present in cytogenetically normal AML 
(CN-AML) with a frequency of 9.8% (4 of 41). In addition, we detected a nonsynonymous 
GATA2 variation in a patient with monosomy 7. No GATA2 variations were found in the 
favorable cytogenetic subgroup (N=67). In all cases, we observed co-occurrence of 
GATA2 variations with various other recurrent mutations including NRAS mutations 
(N=4), NPM1 mutations (N=2), biallelic CEBPA mutations (N=2), and WT1 mutations 
High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia
93
4
Ta
bl
e 
1 
 N
on
sy
no
ny
m
ou
s 
va
ria
tio
ns
 in
 th
e 
zi
nc
-fi
ng
er
 d
om
ai
ns
 o
f G
AT
A2
Ex
on
Va
ri
at
io
n
N
uc
le
ot
id
e 
va
ri
an
t
A
m
in
o 
ac
id
 
ch
an
ge
A
ge
 
(y
ea
rs
)
Se
x
W
BC
-c
ou
nt
 
(x
10
E9
/L
)
FA
B
Ka
ry
ot
yp
e
O
th
er
M
ut
at
io
ns
Fo
llo
w
-u
p
Pr
ev
io
us
ly
 
Re
po
rt
ed
Ex
on
 4
M
is
se
ns
e
c.
95
3C
>T
A
31
8V
18
.5
M
43
.1
M
2
CN
CE
BP
A-
D
M
Re
la
ps
e 
at
 3
.2
 
ye
ar
s, 
al
iv
e 
at
 
LF
U
 3
 m
on
th
s 
af
te
r r
el
ap
se
N
o
Ex
on
 5
M
is
se
ns
e
c.
10
84
C>
G
R3
62
G
15
.3
M
30
.8
M
4
CN
N
PM
1 
N
RA
S 
CC
R1
, 3
.4
 y
ea
rs
N
o
M
is
se
ns
e
c.
10
85
G
>C
R3
62
P
14
.8
F
16
.0
M
4
CN
N
PM
1 
N
RA
S
CC
R1
, 1
.8
 y
ea
rs
N
o
M
is
se
ns
e
c.
10
85
G
>A
R3
62
Q
4.
0
M
35
4.
0
M
1
CN
CE
BP
A-
D
M
W
T1
N
RA
S
CC
R1
, 3
.7
 y
ea
rs
Ye
s2
6
D
el
et
io
n
c.
10
85
de
lG
R3
62
fs
X2
4
14
.1
F
N
A
M
4
-7
N
RA
S
N
A
N
o
CC
R1
 =
 c
on
tin
uo
us
 fi
rs
t c
om
pl
et
e 
re
m
is
si
on
, L
FU
 =
 lo
st
 to
 fo
llo
w
-u
p,
 N
A
 =
 n
ot
 a
va
ila
bl
e
Chapter 4
94
Figure 1   Sequence variations in the zinc-finger domains of GATA2 in myeloid malignancies
(A) Schematic representation of the human GATA2 gene and protein. The GATA2 gene consists 
of 6 exons. The coding exons (exon 2 -6) are depicted in black and the 5’ and 3’ untranslated 
regions are depicted in gray. The GATA2 gene has three transcript variants that encode for two 
different protein isoforms with the same translation start site in exon 2. Isoform 1, encoded by 
transcript variant 1 or 2, contains 480 amino acids (50.5 kD). Isoform 2, encoded by transcript 
variant 3, contains a smaller fifth exon resulting in a protein of 466 amino acids (49.1 kD). 
Transcript variant 2, in which transcription is initiated from a distal first exon (1S), is specific for 
hematopoietic and neuronal cells. The encoded protein has two transactivation domains (TAD), 
a negative regulatory domain (NRD), a nuclear localization signal (N), and two zinc-finger 
domains (ZF). (B) Acquired mutations and sequence variations in the N-terminal (N-ZF) and 
C-terminal (C-ZF) zinc-finger domain of GATA2 in myeloid malignancies. Sequence variations in 
Δ
Δ
A
B
C
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(N=1). The outcome of patients with nonsynonymous GATA2 variations is described in 
Table 1. Because of the low frequency of nonsynonymous GATA2 variants in this pediatric 
AML cohort, prognostic implications of GATA2 variations could not be determined. 
GATA2 expression in morphological and genetic AML subgroups
In 237 de novo pediatric AML patients (Table 2), microarrays were used to determine 
the expression of GATA2 at diagnosis. In these AML samples, the expression of GATA2 
varied more than 20-fold (range 145-3405 AU; median 379 AU). In 80 normal bone 
marrow samples a relatively homogeneous GATA2 expression was observed (range 
146-349 AU; median 226 AU). The GATA2 expression was significantly higher in AML 
compared with normal BM  (P < .0001; Figure 2A). GATA2 expression was not related to 
sex (P = .22), age (P = .52) or WBC count (P = .33; Supplemental figure S1). 
In patients with FAB-M4 (N=56) or FAB-M5 (N=48) morphology, the median GATA2 
expression was significantly lower than in patients with other FAB-subtypes (P = .019 
and P < .0001, respectively), whereas higher expression was observed in patients with 
FAB-M1 (N=25) or FAB-M7 (N=8) morphology compared to other FAB-subtypes 
(P = .001 and P < .0001, respectively; Figure 2B). In cytogenetic subgroups, GATA2 
expression was significantly lower in patients with 11q23 translocations (N=50) or 
inv(16) (N=27; P < .0001 and P = .012, respectively) compared to other cytogenetic 
subgroups, whereas GATA2 expression levels were higher in patient with CN-AML 
(N=40) or rare cytogenetic aberrations (N=58; P = .039 and P = .003, respectively; 
Figure 2C) than in patients with other cytogenetic aberrations. No particular rare 
cytogenetic aberrations were associated with high levels of GATA2 expression. In 
addition, no chromosomal abnormalities involving the GATA2 locus (3q21) or located 
close to the GATA2 locus (e.g. 3q26 aberrations) were present. No evident correlation 
between GATA2 expression levels and specific 11q23 translocation partners was 
observed. In the molecular subgroups, we observed that the median GATA2 expression 
was higher in patients with FLT3-ITD (N=48), NPM1 (N=17), CEBPA (N=16), or WT1 
mutations (N=20; P = .003, P = .046, P = .02, P = .035, respectively; Figure 2D-E), 
compared to the patients with wild-type FLT3, NPM1, CEBPA, or WT1, respectively. 
4
pediatric AML from the present study are depicted in black. Previously reported mutations in 
adult AML with FAB-M5 morphology or in blast crisis of CML are depicted in white and gray, 
respectively.26;27 (C) Recently reported germline mutations in N-ZF and C-ZF domain of GATA2 in 
(familial) MDS/ AML,29-32 Emberger syndrome,35 syndrome of monocytopenia and mycobacterial 
infection (MonoMAC),33 and  syndrome of dendritic cell, monocyte, and B and natural killer 
lymphoid cell deficiency (DCML),34 depicted in white, black, dark gray and light gray, respectively. 
Each symbol represents an independent GATA2 mutation or variation. Numbers indicate the 
amino acid affected by each mutation or variation. The type of mutation is indicated by the 
symbol.
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Table 2  Clinical and biological characteristics of de novo pediatric AML cohort
Overall 
population 
(N=237)
Normal GATA2  
expression 
(N=82)
High GATA2 
expression 
(N=155)
No. (%) No. (%) No. (%) p-value
Sex (n=237) p=0.320 a
     Male 137 51 (37.2%) 86 (62.8%)
     Female 100 31 (31.0%) 69 (69.0%)
Age (years, median) (N=237) 9.6 8.9 9.8 p=0.059 c
      <2 years 38 18 (47.4%) 20 (52.6%) p=0.071 a
     2-10 years 87 31 (35.6%) 56 (64.4%) p=0.799 a
     >10 years 112 33 (29.5%) 79 (70.5%) p=0.116 a
WBC-count (x10E9/L, median) 
(N=216)
41.8 34.5 42.7 p=0.276 c
     <50 x10E9/L 123 44 (35.8%) 79 (64.2%) p=0.905 a
     >50 x10E9/L 93 34 (36.6%) 59 (63.4%)
FAB subgroups (N=226) p<0.001 a
     M0 16 5 (31.2%) 11 (68.8%) p=0.747 a
     M1 25 3 (12.0%) 22 (88.0%) p=0.011 a
     M2 51 14 (27.5%) 37 (72.5%) p=0.201 a
     M3 19 4 (21.1%) 15 (78.9%) p=0.184 a
     M4 56 24 (42.9%) 32 (57.1%) p=0.153 a
     M5 48 28 (58.3%) 20 (41.7%) p<0.001 a
     M6 3 1 (33.3%) 2 (66.7%) p=0.953 b
     M7 8 0 (0%) 8 (100%) p=0.053 b
Cytogenetic abnormalities  
(N=222)
p=0.001 a
     t(8;21)(q22;q22) 28 8 (28.6%) 20 (71.4%) p=0.499 a 
     inv(16)(p13q22) 27 12 (44.4%) 15 (55.6%) p=0.233 a
     t(15:17)(q22;q21) 19 4 (21.1%) 15 (78.9%) p=0.205 a
     11q23 translocations 50 30 (60.0%) 20 (40.0%) p<0.001 a
     Rare cytogenetics 58 12 (20.7%) 46 (79.3%) p=0.044 a
     Normal cytogenetics (CN) 40 10 (25.0%) 30 (75.0%) p=0.174 a
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When CEBPA single mutants (N=4) and double mutants (N=12) were analyzed as two 
distinct entities, a trend towards higher GATA2 expression was observed in both 
groups compared with patients with wild-type CEBPA (P = .11 and P = .05, respectively). 
The expression of GATA2 showed a positive correlation with expression of the 
transcription factor WT1 (Spearman correlation coefficient = 0.51, P < .0001), which is 
known to be highly expressed in several hematopoietic malignancies including AML 
and has been identified previously as a molecular marker associated with disease 
outcome in AML.44;46;47 
High GATA2 expression is an independent poor prognostic factor
To determine the clinical significance of GATA2 expression in pediatric AML, we 
studied the relation between GATA2 expression at diagnosis and parameters of 
long-term outcome (pOS, pEFS, and pDFS). Because the level of expression of GATA2 
appears to be a continuum, we defined a threshold for high versus normal GATA2 
expression based on the expression of GATA2 in normal BM (threshold: median 
4
Table 2  Continued
Overall 
population 
(N=237)
Normal GATA2  
expression 
(N=82)
High GATA2 
expression 
(N=155)
No. (%) No. (%) No. (%) p-value
Other genetic abnormalities
     NPM1 mutations (N=237) 17 3 (17.6%) 14 (82.4%) p=0.127 a
     CEBPA mutations (N=227) 16 2 (12.5%) 14 (87.5%) p=0.056 a
        CEBPA single mutations (N=227) 4 0 (0%) 4 (100%) p=0.301 b
        CEBPA double mutations (N=227) 12 2 (16.7%) 10 (83.3%) p=0.227 b
     MLL-PTD (N=237) 6 2 (33.3%) 4 (66.7%) p=1.000 b 
     FLT3-ITD (N=237) 48 9 (18.7%) 39 (81.3%) p=0.010 a
     WT1 mutations (N=230) 20 2 (10.0%) 18 (90.0%) p=0.015 a
     NRAS/KRAS mutations (N=237) 41 17 (41.5%) 24 (58.5%) p=0.310 a
     KIT mutations (N=237) 18 7 (38.9%) 11 (61.1%) p=0.691 a
     PTPN11 mutations (N=237) 5 2 (40.0%) 3 (60.0%) p=1.000 b
     High EVI1 expression (N=237) 20 6 (30.0%) 14 (70.0%) p=0.651 a
     High WT1 expression (N=237) 176 42 (23.9%) 134 (76.1%) p<0.001 a
Patients with high GATA2 expression are compared with patients with normal GATA2 expression. P-values 
(bold) indicate whether differences are significant at the level of .05. a c2- test; b Fisher exact test; 
c Mann-Whitney U test. Percentages of patients with normal GATA2 expression versus high GATA2 expression 
in each subgroup are presented.
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expression in normal BM + 2SDs). In 155 patients (65%), GATA2 levels were expressed 
above this threshold of 320 AU (range 320-3405 AU; median 506 AU). The remaining 
82 patients (35%) were classified as having normal GATA2 levels (range 145-319 AU; 
median 250 AU; Table 2). 
Survival data were available for 205 patients, including 127 patients with high GATA2 
expression (62%). High GATA2 expression was associated with worse pOS and pEFS, 
although the differences did not reach statistical significance at the P = .05 level in 
univariate analysis. No effect on pDFS was observed. The 4-year pOS was 56% ± 5% 
for patients with high GATA2 expression (N=127) compared with 68% ± 6% for patients 
with normal GATA2 levels (N=78; P = .15; Figure 3A), the 4-year pEFS was 35% ± 5% 
compared with 50% ± 6% (P = .08; Figure 3B), and the 4-year pDFS was 49% ± 5% 
compared with 59% ± 6% (P = .26; Figure 3C), respectively.
The prognostic impact of GATA2 was particularly evident in patients with FAB-M5 
morphology (N=42) and inv(16) (N=26). In patients with FAB-M5 morphology, high 
GATA2 expression was associated with worse pOS, pEFS, and pDFS. The 4-year pOS 
was 7% ± 7% in FAB-M5 patients with high GATA2 expression (N=15) compared with 
63% ± 9% in FAB-M5 patients with normal GATA2 levels (N=27, P = .004); the 4-year 
pEFS was 7% ± 6% compared with 44% ± 10% (P = .036) and the 4-year DFS was 8% ± 
8% compared with 67% ± 11% (P = .001; Figure 4A), respectively. In patients with 
inv(16), high GATA2 expression was associated with worse pEFS and pDFS, whereas no 
effect on pOS was observed. The 4-year pEFS was 47% ± 14% in inv(16) cases with high 
GATA2 expression (N=14) compared with 100% in inv(16) cases with normal GATA2 
levels (N=12; P = .009); the 4-year pDFS was 56% ± 14% compared with 100% (P = .018; 
Figure 4B), respectively. Moreover, in patients with high WT1 expression, 11q23 
translocations or FLT3-ITD positivity, a trend towards worse outcome was observed in 
patients with high GATA2 expression versus normal GATA2 expression (Figure 4C and 
Supplemental Figure S2). Within other morphological, cytogenetic, or molecular 
subgroups, we did not observe differences in outcome between patients with high 
versus normal GATA2 expression (Supplemental Table S3).
4
Figure 2  GATA2 expression in normal BM and different morphologic, cytogenetic and 
molecular AML subgroups
(A) Normalized expression levels of GATA2 in pretreatment samples of 237 children with de novo 
AML and 80 normal BM samples. Expression was significantly higher in AML compared with 
normal BM. Normalized expression levels of GATA2 in different morphological FAB subgroups 
(B), in cytogenetic subgroups (C), and in molecular subgroups incluing molecular aberrations 
(D) and AML with WT1 or EVI1 overexpression (E). GATA2 expression was determined using 
gene-expression arrays (Affymetrix HGU133 Plus 2.0 microarray, probeset 209710_at) or 
real-time quantitative PCR. Median values are depicted by the horizontal lines. Mann-Whitney 
U test was used to compare expression levels between groups. The threshold for high versus 
normal GATA2 expression is based on median GATA2 in normal BM + 2SDs and is depicted as a 
dashed line.
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To assess the independent prognostic contribution of GATA2 expression, a multiple 
Cox regression analysis was conducted. In pediatric AML, several prognostic factors 
have been identified previously: age, WBC count, favorable karyotype, NPM1 mutation, 
biallelic CEBPA mutation, and FLT3-ITD.45 When GATA2 was entered into a multiple Cox 
regression analysis adjusting for these established prognostic factors, we observed 
a significant correlation between high GATA2 expression with worse pOS (HR = 1.7, 
P = .045), pEFS (HR = 2.1, P = .002), and pDFS (HR = 2.3, P = .004) (Table 3 and Supplemental 
Table S4). 
Figure 3   Correlation of GATA2 expression with pOS, pEFS, and pDFS
Kaplan-Meier estimates for pOS (A), pEFS (B), and pDFS (C). Patients with high GATA2 expression 
were compared with patients with normal GATA2 expression using a log-rank test. High GATA2 
expression suggested a worse pOS and pEFS, although the differences did not reach statistical 
significance at the P = .05 level in univariate analysis.
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4
Figure 4  Relation of GATA2 expression with survival in morphologic and genetic AML 
subgroups
Kaplan-Meier estimates for pOS, pEFS, and pDFS in AML patients with FAB-M5 morphology (A), 
inv(16) (B), or high WT1 expression (C). Patients with high GATA2 expression were compared 
with normal GATA2 expression using a log-rank test. High GATA2 expression was associated 
with worse outcome. P < .05 was considered statistically significant (2-tailed testing). Patient 
characteristics are described in Supplemental Tables S5-7.
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Figure 4   Continued
pOS in AML with high WT1
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GATA2 expression during treatment and follow up
To study the prognostic relevance of GATA2 expression after induction and consolidation 
treatment, consecutive GATA2 expression levels were determined using real-time 
quantitative PCR in a representative subgroup of 38 patients (Supplemental Table S10). 
Thirthy-three patients reached CR with a median time to first CR (CR1) of 1.4 months 
(range 0.9-4.4 months), three patients died within one week after diagnosis (categorized 
as early death), and two patients had RD. Twelve patients relapsed, with a median time 
to relapse of 12.6 months (range 6.0-65.4 months). 
Both at diagnosis and clinical relapse, GATA2 expression was heterogeneous (> 2 log 
difference between highest and lowest expression). No differences were observed in 
median GATA2 expression at diagnosis versus relapse (P = .87). After induction and 
consolidation therapy, normalization of GATA2 expression was observed in patients 
who reached CR (Figure 5A+B), whereas GATA2 expression levels stayed high in 
patients with RD (Figure 5C). In 2 of 38 AML patients, GATA2 was sufficiently highly 
expressed to allow detection of at least a 2-log reduction (i.e. sensitivity < .01). GATA2 
expression was assessed in parallel with additional markers that have been used 
previously for the detection of residual disease: WT1 expression (N=38), AML1-ETO 
fusion gene expression (patient with t(8;21), N=3), and EVI1 expression (patients with 
high EVI1 expression, N=3; Figure 6).6;44;47;48 The expression patterns of GATA2 were 
comparable to the expression patterns of the AML1-ETO fusion gene, EVI1, and WT1. 
However, the log reduction for WT1 and AML1-ETO was higher than for GATA2. 
To determine whether GATA2 expression was related to outcome, we compared 
GATA2 expression of patients who relapsed versus patients in continuous CR1 at 
different time points. Neither at diagnosis nor during chemotherapy, differences in 
GATA2 expression levels were detected between both groups. After consolidation 
therapy, an increase of GATA2, WT1, and EVI1 expression was observed in one patient 
who was diagnosed with a clinical relapse three months later (Figure 6B, lower panel). 
In two other patients who suffered an early relapse with high GATA2 expression, we 
did not observe a rise in GATA2 expression levels after consolidation therapy (2.6- 5.4 
months before clinical relapse). 
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Table 3  Multivariate analysis for pOS, pEFS, and pDFS
A
95% CI
pOS HR Lower Upper p-value
High GATA2 expression 1.724 1.012 2.938 0.045
Age 1.031 0.982 1.083 0.219
WBC-count 1.003 1.001 1.006 0.008
FLT3-ITD 0.924 0.502 1.700 0.799
NPM1 mutation 0.169 0.040 0.714 0.016
Favorable karyotype 0.145 0.069 0.306 <0.001
Biallelic CEBPA mutation 0.128 0.017 0.949 0.044
B
95% CI
pEFS HR Lower Upper p-value
High GATA2 expression 2.050 1.312 3.204 0.002
Age 1.058 1.014 1.104 0.010
WBC-count 1.002 0.999 1.004 0.189
FLT3-ITD 0.791 0.467 1.342 0.385
Favorable karyotype 0.204 0.121 0.345 <0.001
Biallelic CEBPA mutation 0.181 0.054 0.601 0.005
NPM1 mutation 0.130 0.039 0.426 0.001
C
95% CI
pDFS HR Lower Upper p-value
High GATA2 expression 2.290 1.300 4.034 0.004
Age 1.073 1.016 1.133 0.011
WBC-count 1.000 0.997 1.004 0.960
FLT3-ITD 0.874 0.456 1.677 0.687
Favorable karyotype 0.160 0.083 0.307 <0.001
NPM1 mutation 0.140 0.041 0.471 0.002
Biallelic CEBPA mutation 0.134 0.030 0.588 0.008
Multivariate Cox regression model for pOS (A), pEFS (B), and pDFS (C). Age and WBC count are analyzed as 
continuous variables, GATA2 expression is dichotomized. P-values (bold) indicate whether differences are 
significant at the level of .05. 95% CI indicates 95% confidence interval. 
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Figure 5  GATA2 expression in continuous 
CR, RD, and clinical relapse
Consecutive GATA2 expression at diagnosis 
and at different time points during treatment in 
a cohort of 38 pediatric AML patients from 
whom material was available for MRD analysis. 
GATA2 expression was determined using 
real-time quantitative PCR at diagnosis 
(N=38), after the first cycle of induction 
therapy (N=27), after completion of induction therapy (N=23), after the first cycle of consolidation 
therapy (N=12), after completion of consolidation therapy (N=25), and at relapse (N=10). 
Expression relative to GAPDH is plotted. GATA2 expression in patients with continuous first CR 
(N=21, A), relapse (N=12, B), and RD (N=2, C). Patients were subdivided into patients with high 
GATA2 expression at diagnosis versus normal GATA2 expression at diagnosis. GATA2 expression 
was considered to be high when the expression was 2 SDs above the median GATA2 expression 
obtained in normal BM (N=74), as determined by real-time quantitative PCR. The threshold is 
depicted as a dashed line.
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Figure 6   Relation between GATA2 expression and other residual disease markers
Consecutive GATA2, WT1, EVI1, and fusion gene expression at diagnosis and at different time 
points during treatment in pediatric AML patients with t(8;21) (N=3, A) or high EVI1 expression 
(N=3, B), determined by real-time quantitative PCR. Expression of GATA2 and WT1 relative to 
GAPDH is plotted. Expression of EVI1 and AML1-ETO relative to PBGD is plotted. For all the 
different markers, expression at different time points during treatment was normalized to 
expression at diagnosis. CCR1 indicates continuous first CR.
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Discussion
In the present study, we investigated the relevance and prognostic value of GATA2 
expression and mutations in a large cohort of de novo pediatric AML patients. 
Mutational analysis was performed by sequencing of the DNA-binding zinc-finger 
domains of GATA2 in 230 patients. We detected nonsynonymous variations in the GATA2 
gene with a frequency of 2.2% overall, and 9.8% in pediatric CN-AML. All GATA2 variants 
affected highly conserved residues within the critical functional DNA-binding domain, 
consisting of two zinc fingers. Functional studies have recently shown significant 
effects of six different mutations located within the N-terminal and C-terminal 
zinc-finger domain of GATA2 on transactivation of target genes, DNA-binding ability, 
protein-protein interactions, cellular differentiation, apoptosis and global gene 
expression.27;29;35 In one patient, we detected a variation in codon 318 of the N-terminal 
zinc-finger domain adjacent to codon 319 in which an acquired mutation was recently 
described in an adult AML patient with FAB-M5 morphology.26 In codon 362 of the 
C-terminal zinc-finger domain, we identified three heterozygous missense variants 
and one heterozygous single nucleotide deletion resulting in loss of the C-terminal 
part of the protein. Because four out of five GATA2 variants were present within codon 
362, this suggests that these variations are indeed true mutations. One of these 
variants (R362Q) was identified recently as an acquired mutation in two adult AML 
patients with FAB-M5 morphology.26 In the highly conserved zinc-finger domains of 
the GATA2 gene, acquired and inherited mutations have been reported in myeloid 
malignancies. In (familial) myelodysplastic syndrome (MDS)/AML and syndromes with 
a predisposition to development of MDS/AML, inherited GATA2 mutations are mainly 
clustered in codon 354 and codon 396-398 of the C-terminal zinc-finger domain 
(Figure 1C).29-35 In contrast, in sporadic AML, the majority of acquired GATA2 variations 
are located within codon 362 in the C-terminal zinc-finger domain (Figure 1B),26 
suggesting that this location may be a mutational hot spot. 
The low frequency of GATA2 variations found in the present study is consistent with 
recent studies in adult AML, which reported acquired GATA2 mutations with a 
frequency of 3.6% in adult AML patients with FAB-M5 morphology.14;26;28;29 Interestingly, 
no GATA2 variations were observed in any of our pediatric patients with FAB-M5 
morphology (N=51). We detected mainly GATA2 variations in CN-AML. In all cases, we 
observed cooccurrence of nonsynonymous GATA2 variations with various other 
recurrent mutations, including NRAS mutations (N=4), NPM1 mutations (N=2), biallelic 
CEBPA mutations (N=2), and WT1 mutations (N=1). In adult AML, co-occurrence of 
GATA2 mutations with other recurrent mutations (e.g. WT1 mutation and CEBPA single 
mutation) has also been reported.26 Although the co-occurrence of these lesions 
remains a rare event in pediatric AML, this observation may suggest that these 
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aberrations cooperate in leukemia development. Determination of the clinical 
significance of GATA2 variations in a larger cohort of pediatric (CN-)AML is highly 
recommended. 
In the present study, GATA2 expression analysis demonstrated that in 155 of 237 
diagnostic samples (65%), GATA2 expression was higher than in normal BM. 
Normalization of GATA2 expression was observed in patients who reached CR, 
whereas GATA2 expression levels stayed high in patients with RD. Although GATA2 
expression during follow-up was studied in a limited number of patients, these data 
suggest that GATA2 may be a interesting marker for residual disease detection. 
However, because of the heterogeneous expression of GATA2 in AML and the relatively 
high background expression in normal hematopoietic cells, the sensitivity of GATA2 as 
a marker for residual disease may be limited. In only 2 out of 38 AML patients GATA2 
was sufficiently highly expressed to allow detection of at least a 2-log reduction (i.e. 
sensitivity < .01). Assessment of quantitative fusion-gene expression was shown to be 
a more robust marker for residual disease. However, this strategy is limited to specific 
AML-subgroups. In addition, MRD detection by multiparameter flow cytometry is a 
promising strategy which is applicable to the vast majority of AML patients.5;6
We have shown herein that high GATA2 expression at diagnosis is an independent 
poor prognostic factor for pOS (HR =  1.7, P = .045), pEFS (HR = 2.1,  P = .002), and pDFS 
(HR = 2.3, P = .004) in pediatric AML overall. In adult AML, studies regarding the 
prognostic value of GATA2 have yielded conflicting results, which might be due to the 
relatively small patient cohorts and technical differences between studies in 
quantification of GATA2 expression.49-52 In a cohort of 112 adult AML patients, Vicente 
et al. showed recently that high GATA2 expression was associated with worse outcome 
(pOS, pEFS, and pDFS).51 The prognostic value of high GATA2 expression was most 
evident in adult CN-AML.51;52 In pediatric AML, we did not observe a difference in 
survival based on GATA2 expression in CN-AML (N=40), which may be due to 
differences in distribution of genetic aberrations underlying pediatric compared with 
adult CN-AML. 
Interestingly, the prognostic impact of GATA2 was particularly high in specific 
morphologic and genetic AML subgroups. High GATA2 expression identified a group 
of patients with a significant worse outcome among patients with high WT1 
expression, which is consistent with recent observations in adult AML.51 Moreover, in 
patients with FAB-M5 morphology and inv(16), we observed pronounced differences 
in survival between patients with high versus normal GATA2 expression, and a trend 
towards worse survival was observed in patients with 11q23 translocations or FLT3-ITD. 
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Based on the results of the present study, we conclude that GATA2 expression is a 
novel independent poor prognostic factor in pediatric AML. The negative correlation 
between GATA2 expression and outcome, especially in specific morphologic and 
genetic AML subgroups, suggests that GATA2 may be a useful marker for identification 
of patients with a dismal prognosis, which could lead to better risk-group stratification 
and risk-adapted therapy in the future. In addition, we identified the presence of 
GATA2 mutations as a recurrent but infrequent event in childhood AML, which mainly 
occurs in CN-AML. The clinical significance of GATA2 mutations should be determined 
in a larger cohort of pediatric (CN-) AML patients and the value of GATA2 expression as 
a predictor for poor OS, EFS, and DFS should be validated in prospective studies. 
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Supplemental Table S1  Primers GATA2 sequence analysis
Exon Primer
Exon 4 Amplification Forward AACCGTGTGCCTGAGAG
Reverse CGTCTGCATTTGAAGGAGTT
Sequence Forward GGCTGGCTGCTTTCCTG
Reverse AGTTTTTTTCCCCTGTAATTAACCG
Exon 5 Amplification Forward ATGGTTCTGAGATGCTTTGA
Reverse CAAGCTGGATATTGTGGCT
Sequence Forward TCCTTGACTGAGCTGGTGG
Reverse CCTGGCAGCACAAAGCG
Exon 6 Amplification Forward CTGGGACCCTCAGCTTGA
Reverse CATTCACAGTAACTGCTGGCA
Sequence Forward GCCTCTGGTCCACGCTG
Reverse GCTGGCAGGCTGCTG
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Supplemental Table S3  Prognostic value of GATA2 in total AML cohort and different 
morphologic and genetic AML subgroups
A
4-year pOS
Category Total GATA2-high GATA2 normal Logrank
Total cohort 60 ± 4% (N=205) 56 ± 5%  (N=127) 68 ± 6% (N=78) p=0.152
FAB subgroups
   M0 25 ± 13% (N=12) 22 ± 14%  (N=9) 33 ± 27% (N=3) p=0.954
   M1 58 ± 11% (N=22) 62 ± 12%  (N=19) 33 ± 27% (N=3) p=0.173
   M2 66 ± 8% (N=45) 65 ± 9%  (N=31) 70 ± 13% (N=14) p=0.721
   M3 75 ± 11% (N=16) 67 ± 14%  (N=12) 100% (N=4) p=0.212
   M4 78 ± 6% (N=52) 78 ± 8%  (N=29) 77 ± 9% (N=23) p=0.993
   M5 44 ± 8% (N=42) 7 ± 7% (N=15) 63 ± 9% (N=27) p=0.004
   M6 100 % (N=3) 100% (N=2) 100% (N=1) UD
   M7 33 ± 19% (N=6) 33 ± 19%  (N=6) NA (N=0) NA
Cytogenetic 
abnormalities
   t(8;21) 79 ± 7% (N=27) 77 ± 10%  (N=19) 88 ± 12% (N=8) p=0.714
   inv(16) 89 ± 11% (N=26) 100% (N=14) 100% (N=12) p=0.480
   t(15;17) 75 ± 11% (N=16) 67 ± 14%  (N=12) 100% (N=4) p=0.212
   11q23 translocations 44 ± 8% (N=45) 24 ± 10% (N=17) 56 ± 10% (N=28) p=0.082
   Rare cytogenetics 35 ± 8% (N=43) 34 ± 9%  (N=32) 42 ± 16% (N=11) p=0.350
   Normal cytogenetics 59 ± 9% (N=36) 57 ± 10%  (N=26) 66 ± 17% (N=10) p=0.982
Other genetic 
abnormalities
   NPM1 mutations 75 ± 11% (N=16) 68 ± 13%  (N=13) 100% (N=3) p=0.297
   CEBPA mutations 71 ± 4% (N=11) 64 ± 17%  (N=9) 100% (N=2) p=0.359
   MLL-PTD 80 ± 18% (N=5) 67 ± 27%  (N=3) 100% (N=2) p=0.414
   FLT3-ITD positive 49 ± 8% (N=50) 40 ± 9% (N=31) 86 ± 13% (N=9) p=0.052
   WT1 mutations 20 ± 10% (N=16) 16 ± 10%  (N=14) 50 ± 35% (N=2) p=0.327
   NRAS/KRAS mutations 78 ± 7% (N=35) 74 ± 11%  (N=18) 82 ± 9% (N=17) p=0.633
   KIT mutations 72 ± 11% (N=18) 73 ± 13%  (N=11) 71 ± 17% (N=7) p=0.820
   PTPN11 mutations 33 ± 27% (N=3) 0%  (N=1) 50 ± 35% (N=2) p=0.808
   High EVI1 expression 42 ± 11% (N=19) 39 ± 14%  (N=13) 50 ± 20% (N=6) p=0.857
   High WT1 expression 62 ± 4% (N=153) 58 ± 5% (N=113) 76 ± 7% (N=40) p=0.038
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Supplemental Table S3  Continued
B
4-year pEFS
Category Total GATA2-high GATA2 normal Logrank
Total cohort 41 ± 4% (N=205) 35 ± 5% (N=127) 50 ± 6% (N=78)  p=0.081
FAB subgroups
   M0 17 ± 11% (N=12) 22 ± 14% (N=9) 63 ± 11% (N=19) p=0.556
   M1 39 ± 11% (N=22) 40 ± 12% (N=19) 63 ± 11% (N=19) p=0.561
   M2 43 ± 8% (N=45) 40 ± 9% (N=31) 63 ± 11% (N=19) p=0.544
   M3 47 ± 15% (N=16) 37 ± 18% (N=12) 63 ± 11% (N=19) p=0.321
   M4 57 ± 7% (N=52) 45 ± 10% (N=29) 63 ± 11% (N=19) p=0.150
   M5 31 ± 7% (N=42) 7 ± 6% (N=15) 44 ± 10% (N=27) p=0.036
   M6 67 ± 27% (N=3) 100% (N=2) 0% (N=1) p=0.157
   M7 17 ± 15% (N=6) 17 ± 15% (N=6) NA (N=0) NA
Cytogenetic 
abnormalities
   t(8;21) 62 ± 10% (N=27) 61 ± 12% (N=19) 63 ± 17% (N=8) p=0.750
   inv(16) 70 ± 10% (N=26) 47 ± 14% (N=14) 100% (N=12) p=0.009
   t(15;17) 47 ± 15% (N=16) 37 ± 19% (N=12) 67 ± 27% (N=4) p=0.321
   11q23 translocations 31 ± 7% (N=45) 12 ± 8% (N=17) 43 ± 9% (N=28) p=0.075
   Rare cytogenetics 21 ± 7% (N=43) 19 ± 8% (N=32) 27 ± 13% (N=11) p=0.508
   Normal cytogenetics 40 ± 8% (N=36) 41 ± 10% (N=26) 38 ± 17% (N=10) p=0.862
Other genetic 
abnormalities
   NPM1 mutations 69 ± 12% (N=16) 62 ± 14% (N=13) 100% (N=3) p=0.239
   CEBPA mutations 52 ± 16% (N=11) 40 ± 18% (N=9) 100% (N=2) p=0.199
   MLL-PTD 40 ± 22% (N=5) 33 ± 27% (N=3) 50 ± 35% (N=2) p=0.782
   FLT3-ITD positive 40 ± 8% (N=40) 35 ± 9% (N=31) 60 ± 18% (N=9) p=0.106
   WT1 mutations 6 ± 6% (N=16) 0 ± 0% (N=14) 50 ± 35% (N=2) p=0.097
   NRAS/KRAS mutations 53 ± 9% (N=35) 42 ± 12% (N=18) 65 ± 12% (N=17) p=0.261
   KIT mutations 50 ± 12% (N=18) 46 ± 15% (N=11) 71 ± 17% (N=7) p=0.302
   PTPN11 mutations 0% (N=3) 0% (N=1) 0% (N=2) p=0.808
   High EVI1 expression 21 ± 9% (N=19) 15 ± 10% (N=13) 33 ± 19% (N=6) p=0.374
   High WT1 expression 41 ± 4% (N=153) 34± 5% (N=113) 59 ± 8% (N=40) p=0.017
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Supplemental Table S3  Continued
C
4-year pDFS
Category Total GATA2-high GATA2 normal Logrank
Total cohort 53 ± 4% (N=173) 49 ± 5% (N=107) 59 ± 6% (N=66) p=0.256
FAB subgroups
   M0 23 ± 14% (N=10) 34 ± 20% (N=7) 0% (N=3) p=0.201
   M1 49 ± 12% (N=20) 48 ± 13% (N=18) 50 ± 36% (N=2) p=0.870
   M2 47 ± 8% (N=41) 45 ± 10% (N=28) 54 ± 14% (N=13) p=0.580
   M3 88 ± 12% (N=12) 100% (N=8) 67 ± 27% (N=4) p=0.197
   M4 65 ± 7% (N=49) 56 ± 10% (N=27) 77 ± 9% (N=22) p=0.318
   M5 43 ± 9% (N=30) 8 ± 8% (N=12) 67 ± 11% (N=18) p=0.001
   M6 67 ± 27% (N=3) 100% (N=2) 0% (N=1) p=0.157
   M7 50 ± 35% (N=3) 50 ± 35% (N=3) NA (N=0) NA
Cytogenetic 
abnormalities
   t(8;21) 62 ± 10% (N=27) 61 ± 12% (N=19) 63 ± 17% (N=8) p=0.996
   inv(16) 75 ± 9% (N=26) 56 ± 14% (N=14) 100% (N=12) p=0.018
   t(15;17) 88 ± 12% (N=12) 100% (N=8) 67 ± 27% (N=4) p=0.197
   11q23 translocations 47 ± 9% (N=30) 18 ± 12% (N=11) 63 ± 11% (N=19) p=0.046
   Rare cytogenetics 31 ± 9% (N=34) 31 ± 11% (N=25) 33 ± 16% (N=9) p=0.865
   Normal cytogenetics 45 ± 9% (N=34) 46 ± 10% (N=25) 42 ± 17% (N=9) p=0.948
Other genetic 
abnormalities
   NPM1 mutations 73 ± 11% (N=15) 67 ± 14% (N=12) 100% (N=3) p=0.282
   CEBPA mutations 58 ± 16% (N=11) 46 ± 19% (N=9) 100% (N=2) p=0.237
   MLL-PTD 50 ±25% (N=5) 50 ± 35% (N=3) 50 ± 35% (N=2) p=0.808
   FLT3-ITD positive 51 ± 9% (N=35) 49 ± 10% (N=26) 60 ± 18% (N=9) p=0.365
   WT1 mutations 15 ± 10% (N=13) 9 ± 9% (N=11) 50 ± 35% (N=2) p=0.160
   NRAS/KRAS mutations 57 ± 9% (N=33) 42 ± 12% (N=18) 73 ± 11% (N=15) p=0.113
   KIT mutations 53 ± 12% (N=17) 36 ± 15% (N=11) 83 ± 15% (N=6) p=0.123
   PTPN11 mutations 0% (N=2) 0% (N=1) 0% (N=1) p=0.317
   High EVI1 expression 29 ± 12% (N=14) 22 ± 14% (N=9) 40 ± 22% (N=5) p=0.768
   High WT1 expression 52 ± 5% (N=131) 48 ± 5% (N=94) 63 ± 8% (N=37) p=0.180
4-year survival data for pOS (A), pEFS (B), and pDFS (C) were estimated by the Kaplan-Meier method and 
compared using log-rank test. P-values (bold) indicate whether differences are significant at the level of  .05. 
UD = undetermined. NA = not applicable.
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Supplemental Table S4  Univariate Cox regression analysis (pOS, pEFS, and pDFS) 
for established prognostic factors in pediatric AML
A
pOS 95% CI
Established prognostic factors HR Lower Upper p-value
Age 0.976 0.936 1.018 0.267
WBC-count 1.005 1.003 1.007 <0.001
FLT3-ITD 1.423 0.850 2.382 0.180
NPM1 mutation 0.549 0.200 1.503 0.243
Favorable karyotype 0.207 0.106 0.403 <0.001
Biallelic CEBPA mutation 0.255 0.035 1.840 0.176
B
pEFS 95% CI
Established prognostic factors HR Lower Upper p-value
Age 0.986 0.952 1.020 0.410
WBC-count 1.003 1.001 1.005 0.007
FLT3-ITD 1.086 0.694 1.701 0.718
NPM1 mutation 0.410 0.167 1.005 0.051
Favorable karyotype 0.365 0.236 0.568 <0.001
Biallelic CEBPA mutation 0.457 0.145 1.442 0.182
C
pDFS 95% CI
Established prognostic factors HR Lower Upper p-value
Age 0.989 0.948 1.032 0.621
WBC-count 1.002 0.999 1.005 0.111
FLT3-ITD 1.236 0.722 2.116 0.440
NPM1 mutation 0.473 0.173 1.294 0.145
Favorable karyotype 0.354 0.207 0.604 <0.001
Biallelic CEBPA mutation 0.417 0.102 1.800 0.222
Univariate Cox regression analysis for established prognostic factors. HR for pOS (A), pEFS (B), and pDFS (C) 
were estimated by the univariate Cox regression model. P-values (bold) indicate whether differences are 
significant at the level of .05.
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Supplemental Table S5  Clinical and biological characteristics of AML patients with 
FAB-M5 morphology
FAB-M5 Total 
(N=48)
GATA2 normal 
(N=28)
GATA2 high 
(N=20)
p- value
Sex (N=48) p=0.762 a 
   Male 30 17 13
   Female 18 11 7
Age (years, median) (N=48) 5.9 2.9 9.2 p=0.034c
   <2 years 16 12 4 p=0.098 a 
   2-10 years 15 8 7 p=0.636 a 
   >10 years 17 8 9 p=0.241 a 
WBC-count (x10E9/L,  median) (N=45) 71.0 71.4 71.0 p=0.648 c
   <50 x10E9/L 17 11 6 p=0.789 a 
   >50x10E9/L 28 17 11
Cytogenetic abnormalities (N=46) p=0.005 a
   11q23 translocations 34 24 10 p=0.015 b
   Rare cytogenetics 9 1 8 p=0.002 b  
   Normal cytogenetics (CN) 3 2 1 p=1.000 b  
Other genetic abnormalities (N=48)
   NPM1 mutations 1 0 1 p=0.417 b  
   MLL-PTD 1 1 0 p=1.000 b  
   FLT3-ITD 4 1 3 p=0.294 b  
   WT1 mutations 5 1 4 p=0.146 b  
   CKIT mutations 1 1 0 p=1.000 b  
   NRAS/KRAS mutations 9 5 4 p=1.000 b  
   PTPN11 mutations 3 2 1 p=1.000 b  
   High EVI1 expression 6 4 2 p=1.000 b  
   High WT1 expression 17 3 14 p<0.001 a
Patients with high GATA2 expression are compared with patients with normal GATA2 expression. 
P-values (bold) indicate whether differences are significant at the level of .05. a c2 test; b Fisher exact test; 
c Mann-Whitney U test.
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Supplemental Table S6  Clinical and biological characteristics of AML patients with 
inv(16)
inv(16) Total 
(N=27)
GATA2 normal 
(N=12)
GATA2 high 
(N=15)
p- value
Sex (N=27) p=1.000 b
   Male 17 8 9
   Female 10 4 6
Age (years, median) (N=27) 10.7 9.4 12.6 p=0.542 c
   <2 years 3 1 2 p=1.000 b
   2-10 years 9 5 4 p=0.448 b 
   >10 years 15 6 9 p=0.603 a
WBC-count (x10E9/L, median) (N=26) 58.1 58.1 57.8 p=0.237 c
   <50 x10E9/L 13 6 7 p=1.000 a 
   >50x10E9/L 13 6 7
Other genetic abnormalities (N=27)
   FLT3-ITD 1 1 0 p=0.444 b 
   NRAS/KRAS mutations 6 3 3 p=1.000 b 
   KIT mutations 8 3 5 p=0.696 b 
   High WT1 expression 26 11 15 p=0.444 b 
Patients with high GATA2 expression are compared with patients with normal GATA2 expression. 
P-values (bold) indicate whether differences are significant at the level of  .05. a c2 test; b Fisher exact test; 
c Mann-Whitney U test.
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Supplemental Table S7  Clinical and biological characteristics of AML patients with 
high WT1 expression
High WT1 expression Total  
(N=176)
GATA2 normal 
(N=42)
GATA2 high 
(N=134)
p-value
Sex (n=176) p=0.397 a
     Male 99 26 73
     Female 77 16 61
Age (years, median) (N=176) 10.7 10.0 10.8 p=0.749 c
       <2 years 10 1 9 p=0.455 b
      2-10 years 71 20 51 p=0.271 a 
      >10 years 95 21 74 p=0.553 a 
WBC-count (x10E9/L, median) (N=160) 41.5 31.1 42.7 p=0.156 c
   <50 x10E9/L 94 25 69 p=0.578 a 
   >50 X10E9/L 66 15 51
FAB subgroups (N=169) p=0.282 a 
   M0 11 2 9 p=1.000 b 
   M1 23 3 20 p=0.177 a 
   M2 42 11 31 p=0.736 a 
   M3 19 4 15 p=1.000 b 
   M4 48 17 31 p=0.033 a 
   M5 17 3 14 p=0.766 b 
   M6 2 1 1 p=0.427 b 
   M7 7 0 7 p=0.197 b 
Cytogenetic abnormalities (N=164) p=0.165 a 
   t(15;17) 19 4 15 p=1.000 b 
   t(8;21) 23 6 17 p=0.721 a
   inv(16) 26 11 15 p=0.012 a
   11q23 translocations 17 4 13 p=1.000 b
   Rare cytogenetics 43 6 37 p=0.095 a 
   Normal cytogenetics (CN) 36 7 29 p=0.549 a 
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High WT1 expression Total  
(N=176)
GATA2 normal 
(N=42)
GATA2 high 
(N=134)
p-value
Other genetic abnormalities (N=176)
   NPM1 mutations 16 2 14 p=0.346 b 
   CEBPA mutations (N=172) 14 2 12 p=0.525 b 
      Single mutant 4 0 4 p=0.574 b 
      Double mutant 10 2 8 p=1.000 b 
   MLL-PTD 5 1 4 p=1.000 b 
   FLT3-ITD 46 9 37 p=0.426 a 
   WT1 mutations (N=174) 19 1 18 p=0.048 b
   NRAS/KRAS mutations 31 10 21 p=0.227 a 
   KIT mutations 13 4 9 p=0.513 b 
   PTPN11 mutations 1 0 1 p=1.000 b 
   High EVI1 expression 15 3 12 p=1.000b
Patients with high GATA2 expression are compared with patients with normal GATA2 expression. P-values 
(bold) indicate whether differences are significant at the level of  .05. a c2 test; b Fisher exact test; c Mann- 
Whitney U test.
Supplemental Table S8  Clinical and biological characteristics of AML patients with 
11q23 translocations
11q23 translocations Total 
(N=50)
GATA2 normal
(N=30)
GATA2 high 
(N=20)
p- value
Sex (N=50) p=0.904 a 
   Male 32 19 13
   Female 18 11 7
Age (years, median) (N=50) 4.1 2.9 7.8 p=0.280 c
   <2 years 19 13 6 p=0.341 a 
   2-10 years 18 9 9 p=0.279 a 
   >10 years 13 8 5 p=0.895 a  
WBC-count (x10E9/L, median) (N=46) 76.4 61.8 105.5 p=0.628 c 
   <50 x10E9/L 19 12 7 p=0.790 a 
   >50x10E9/L 27 16 11
High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia
123
4
Supplemental Table S8   Continued
11q23 translocations Total 
(N=50)
GATA2 normal
(N=30)
GATA2 high 
(N=20)
p- value
FAB subgroups (N=49) p=0.077 a 
   M0 3 1 2 p=0.559 b  
   M1 2 0 2 p=0.162 b  
   M2 1 0 1 p=0.408 b  
   M4 7 4 3 p=1.000 b  
   M5 34 24 10 p=0.014 a
   M7 2 0 2 p=0.162 b  
11q23 translocation partners (N=50) p=0.337 a
   AF9 18 11 7 p=0.904 a
   AF10 16 10 6 p=0.804 a
   AF6 6 2 4 p=0.202 b  
   ELL 4 2 2 p=1.000 b  
   ENL 1 0 1 p=0.400 b  
   AF17 1 1 0 p=1.000 b  
   AF4 0 0 0 NA
   Other 4 4 0 p=0.140 b  
Other genetic abnormalities (N=50)
   MLL-PTD 1 1 0 p=1.000 b  
   FLT3-ITD 2 0 2 p=0.155 b  
   NRAS/KRAS mutations 11 7 4 p=1.000 b  
   KIT mutations 1 1 0 p=1.000 b  
   PTPN11 mutations 1 1 0 p=1.000 b  
   High EVI1 expression 11 4 7 p=0.090 b  
   High WT1 expression 17 4 13 p<0.001 a
Patients with high GATA2 expression are compared with patients with normal GATA2 expression. P-values 
(bold) indicate whether differences are significant at the level of  .05. a c2 test; b Fisher exact test; c Mann- 
Whitney U test.
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Supplemental Table S9  Clinical and biological characteristics of AML patients with 
FLT3-ITD positivity
FLT3-ITD Total   
(N=48)
GATA2 normal    
(N=9)
GATA2 high 
(N=39)
p- value
Sex (N=48) p=0.713 b  
   Male 22 5 17
   Female 26 4 22
Age (years, median) (N=48) 11.2 12.6 11.0 p=0.751 c
   <2 years 1 1 0 p=0.188 b  
   2-10 years 18 2 16 p=0.451 b  
   >10 years 29 6 23 p=1.000 b  
WBC-count (x10E9/L, median) (N=42) 66.1 57.1 71.0 p=0.305 c
   <50 x10E9/L 16 4 12 p=0.711 b  
   >50x10E9/L 26 5 21
FAB subgroups (N=46) p=0.764 a
   M0 2 0 2 p=1.000 b  
   M1 11 1 10 p=0.658 b  
   M2 10 1 9 p=0.664 b  
   M3 12 3 9 p=0.412 b  
   M4 7 2 5 p=0.587 b  
   M5 4 1 3 p=0.548 b  
Cytogenetic abnormalities (N=46) p=0.159 a
   t(15:17) 12 3 9 p=0.412 b  
   t(8;21) 3 1 2 p=0.444 b  
   inv(16) 1 1 0 p=0.174 b  
   11q23 translocations 2 0 2 p=1.000 b  
   Rare cytogenetics 8 0 8 p=0.317 b  
   Normal cytogenetics (CN) 20 3 17 p=1.000 b  
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Supplemental Table S9   Continued
FLT3-ITD Total   
(N=48)
GATA2 normal    
(N=9)
GATA2 high 
(N=39)
p- value
Other genetic abnormalities (N=48)
   NPM1 mutations 7 1 6 p=1.000 b  
   CEBPA mutations 2 0 2 p=1.000 b  
     Single mutations 0 0 0 NA
     Double mutation 2 0 2 p=1.000 b  
   MLL-PTD 3 0 3 p=1.000 b  
   WT1 mutations 9 1 8 p=1.000 b  
   NRAS/KRAS mutations 2 1 1 p=0.343 b  
   High EVI1 expression 1 0 1 p=1.000 b  
   High WT1 expression  46 9 37 p=1.000 b  
Patients with high GATA2 expression are compared with patients with normal GATA2 expression. P-values 
(bold) indicate whether differences are significant at the level of  .05. a c2 test; b Fisher exact test; c Mann- 
Whitney U test.
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Supplemental Table S10  Clinical and biological characteristics of AML patients 
follow up cohort
Follow up 
(N=38)
Follow up 
(N=38)
No. (%) No. (%)
Sex (N=38) Other genetic abnormalities
   Male 27 (71%)    NPM1 mutations (N=29) 1 (3%)
   Female 11 (29%)    CEBPA mutations (N=24) 0
        CEBPA single mutations (N=24) 0
Age (years, median) 8.1 years         CEBPA double mutations (N=24) 0
      <2 years 10 (26%)    MLL-PTD (N=24) 1 (4%)
     2-10 years 12 (32%)    FLT3-ITD (N=31) 6 (19%)
     >10 years 16 (42%)    WT1 mutations (N=28) 2 (7%)
   NRAS/KRAS mutations (N=21) 2 (10%)
Blast-count (%, median) 89%    KIT mutations (N=30) 0
   PTPN11 mutations (N=14) 0
FAB subgroups (N=36)    High EVI1 expression (N=14) 3 (21%)
   M0 3 (8%)    High WT1 expression (N=38) 22 (58%)
   M1 4 (11%)
   M2 1 (3%) Response to therapy
   M3 1 (3%)    First Complete Remission (CR1) 33
   M4 12 (33%)    Refractory disease 2
   M5 10 (28%)    Early death 3
   M6 2 (6%)
   M7 3 (8%) Outcome
   Continuous CR1 21
Cytogenetic abnormalities (N=38)    Relapse 12
   t(8;21) 3 (8%)    Death 14
   inv(16) 3 (8%)      - Early Death 3
   t(15;17) 1 (3%)      - Death in RD 2
   11q23 translocations 14 (37%)      - Death in Relapse 7
   Rare cytogenetics 10 (26%)      - Death in CR1 2
   Normal cytogenetics (CN) 7 (18%)
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Supplemental Figure S1   Correlation of GATA2 expression with sex, age and WBC count
Normalized expression levels of GATA2 in pretreatment samples of 237 children with de novo 
AML stratified by sex (A), age (B), or WBC count (C). GATA2 expression was determined by gene-
expression profiling (Affymetrix HGU133 Plus 2.0 microarray, probeset 209710_at). Median 
values are depicted by the horizontal lines. Mann-Whitney U test was used to compare 
expression levels between two groups, Kruskal Wallis test to compare expression levels 
between more than two groups.
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Supplemental Figure S2  Relation of GATA2 expression with survival in patients with 
11q23 translocations or FTL3-ITD positivity
Kaplan-Meier estimates for pOS, pEFS, and pDFS in AML patients with 11q23 translocations (A), 
or FLT3-ITD (B). Patients with high GATA2 expression were compared with patients with normal 
GATA2 expression using a log-rank test. High GATA2 expression was associated with (a trend 
towards) worse outcome. P < .05 was considered statistically significant (2-tailed testing). 
Patient characteristics are described in Supplemental Table S8 and S9.
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Abstract
In acute promyelocytic leukemia (APL), differentiation therapy with all-trans retinoic 
acid (ATRA) and/or arsenic trioxide (ATO) can induce a differentiation syndrome (DS) 
with massive pulmonary infiltration of differentiating leukemic cells. Because chemokines 
are implicated in migration and extravasation of leukemic cells, chemokines might 
play a role in DS. ATRA stimulation of the APL cell line NB4 induced expression of 
multiple CC-chemokines (CCLs) and their receptors (≥ 19-fold), resulting in increased 
chemokine levels and chemotaxis. Induction of CCL2 and CCL24 was directly mediated 
by ligand-activated retinoic acid receptors. In primary leukemia cells derived from 
APL patients at diagnosis, ATRA induced chemokine production as well. Furthermore, 
in plasma of an APL patient with DS we observed chemokine induction, suggesting 
that chemokines might be important in DS. Dexamethasone, which efficiently reduces 
pulmonary chemokine production, did not inhibit chemokine induction in APL cells. 
Finally, chemokine production was also induced by arsenic trioxide as single agent or 
in combination with ATRA. We propose that differentiation therapy may induce 
chemokine production in the lung and in APL cells, which both trigger migration of 
leukemic cells. Because dexamethasone does not efficiently reduce leukemic chemokine 
production, pulmonary infiltration of leukemic cells may induce an uncontrollable 
hyper-inflammatory reaction in the lung.
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Introduction
Acute promyelocytic leukemia (APL) is characterized by a specific t(15;17) chromosomal 
translocation, which fuses the promyelocytic leukemia (PML) gene on chromosome 
15 to the retinoic acid receptor-alpha (RARA) gene on chromosome 17. This 
translocation results in blockage of terminal granulocytic differentiation at the 
promyelocytic stage.1;2 Treatment with high dosage of the RARA ligand all-trans 
retinoic acid (ATRA) relieves this blockage, resulting in terminal differentiation of the 
APL blasts. Presently, standard therapy for patients with newly diagnosed APL consists of 
a combination of ATRA and anthracycline-based chemotherapy which results in the 
induction of a complete remission in more than 90% of the patients, and a 5-year 
overall survival rate of more than 80%.3-11 In addition, arsenic trioxide (ATO) treatment 
has been shown to be highly effective in relapsed APL patients and has also been 
used successfully as a single agent or in combination with ATRA in newly diagnosed 
APL patients.12-21 
Despite the high cure rates, mortality during induction chemotherapy is a still a 
problem in APL. In a large series of 732 APL patients who received ATRA plus 
idarubicine, mortality during induction chemotherapy was 9%. The most common 
causes of death were hemorrhage, infection, and the differentiation syndrome (DS), 
formerly known as retinoic acid syndrome.22 DS is reported in 2.5%-31% of the APL 
patients who receive induction therapy with ATRA and/or ATO.5-7;10;14;16;19;20;23-30 DS is not 
observed during consolidation or maintenance therapy with ATRA and/or ATO in APL 
patients, nor is DS observed during ATRA- and/or ATO-treatment in non-APL 
malignancies, implicating that the APL cells play a crucial role in the development of 
DS.6;7;14;20;23;26;27;31 DS is characterized by respiratory distress, unexplained fever, weight 
gain, interstitial pulmonary infiltrates, pleural or pericardial effusions, hypotension, 
and acute renal failure. The diagnosis DS is made on clinical grounds by the presence 
of at least three of the aforementioned signs and/or symptoms, in the absence of 
alternative explanations.10;23;26;27;29  In addition, DS is often associated with the 
development of hyperleukocytosis, pulmonary edema, generalized edema, headache, 
and bone pain.10;23;26;27;29;30  The diagnosis DS has proven to be difficult, because none 
of the aforementioned symptoms is pathognomonic of the syndrome and can be the 
result of other medical problems, such as bacteremia, sepsis, pneumonia, pulmonary 
hemorrhage, or congestive heart failure.32;33 Therefore, DS may be underdiagnosed as 
well as overdiagnosed.
In DS, an excessive systemic inflammatory response is observed which can result in 
massive tissue infiltration of differentiating APL cells. The lung is one of the most 
relevant target organs of the inflammatory response in DS, illustrated by marked his-
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topathological changes and respiratory problems, requiring mechanical ventilation in 
15%-55% of the APL patients with DS.10;23;26;27;29;34;35 Furthermore, the excessive 
inflammatory response can induce a life-threatening capillary-leak syndrome and 
multi-organ failure.10;23;26;27;36 Although early recognition of DS and prompt treatment 
with high-dose dexamethasone have reduced the DS-related mortality significantly, 
still 15% of the induction deaths in APL are associated with DS.5-7;10;22;24-28  Furthermore, 
the development of DS has additional implications, such as an increased morbidity 
(e.g. increased risk of hemorrhage, higher incidence of thrombosis, increased rate of 
grade 3-4 hepatotoxicity), and may be associated with a higher risk of relapse.10;22;28;29
The pathogenic mechanism of the hyper-inflammatory cascade in DS is not fully 
understood. Two different mechanisms play an important role in the development of 
DS: the migration of APL cells to the lung and the differentiation of APL cells. The 
initial migration of APL cells to the lung seems to be triggered by alveolar chemokine 
secretion.34;37;38 ATRA is able to significantly increase the expression and production of 
specific chemokines (CCL2 and CXCL8) by alveolar epithelial cells in vitro and in vivo, 
resulting in increased migration of APL cells towards alveolar epithelial cells.34;37;38 
Suppression of alveolar chemokine secretion with dexamethasone or neutralization 
with specific chemokine antibodies resulted in reduction of the migration.34;37;38 Dif-
ferentiation of APL cells may be an additional crucial factor in the development of DS, 
because it seems to be required for the pulmonary infiltration of APL cells, observed 
in DS.34;37-39 In this respect, Tsai et al. showed that ATRA stimulation of APL cells 
significantly increased the migration of APL cells towards alveolar epithelial cells in 
vitro.37;38 In addition, in a murine APL-model, transplantation of ATRA-treated APL cells 
resulted in the development of DS with pulmonary infiltration and lung edema, which 
was not observed when untreated APL cells or ATRA-resistant APL cells were used for 
transplantation.34
Differentiation induction of APL cells is associated with increased expression of 
specific adhesion molecules and inflammatory cytokines, which may promote 
activation, migration, and adhesion of these cells. Furthermore, up-regulation of 
specific chemokines (CCL2 and CXCL8) has been reported during differentiation 
induction of APL cells.33;34;37-48 Because chemokines coordinate the development, dif-
ferentiation, and trafficking of leukocytes during inflammatory reactions and mediate 
the migration of leukemic cells, increased production of chemokines by differentiat-
ing APL cells may be important for the development of DS.49 Therefore, we examined 
the role of chemokines in the development of DS.
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Material and Methods
Cell culture and in vitro differentiation induction
NB4 cells, a retinoic acid-sensitive human APL cell line with the typical t(15;17) 
chromosomal translocation, were cultured in Roswell Park Memorial Institute 
(RPMI)-1640 culture medium (Invitrogen) supplemented with 10% heat-inactivated 
Fetal Bovine Serum (FBS; Invitrogen) and 1% penicillin/streptomycin (MP Biomedicals).50 
Primary leukemia cells were isolated from bone marrow or peripheral blood of five 
APL patients at diagnosis after informed consent. Mononuclear cells were isolated by 
means of a Ficoll-1077 (GE Healthcare) gradient and stored in liquid nitrogen. After 
thawing, leukemic cells were cultured in RPMI-1640 medium, supplemented with 20% 
FBS and 1% penicillin/streptomycin. Cultures were incubated at 37 0C in a 5% CO2 
completely humidified atmosphere. Leukemic cells were cultured in the presence or 
absence of ATRA (Sigma-Aldrich) for 0 to 48 hours. NB4 cells were cultured in the 
presence or absence of ATRA, ATO (Sigma-Aldrich), dexamethasone (Sigma-Aldrich), 
or cycloheximide (Sigma-Aldrich) for 0 to 96 hours. ATRA, ATO, and dexamethasone 
were used at a final concentration of 10-6 M. Cycloheximide was added 30 minutes 
prior to ATRA at a final concentration of 50 µg/ml.
Morphology and flow cytometry analysis
NB4 cells, treated with ATRA and/or ATO were harvested at the indicated time points. 
To evaluate morphologic status of NB4 cells, May-Grünwald-Giemsa (MGG) staining of 
cytospins was performed at the indicated time points using the Axioskop microscope 
(Plan-NEOFLUAR 40x/0.75 objective; Zeiss). Images were acquired using the Sony 
3CCD color video camera (DXC-950P; Sony). Microsoft Photo Editor Version 3.01 was 
used for image acquisition (Microsoft Corporation). To analyze the differentiation of 
NB4 cells during ATRA and/or ATO induction, cells were stained with a phycoerythrin 
(PE)-conjugated human CD11b antibody (Dako Cytomation). To analyze apoptosis of NB4 
cells during ATRA and/or ATO induction, cells were stained with a fluorescein isothiocyanate 
(FITC)-conjugated Annexin V antibody (VPS Diagnostics) in combination with a 
propidium iodide antibody (P-4170, Sigma-Aldrich). Stained cells were analyzed with 
CXP software (Beckman Coulter) on a Beckman Coulter Cytomics Flow Cytometer 500 
(Beckman Coulter).
APL patients, induction therapy and diagnosis of DS
After informed consent was obtained in accordance with the Declaration of Helsinki, 
we obtained blood plasma from newly diagnosed APL patients before and during 
treatment according to the AIDA-2000/P protocol. 5;51 Institutional review board 
approval for these studies was obtained from the Radboud University Nijmegen 
Medical Center according to local laws and regulations. Induction therapy was 
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composed of ATRA (45 mg/m2/day, from day 1 until day 30) and Idarubicine (12 mg/
m2/day on day 2, 4, 6, 8). 5;51 Prednisone (0.5 mg/kg/day) was added to the treatment 
from day 1 until the end of ATRA therapy to prevent DS. Diagnosis of APL was based 
on cell morphology, cytogenetics, immune phenotyping and polymerase chain 
reaction (PCR) for PML-RARα. Diagnosis of DS was made according to the presence of 
at least three of the following signs or symptoms described by Frankel et al.: respiratory 
distress, weight gain, unexplained fever, pulmonary infiltrates, pleuropericardial 
effusions, hypotension, and acute renal failure.23 The presence of a high white blood 
cell (WBC) counts, headache, bone pain, pulmonary edema, or generalized edema 
was considered as supporting evidence for the diagnosis DS.10;27;29 The diagnosis 
disseminated intravascular coagulation (DIC) was based on the presence of 
hemorrhage, thrombocytopenia, low fibrinogen concentrations, high levels of fibrin 
degradation products (D-dimer). WBC counts and coagulation parameters (including 
fibrinogen, D-dimer, and platelet counts) of the patients at diagnosis and during the 
first two weeks of induction therapy are described in detail in Supplemental Figure 1.
Microarray and data analysis
Total RNA was isolated from NB4 cells before and after differentiation induction with 
ATRA using RNA-Bee (Iso-Tex Diagnostics). A second purification step of the total RNA 
was performed using sodium acetate (0.5M, Calbiochem-Novabiochem) and ethanol 
(96%, Merck KGaA). RNA quality was tested using the Agilent 2100 Bioanalyzer (Agilent 
Technologies). An amount of of 5 μg of total RNA from each sample was used for 
hybridization on the GeneChip® Human Exon 1.0 sense target Array containing 1.4 
million probe sets (Affymetrix) according to the manufacturer’s instructions. Gene 
level expression data were calculated for the CORE transcripts with help of Affymetrix 
Expression Console software using sketch-quantile normalization, PM-GCBG 
background correction, and summarization with the iterPLIER (Probe Logarithmic 
Intensity Error Estimation) algorithm. For all arrays the AUC score was above 0.90, 
indicating a good separation of the positive controls from the negative controls. 
Pearson correlation was used to check the correspondence pattern between time 
points. For each time point and for each gene the fold change with respect to the 
expression at time point t=0 hour was calculated. Genes encoding for CC-chemokines 
(CCLs) with more than a 5-fold change compared to time point t=0 hour were selected 
for validation. All microarray data have been deposited in the GEO public database 
under accession number GSE18397.
Quantitative PCR analysis
RNA was isolated from NB4 cells using RNA-Bee (Iso-Tex Diagnostics). RNA from 
leukemic cells (derived from five APL patients) was isolated using the mini RNA 
Isolation II kit (Zymo Research). For complementary DNA (cDNA) synthesis, 1 mg of 
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total RNA from NB4 cells and 300-600 ng of total RNA from leukemic cells was used. 
To measure CCL-mRNA expression, Premixed TaqmanÒ Gene Expression assays were 
used (CCL1: Hs00171072_m1, CCL2: Hs00234140_m1, CCL3: Hs00234142_m1, CCL4: 
Hs00237011_m1, CCL7: Hs00171147_m1, CCL20: HS00171125_m1, CCL22: Hs00171080_
m1, CCL24: Hs00171082_m1, Applied Biosystems). As a reference gene a premixed 
assay for GAPDH was used (4326317E, Applied Biosystems). Quantitative PCR reactions 
contained 2.5 µl cDNA, 1x TaqMan® Universal PCR Master Mix (58003365-01, Applied 
Biosystems), 1x TaqMan® Gene Expression Assay (Applied Biosystems). The 25 µl 
reactions were incubated in a 96-well plate for 10 minutes at 95 0C, followed by 45 
cycles of 10 seconds at 95 0C and 1 minute at 60 0C. Quantitative PCR reactions were 
performed on the ABI/PRISM 7700 or 7900 Sequence Detection system (ABI/PE).
Protein level measurements
EDTA-plasma of three APL patients and cell culture supernatant of NB4 cells and 
leukemic cells (derived from five APL patients) were stored at -20 oC and used for 
quantification of CCLs. Protein levels of CCL1, CCL20, and CCL22 were quantified using 
Quantikine® human enzyme-linked immunosorbant assay (ELISA) kits (R&D Systems). 
CCL24 was quantified using a Quantikine® human ELISA kit (R&D Systems) or a RayBio® 
human ELISA kit (RayBiotech). CCL2, CCL4 and CCL7 were quantified using Biosource 
antibody bead kits (Biosource International) for the cytometric bead-based 
immunoassay system (Luminex). All assays were performed according to the 
manufacturer’s protocols. The detection limits were as follows: for CCL20: 0.47 pg/ml; 
for CCL1: 0.71 pg/ml; for CCL24: 2.0-2.5 pg/ml; for CCL2 and CCL4: 10 pg/ml; for CCL7: 
15 pg/ml; for CCL22: 62.5 pg/ml. 
Migration assay
The chemoattractive effect of ATRA-treated APL cells on WBCs was evaluated using 
transwell polycarbonate inserts (6.5 mm diameter) with 5 mm pores (Costar Corning). 
Blood from healthy donors was drawn in EDTA. WBCs were isolated with a 1085 g/l 
Percoll gradient (Pharmacia Fine Chemical) or erythrocyte lysis buffer (140 mM NH4Cl, 
9 mM KHCO3, 0.9 mM Na2EDTA, pH 7.4; MERCK KGaA). WBCs were resuspended in 
RPMI-1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin to a 
cell concentration of 2-6 X 10E6/ml. This cell suspension was incubated for one hour 
at 37 0C and 5% CO2. A total of 200 µl of the WBC suspension was added to the upper 
compartment. To the lower compartment, 750 ml NB4 cell culture supernatant (before 
or after ATRA stimulation) was added. WBCs were allowed to migrate for 45-55 
minutes at 37 °C and 5% CO2. Next, the inserts were removed and WBCs that had 
migrated to the lower compartment were counted under the microscope. Migration 
experiments with NB4 cell culture supernatants were performed four times. Statistical 
significance between time points was determined by using the Student t test.
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Results
ATRA induces CCL expression and production in NB4 cells
We evaluated the expression profiles of chemokines in the APL cell line NB4 during 
ATRA-induced differentiation using the GeneChip® Human Exon 1.0 ST Array 
(Affymetrix). Expression of 8 of 23  CCLs was up-regulated more than 5-fold after ATRA 
stimulation (6- to 151-fold, Table 1). The expression of several CC-chemokine receptors 
(CCRs) was upregulated more than 5-fold as well (19- to 21-fold, Table 1). We focused 
on the effect of ATRA on CCL expression and confirmed induction of 7 of these CCLs 
at the mRNA level using quantitative PCR (57- to 11,502-fold; Figure 1A). CCL3 showed 
an induction of less than 5-fold by quantitative PCR (data not shown). Subsequently, 
we verified whether the upregulation at the mRNA level also translated into increased 
protein levels in supernatant of NB4 cells using ELISA. Protein levels of all seven CCLs 
increased significantly after ATRA stimulation (Figure 1B). 
Next, we investigated whether the supernatant of ATRA-treated NB4 cells could 
induce chemo-attraction of leukocytes in a transwell system. In four independent 
experiments, 7% (± 4%) of healthy WBCs migrated from the insert toward the lower 
compartment with supernatant of untreated NB4 cells within 45 to 55 minutes. When 
Table 1  ATRA induces expression of CCLs and CCRs in NB4 cells
Gene expression intensity 
before ATRA (AU)
Maximum gene expression 
intensity after ATRA (AU)
Fold change
CCL2 71 10285 151
CCL22 18 1822 104
CCL24 13 969 78
CCL4 14 896 61
CCL20 72 1441 21
CCL3 181 3576 20
CCL1 42 754 19
CCL7 19 108 6
CCR1 48 1331 28
CCR2 41 851 21
CCR3 25 489 19
mRNA expression of CCLs and CCRs was determined in total RNA from NB4 cells cultured with ATRA (10-6 M) 
for 0, 4, 8, 24, 48, 72, and 96 hours using the GeneChip® Human Exon 1.0 ST Array. The table represents 
chemokines and receptors with at least 5-fold up-regulation of the gene expression intensity (in arbitrary 
units (AU)) after 48 to 96 hours of ATRA treatment.
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Figure 1   ATRA induces expression of CCLs in NB4 cells
NB4 cells were cultured with ATRA (10-6M) for 0, 4, 8, 24, 48, 72, and 96 hours. (A) CCL mRNA 
expression (mean + SD of three independent experiments) was determined at the indicated 
time points by quantitative PCR. Expression, relative to GAPDH, is plotted. (B) CCL protein levels 
(mean of two independent experiments) were determined in supernatant of NB4 cells at the 
indicated time points using ELISA. (C) The effect of ATRA on chemoattraction of normal WBCs 
toward the supernatant of ATRA-stimulated NB4 cells. The percentages of migrated WBCs 
(mean + SD of four independent experiments) were determined before and 8, 24, 72 and 96 
hours after ATRA-stimulation of NB4 cells, using a transwell system. *P  <  .01; ** P <  .05 compared 
with supernatant of untreated NB4 cells. (D) Direct regulation of CCL2 and CCL24 by ligand- 
activated retinoic acid receptors in NB4 cells. NB4 cells were cultured with ATRA alone (10-6M), 
with cycloheximide alone (50 µg/ml), or with the combination of ATRA and cycloheximide for 0, 
2, 4, and 8 hours. mRNA expression of CCL2 and CCL24 (top panels, mean ± SD of three 
independent experiments) was determined at the indicated time points by quantitative PCR. 
Expression relative to GAPDH is plotted. Protein levels of CCL2 and CCL24 (bottom panels) were 
measured in supernatant of NB4 cells before and 8 hours after treatment with ATRA and/or 
cycloheximide using ELISA. ND indicates not detectable; MDD indicates minimal detectable 
dose, according to the manufacturer.
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supernatant collected 72 or 96 hours after ATRA stimulation was used, the percentage 
of transmigrating WBCs increased significantly to 41% (± 10%, P = .001) and 30% 
(±16%, P = .03), respectively (Figure 1C). Overall, we observed an increased chemoat-
tractive capacity of supernatant of ATRA-treated NB4 cells compared with untreated 
NB4 cells, in parallel with the increased chemokine production (Figures 1A-C).
Interestingly, the expression of CCL2 and CCL24 was already more than 5-fold 
up-regulated within four hours after ATRA-stimulation (18- and 98-fold, respectively; 
Figure 1A), suggesting that these chemokines may be directly regulated by ligand-
activated retinoic-acid receptors. The early up-regulation of these chemokines 
resulted in increased protein levels in the supernatant eight hours after ATRA-stimu-
lation (6- and 8 fold, respectively; Figure 1B). To investigate whether the induction of 
Figure 1   Continued
C
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CCL2 and CCL24 gene expression was directly regulated by ligand-activated retinoic 
acid receptors or, alternatively, was regulated by intermediate proteins that were 
induced in response to ATRA, NB4 cells were treated with the protein translation 
inhibitor cycloheximide, before the addition of ATRA. Despite the addition of 
cycloheximide, CCL2 and CCL24 mRNA expression was up-regulated (13- and 76-fold, 
respectively) four hours after ATRA stimulation (Figure 1D). As expected, CCL2 and 
CCL24 protein levels were not induced, indicating that protein translation was indeed 
effectively inhibited (Figure 1D). These results indicate that CCL2 and CCL24 are directly 
regulated by ligand-activated retinoic acid receptors.
Dexamethasone does not abrogate ATRA-induced CCL expression
Dexamethasone is used for the prevention and treatment of DS. Therefore, we 
investigated the effect of dexamethasone on the ATRA-induced chemokine expression 
5
Figure 2   Dexamethasone does not abrogate ATRA-induced CCL expression in NB4 cells
NB4 cells were cultured with ATRA alone (10-6M), with dexamethasone alone (10-6M), or with the 
combination of ATRA and dexamethasone for 0, 4, 8, 24, 48, 72, and 96 hours. CCL mRNA 
expression was determined at the indicated time points by quantitative PCR. Expression relative 
to GAPDH is plotted.
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in APL in vitro. NB4 cells were treated with ATRA, dexamethasone, or both. Subsequently, 
chemokine expression was measured by quantitative PCR. We observed induction of 
CCL expression by ATRA, regardless of the addition of dexamethasone. In the absence 
of ATRA, the expression of these CCLs was not induced (Figure 2). These results show 
that dexamethasone does not abrogate the induction of CCLs in ATRA-stimulated APL 
cells in vitro.
ATRA induces CCL expression in APL patients in vitro and in vivo
Next, we investigated whether the seven CCLs that were induced in NB4 cells were 
also induced in primary leukemia cells from APL patients. Leukemic cells derived from 
five APL patients at diagnosis were induced with ATRA in vitro. CCL2 was the only 
chemokine that was consistently up-regulated on mRNA and protein level in all five 
patients during ATRA induction. mRNA levels of CCL2 were 3- to 6-fold up-regulated 
48 hours after ATRA-stimulation (Figure 3A), resulting in a 2- to 14-fold up-regulation 
of CCL2 protein levels in the supernatant of these cells (Figure 3B).
To determine whether ATRA could also induce chemokine production in vivo, we 
measured plasma levels of CCLs in three APL patients during induction therapy with 
ATRA, idarubicine and prednisone (AIDA-2000/P protocol).5;51 All three patients 
presented with hemorrhage, thrombocytopenia (12-31 X 109/L), low to normal 
fibrinogen concentrations (1410-1640 mg/L), and high levels of fibrin degradation 
products (D-dimer: 14720-31820 ng/ml), which are indicative for disseminated 
intravascular coagulation, and therefore received multiple transfusions with fresh 
frozen plasma, platelets, and red blood cells (Supplemental figure S1). In patient A and B, 
induction therapy was not complicated by DS or hyperleukocytosis (maximum 
WBC count 2.1 X 109/L and 1.9 X 109/L,  respectively; Supplemental figure S1). In both 
patients, no evident induction of chemokines was observed in plasma during 
induction therapy with ATRA and idarubicine (Figure 3C and Supplemental table 1). 
Patient C presented with a high WBC count at diagnosis (8.2 X 109/L) and developed 
DS within 24 hours after start of induction therapy with ATRA and prednisone (Figure 
3D). The diagnosis DS was based on development of respiratory distress in combination 
with diffuse pulmonary infiltrates and pleural effusion on chest X-ray, without any 
signs of infection. Therefore, ATRA was discontinued and dexamethasone treatment 
was started immediately. The diagnosis DS was supported by the development of 
hyperleukocytosis, weight gain, headache, generalized edema, and pulmonary edema 
(interstitial and alveolar) without focal infiltrations on high resolution computed 
tomography scan (Figure 3D). Interestingly, we observed evident induction of multiple 
chemokines (2- to 5-fold), including CCL2, during induction therapy in the plasma of 
patient C, which may be associated with the development of DS (Figure 3C and 
Supplemental table 1).
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Figure 3   ATRA induces CCL expression in APL patients in vitro and in vivo
(A) Primary leukemia cells derived from five different APL patients at diagnosis were cultured 
with ATRA (10-6M) for 0, 8, and 48 hours. CCL2 mRNA expression was determined at the indicated 
time points by quantitative PCR. Expression relative to GAPDH is plotted. (B) CCL2 protein levels 
were determined in supernatant of the leukemic cells at the indicated time points using ELISA. 
(C) Protein levels of CCLs were determined in plasma of three APL patients before and during 
induction therapy with ATRA (45 mg/m2/day), idarubicine (Ida, 12 mg/m2/day on day 2, 4, 6, 8), 
and prednisone (PRED, 0.5 mg/kg/day) using ELISA. Patient A (left panel) and patient B (middle 
panel) had no signs of DS. Patient C (right panel) developed a DS within 24 hours after initiation 
of induction therapy. (D) Clinical course of APL patient C who developed DS. The patient 
presented with a high WBC count (8.2 X 109/L). One day after onset of induction therapy DS 
manifested with mild respiratory distress, pleural effusion, and diffuse pulmonary infiltrates 
on chest X-ray. ATRA was discontinued and dexamethasone (10 mg/12 hours) was administered. 
A peak WBC count of 17.1 X 109/L (black line) was reached three days after start of therapy. 
Although ATRA therapy was discontinued, the patient developed generalized edema, weight 
gain (gray line) and headache. Respiratory distress aggravated on day 4 to 5, resulting in an 
increasing need for oxygen supply. High resolution computed tomography on day 6 showed 
evident signs of interstitial and alveolar pulmonary edema. After DS completely resolved, 
ATRA was resumed on day 8 at a 20% dose and gradually increased to a 100% dose at day 12. 
Dexamethasone was continued until day 11.
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ATO induces expression and production of CCL2 and CCL7 in NB4 cells
Because DS is also observed during induction therapy with ATO as a single agent or in 
combination with ATRA, we subsequently investigated the effect of both treatment 
modalities on chemokine expression in APL.14;16;19;20 NB4 cells were cultured in medium in 
the presence or absence of ATRA, ATO, or their combination for 96 hours. Morphological 
analysis showed that ATRA induced differentiation of NB4 cells, which was confirmed 
Figure 3   Continued
C
D
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Figure 4   Induction of differentiation and apoptosis by ATRA and ATO in NB4 cells
NB4 cells were cultured in medium in the presence or absence of ATRA (10-6M), ATO (10-6M), or 
their combination, for 0, 4, 8, 24, 48, 72, and 96 hours. (A) May-Grünwald- Giemsa staining was
A
B
C
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by a significant increase in CD11b expression, measured by flow cytometry (Figures 
4A-B). ATO treatment resulted in morphologically apoptotic cells with partial differen-
tiation, as described by Chen et al. (Figure 4A).52;53 In addition, flow cytometric analysis 
showed a significant increase in Annexin V-positive and double-positive cells (Annexin 
V and propidium iodide) cells during ATO treatment, which is a hallmark for apoptosis 
induction, and a slight increase of CD11b expression (Figures 4B-C). When ATRA and 
ATO were combined, we observed evident induction of differentiation and apoptosis, 
as expected (Figure 4A-C).54 Subsequently, we investigated the effect of ATO on the 
expression of the seven CCLs that were induced by ATRA in NB4 cells. CCL2 and CCL7 
were consistently up-regulated at the mRNA and protein level in ATO-treated NB4 
cells. At 96 hours after ATO-stimulation, mRNA levels of CCL2 and CCL7 were 
upregulated 37- and 124-fold, respectively, resulting in a significant increase of protein 
levels of both CCLs in supernatant of ATO-treated NB4 cells (Figure 5A-B). The 
expression of CCL1, CCL4, CCL20, CCL22, and CCL24 was less than 5-fold up-regulated in 
ATO-treated NB4 cells (Supplemental figure S2). When ATO was combined with ATRA, 
the expression of all seven CCLs was induced (32- to 1664-fold; Figure 5A-B and 
Supplemental figure S2). 
performed on cytospins after the indicated treatments for 96 hours. ATRA-treated cells showed 
typical differentiation features, such as wider cytoplasm and more lobulated nuclei. ATO-treated 
cells showed evident signs of apoptosis, including fragmentation of the nuclei and formation of 
apoptotic bodies. (B) After 72 hours of ATRA and/or ATO treatment, CD11b expression was 
analyzed by flow cytometry to determine differentiation. Mean fluorescence intensity (MFI) of 
the life-gated cells is plotted. (C) Annexin V and propidium iodide (PI) staining was performed 
to determine apoptosis after 72 hours of ATRA and/or ATO treatment. Analysis was performed 
on the ungated cells. The percentages of negative, single-positive and double-positive cells are 
depicted.
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Figure 5   ATO induces expression of CCL2 and CCL7 in NB4 cells
NB4 cells were cultured in medium in the presence or absence of ATRA (10-6M), ATO (10-6M), or 
their combination for 0, 4, 8, 24, 48, 72, and 96 hours. (A) CCL mRNA expression was determined 
at the indicated time points by quantitative PCR. Expression relative to GAPDH is plotted. 
(B) CCL protein levels were determined in supernatant of NB4 cells at the indicated time points 
using ELISA. MDD indicates minimal detectable dose, according to the manufacturer.
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Figure 6   Model of the role of chemokines and dexamethasone in DS
Schematic representation of the role of chemokines (A) and dexamethasone (B) in DS. (A) ATRA 
forces APL blasts to differentiate into mature granulocytes (1). In addition, ATRA induces 
chemokine production by the differentiating APL cells (2) as well as by alveolar epithelial cells 
(3). Alveolar chemokine secretion triggers the migration of differentiating APL cells to the lung 
(gray arrows). Enhanced migration of leukemic cells in response to massive chemokine 
production by the differentiating APL cells infiltrating the lung (black arrows) will aggravate the 
hyperinflammatory reaction in the lung. (B) Reduction of the alveolar chemokine secretion by 
A
B
Chemokine induction by ATRA and ATO in APL - triggering the differentiation syndrome
149
Discussion
In this study, we show that differentiation induction with ATRA and/or ATO causes a 
strong up-regulation of chemokine production by APL cells. This is in line with results 
of Shibakura et al. who reported induction of chemokines in APL patients with DS.46 
We propose that massive production of chemokines by differentiating APL cells may 
play an important role in the development of DS. Previously, it was shown that the 
production of chemokines by alveolar epithelial cells in the lung, which can be 
enhanced by ATRA, might be implicated in DS.34;37;38 In addition, we observed that dif-
ferentiation induction causes up-regulation of the chemokine receptors CCR1, CCR2, 
and CCR3, which can bind to CCL2, CCL7, CCL24 and several other CCLs (Table 1 and 
Supplemental Table 2). The induction of chemokine receptors on differentiating APL 
cells, together with enhanced secretion of chemokines by alveolar epithelial cells, 
might trigger the migration of leukemic cells toward the lung. Tissue infiltration of 
differentiating leukemic cells, which massively produce chemokines, might further 
enhance the migration of leukemic cells from the blood to the tissues and thereby 
aggravate the inflammatory response in the tissues. This is supported by results from 
Tsai et al. who showed that blockage of specific chemokine receptors on differentiating 
APL cells reduced the migration of APL cells towards alveolar epithelial cells in vitro.37;38
Corticosteroid therapy may effectively prevent the development of DS when administered 
at early stages but the exact mechanism of action is not completely clear.34 In a previous 
study, we showed that dexamethasone did not affect the induction of terminal 
 differentiation in APL cells.55 In the present study, we demonstrate that dexamethasone 
does not abrogate the induction of chemokines in the differentiating APL cells either. 
In line with these results, Tsai et al. showed that dexamethasone did not reduce the 
secretion of CCL2 and CXCL8 by differentiating APL cells in vitro.37;38 On the other hand, 
the production of chemokines by the alveolar epithelial cells can effectively be 
diminished by dexamethasone in vitro as well as in vivo, resulting in reduced migration 
of APL cells toward alveolar epithelial cells.34;37;38 Together, these results indicate that 
corticosteroids might prevent pulmonary infiltration of APL cells via reduction of the 
alveolar chemokine secretion, and thereby might prevent the development of DS. In 
a full-blown DS, differentiating APL cells have already invaded target tissues, such as 
the lung, and the massive chemokine production by these leukemic cells may induce 
5
dexamethasone (DEX) can eliminate the initial trigger for migration of APL cells to the lung and 
thereby may prevent pulmonary infiltration of APL cells (gray arrows). Dexamethasone does not 
abrogate the chemokine induction in APL cells. As soon as differentiating APL cells have 
infiltrated the lung, the ongoing chemokine production by these cells will enhance migration 
of leukemic cells towards the lung (black arrows), resulting in a severe hyperinflammatory 
reaction.
Chapter 5
150
ongoing chemoattraction and inflammation in these tissues. Because dexamethasone 
does not reduce the chemokine production by differentiating APL cells, corticosteroids 
may be less effective in the treatment of a full-blown DS. In addition, we show that the 
expression of two strongly induced chemokines (CCL2 and CCL24) is directly regulated 
by ligand-activated retinoic acid receptors in APL cells, suggesting a direct role for the 
PML-RARα fusion protein in the induction chemokines. The involvement of the 
PML-RARα fusion protein might explain why DS seems to be confined to APL and is 
not observed during ATRA treatment in non-APL malignancies. Furthermore, this 
might explain why dexamethasone can reduce the production of chemokines by 
alveolar epithelial cells whereas the chemokine induction in APL cells is not affected 
by dexamethasone.34;37;38
In conclusion, differentiation therapy may cause massive chemokine production in 
APL cells, in vitro as well as in vivo. We propose a model illustrating the role of 
chemokine induction in the development of DS (Figure 6). The first component is the 
migration of differentiating APL cells toward the lung in response to pulmonary 
chemokine production. The second component is the enhanced migration of leukemic 
cells in response to chemokines produced by differentiating APL cells infiltrating the 
lung (Figure 6A). This process can aggravate the hyperinflammatory reaction in the 
lung. Because the massive chemokine induction in differentiating APL cells is not 
abrogated by corticosteroids, disruption of this process may be difficult. Therefore, 
corticosteroid treatment may not be sufficient to reverse a fully developed DS. 
According to this model, intervention with corticosteroid may be effective in the 
initiation phase of DS through reduction of the pulmonary chemokine secretion, 
eliminating the initial trigger for migration of APL cells to the lung (Figure 6B). Thereby, 
this model underlines the importance of early recognition of DS and prompt treatment 
with corticosteroids. For a full-blown differentiation syndrome the optimal treatment 
approach is not clear. Interventions that directly target the secreted chemokines or 
their receptors might inhibit the hyperinflammation and chemotaxis driven by the 
differentiating APL cells. To this end, the application of chemokine (receptor) 
antagonists might be effective in a full-blown DS. 
Acknowledgements
The authors thank Richard Huijbens, Rheumatology Research and Advanced Therapeutics 
Department, Radboud University Nijmegen Medical Centre, for his help with protein 
level measurements; Robbert van der Voort, Department of Laboratory Medicine, 
Laboratory of Hematology, Radboud University Nijmegen Medical Center, for critically 
reading the manuscript; Christian Gilissen, Department of Human Genetics, Radboud 
University Nijmegen Medical Centre, for his help with analyzing the microarray data. 
This work was supported by the Dutch Cancer Society (grant no. 03-2897).
Chemokine induction by ATRA and ATO in APL - triggering the differentiation syndrome
151
Reference List
1.  de The H, Lavau C, Marchio A, Chomienne C, De-
gos L, Dejean A. The PML-RAR alpha fusion 
mRNA generated by the t(15;17) translocation in 
acute promyelocytic leukemia encodes a func-
tionally altered RAR. Cell. 1991;66(4):675-684.
2.  Kakizuka A, Miller WH, Jr., Umesono K, et al. 
Chromosomal translocation t(15;17) in human 
acute promyelocytic leukemia fuses RAR alpha 
with a novel putative transcription factor, PML. 
Cell. 1991;66(4): 663-674.
3.  Warrell RP, Jr., Frankel SR, Miller WH, Jr., et al. Dif-
ferentiation therapy of acute promyelocytic leu-
kemia with tretinoin (all-trans-retinoic acid). N 
Engl J Med. 1991;324(20):1385-1393.
4.  Warrell RP, Jr., de The H, Wang ZY, Degos L. Acute 
promyelocytic leukemia. N Engl J Med. 1993;329 
(3):177-189.
5.  Mandelli F, Diverio D, Avvisati G, et al. Molecular 
remission in PML/RAR alpha-positive acute pro-
myelocytic leukemia by combined all-trans reti-
noic acid and idarubicin (AIDA) therapy. Gruppo 
Italiano-Malattie Ematologiche Maligne dell’A-
dulto and Associazione Italiana di Ematologia 
ed Oncologia Pediatrica Cooperative Groups. 
Blood. 1997;90(3):1014-1021.
6.  Fenaux P, Chastang C, Chevret S, et al. A rand-
omized comparison of all transretinoic acid 
(ATRA) followed by chemotherapy and ATRA 
plus chemotherapy and the role of maintenance 
therapy in newly diagnosed acute promyelo-
cytic leukemia. The European APL Group. Blood. 
1999;94(4):1192-1200.
7.  Sanz MA, Martin G, Gonzalez M, et al. Risk-adapt-
ed treatment of acute promyelocytic leukemia 
with all-trans-retinoic acid and anthracycline 
monochemotherapy: a multicenter study by the 
PETHEMA group. Blood. 2004;103(4):1237-1243.
8.  Asou N, Kishimoto Y, Kiyoi H, et al. A randomized 
study with or without intensified maintenance 
chemotherapy in patients with acute promyelo-
cytic leukemia who have become negative for 
PML- RARalpha transcript after consolidation 
therapy: the Japan Adult Leukemia Study Group 
(JALSG) APL97 study. Blood. 2007;110(1):59-66.
9.  Wang ZY, Chen Z. Acute promyelocytic leuke-
mia: from highly fatal to highly curable. Blood. 
2008;1 11(5):2505-2515.
10.  Montesinos P, Bergua JM, Vellenga E, et al. Dif-
ferentiation syndrome in patients with acute 
promyelocytic leukemia treated with all-trans-
 retinoic acid and anthracycline chemotherapy: 
characteristics, outcome and prognostic factors. 
Blood. 2009;113(4):775-783.
11.  Sanz MA, Montesinos P, Vellenga E, et al. Risk-
adapted treatment of acute promyelocytic leu-
kemia with all-trans retinoic acid and anthracy-
cline monochemotherapy: long-term outcome 
of the LPA 99 multicenter study by the PETHEMA 
Group. Blood. 2008;112(8):3130-3134.
12.  Soignet SL, Frankel SR, Douer D, et al. United 
States multicenter study of arsenic trioxide in 
relapsed acute promyelocytic leukemia. J Clin 
Oncol. 2001;19(18):3852-3860.
13.  Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic tri-
oxide (As2O3) in the treatment of acute promye-
locytic leukemia (APL): II. Clinical efficacy and 
pharmacokinetics in relapsed patients. Blood. 
1997;89(9):3354-3360.
14.  Mathews V, George B, Lakshmi KM, et al. Single-
agent arsenic trioxide in the treatment of newly 
diagnosed acute promyelocytic leukemia: dura-
ble remissions with minimal toxicity. Blood. 
2006;107(7): 2627-2632.
15.  Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, 
et al. Treatment of acute promyelocytic leuke-
mia with arsenic trioxide without ATRA and/or 
chemotherapy. Ann Oncol. 2006;17(1):131-134.
16.  Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of 
all-trans retinoic acid plus arsenic trioxide as an 
alternative to chemotherapy in untreated acute 
promyelocytic leukemia. Blood. 2006;107(9): 
3469-3473.
17.  Hu J, Liu YF, Wu CF, et al. Long-term efficacy and 
safety of all-trans retinoic acid/arsenic trioxide-
based therapy in newly diagnosed acute pro-
myelocytic leukemia. Proc Natl Acad Sci U S A. 
2009;106(9):3342-3347.
18.  Wang G, Li W, Cui J, et al. An efficient therapeutic 
approach to patients with acute promyelocytic 
leukemia using a combination of arsenic triox-
ide with low-dose all-trans retinoic acid. Hema-
tol Oncol. 2004;22(2):63-71.
19.  Ravandi F, Estey E, Jones D, et al. Effective treat-
ment of acute promyelocytic leukemia with all-
trans-retinoic acid, arsenic trioxide, and gemtu-
zumab ozogamicin. J Clin Oncol. 2009;27(4):504-
510.
20.  Dai CW, Zhang GS, Shen JK, et al. Use of all-trans 
retinoic acid in combination with arsenic triox-
ide for remission induction in patients with 
5
Chapter 5
152
newly diagnosed acute promyelocytic leukemia 
and for consolidation/maintenance in CR pa-
tients. Acta Haematol. 2009;121(1):1-8.
21.  Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic 
acid/As2O3 combination yields a high quality 
remission and survival in newly diagnosed acute 
promyelocytic leukemia. Proc Natl Acad Sci U S A. 
2004;101(15):5328-5335.
22.  de la Serna J, Montesinos P, Vellenga E, et al. 
Causes and prognostic factors of remission in-
duction failure in patients with acute promyelo-
cytic leukemia treated with all-trans retinoic 
acid and idarubicin. Blood. 2008;111(7):3395-
3402.
23.  Frankel SR, Eardley A, Lauwers G, Weiss M, War-
rell RP, Jr. The “retinoic acid syndrome” in acute 
promyelocytic leukemia. Ann Intern Med. 
1992;117(4):292-296.
24.  Vahdat L, Maslak P, Miller WH, Jr., et al. Early mor-
tality and the retinoic acid syndrome in acute 
promyelocytic leukemia: impact of leukocytosis, 
low-dose chemotherapy, PMN/RAR-alpha iso-
form, and CD13 expression in patients treated 
with all-trans retinoic acid. Blood. 1994;84(11): 
3843-3849.
25.  Asou N, Adachi K, Tamura J, et al. Analysis of 
prognostic factors in newly diagnosed acute 
promyelocytic leukemia treated with all-trans 
retinoic acid and chemotherapy. Japan Adult 
Leukemia Study Group. J Clin Oncol. 1998;16 
(1):78-85.
26.  de Botton S, Dombret H, Sanz M, et al. Incidence, 
clinical features, and outcome of all trans-retino-
ic acid syndrome in 413 cases of newly diag-
nosed acute promyelocytic leukemia. The Euro-
pean APL Group. Blood. 1998;92(8):2712-2718.
27.  Tallman MS, Andersen JW, Schiffer CA, et al. Clin-
ical description of 44 patients with acute pro-
myelocytic leukemia who developed the reti-
noic acid syndrome. Blood. 2000;95(1):90-95.
28.  de Botton S, Chevret S, Coiteux V, et al. Early on-
set of chemotherapy can reduce the incidence 
of ATRA syndrome in newly diagnosed acute 
promyelocytic leukemia (APL) with low white 
blood cell counts: results from APL 93 trial. Leu-
kemia. 2003;17(2):339-342.
29.  Breccia M, Latagliata R, Carmosino I, et al. Clini-
cal and biological features of acute promyelo-
cytic leukemia patients developing retinoic acid 
syndrome during induction treatment with all-
trans retinoic acid and idarubicin. Haematologi-
ca. 2008;93(12):1918-1920.
30.  Dore AI, Santana-Lemos BA, Coser VM, et al. The 
association of ICAM-1 Exon 6 (E469K) but not of 
ICAM-1 Exon 4 (G241R) and PECAM-1 Exon 3 
(L125V) polymorphisms with the development 
of differentiation syndrome in acute promyelo-
cytic leukemia. J Leukoc Biol. 2007;82(5):1340-
1343.
31.  Tallman MS, Andersen JW, Schiffer CA, et al. All-
trans retinoic acid in acute promyelocytic leuke-
mia: long-term outcome and prognostic factor 
analysis from the North American Intergroup 
protocol. Blood. 2002;100(13):4298-4302.
32.  Sanz MA, Tallman MS, Lo-Coco F. Tricks of the 
trade for the appropriate management of newly 
diagnosed acute promyelocytic leukemia. 
Blood. 2005;105(8):3019-3025.
33.  Larson RS, Brown DC, Sklar LA. Retinoic acid in-
duces aggregation of the acute promyelocytic 
leukemia cell line NB-4 by utilization of LFA-1 
and ICAM-2. Blood. 1997;90(7):2747-2756.
34.  Ninomiya M, Kiyoi H, Ito M, Hirose Y, Ito M, Naoe 
T. Retinoic acid syndrome in NOD/scid mice in-
duced by injecting an acute promyelocytic leu-
kemia cell line. Leukemia. 2004;18(3):442-448.
35.  Camacho LH, Soignet SL, Chanel S, et al. Leuko-
cytosis and the retinoic acid syndrome in pa-
tients with acute promyelocytic leukemia treat-
ed with arsenic trioxide. J Clin Oncol. 2000;18(13): 
2620-2625.
36.  Puneet P, Moochhala S, Bhatia M. Chemokines in 
acute respiratory distress syndrome. Am J Physi-
ol Lung Cell Mol Physiol. 2005;288(1):L3-15.
37.  Tsai WH, Hsu HC, Lin CC, Ho CK, Kou YR. Role of 
interleukin-8 and growth-regulated oncogene-
alpha in the chemotactic migration of all-trans 
retinoic acid-treated promyelocytic leukemic 
cells toward alveolar epithelial cells. Crit Care 
Med. 2007;35(3):879-885.
38.  Tsai WH, Shih CH, Lin CC, Ho CK, Hsu FC, Hsu HC. 
Monocyte chemotactic protein-1 in the migra-
tion of differentiated leukaemic cells toward al-
veolar epithelial cells. Eur Respir J. 2008;31(5):957-
962.
39.  Cunha De Santis G, Tamarozzi MB, Sousa RB, et 
al. Adhesion molecules and Differentiation Syn-
drome: phenotypic and functional analysis of 
the effect of ATRA, As2O3, phenylbutyrate, and 
G-CSF in acute promyelocytic leukemia. Haema-
tologica. 2007;92(12):1615-1622.
40.  Marchetti M, Falanga A, Giovanelli S, Oldani E, 
Barbui T. All-trans-retinoic acid increases adhe-
sion to endothelium of the human promyelo-
cytic leukaemia cell line NB4. Br J Haematol. 
1996;93(2):360-366.
Chemokine induction by ATRA and ATO in APL - triggering the differentiation syndrome
153
41.  Taraboletti G, Borsotti P, Chirivi RG, et al. Effect of 
all trans-retinoic acid (ATRA) on the adhesive 
and motility properties of acute promyelocytic 
leukemia cells. Int J Cancer. 1997;70(1):72-77.
42.  Zang C, Liu H, Ries C, Ismair MG, Petrides PE. En-
hanced migration of the acute promyelocytic 
leukemia cell line NB4 under in vitro conditions 
during short-term all-trans-retinoic acid treat-
ment. J Cancer Res Clin Oncol. 2000;126(1):33-40.
43.  Hsu HC, Tsai WH, Chen PG, Hsu ML, Ho CK, Wang 
SY. In vitro effect of granulocyte-colony stimu-
lating factor and all-trans retinoic acid on the 
expression of inflammatory cytokines and adhe-
sion molecules in acute promyelocytic leukemic 
cells. Eur J Haematol. 1999;63(1):11-18.
44.  Behringer D, Schaufler J, Kresin V, Lubbert M, 
Lindemann A. Differentiation associated modu-
lation of the cytokine and chemokine expres-
sion pattern in human myeloid cell lines. Leuk 
Res. 2001;25(2):141-149.
45.  Di Noto R, Lo Pardo C, Schiavone EM, et al. All-
trans retinoic acid (ATRA) and the regulation of 
adhesion molecules in acute myeloid leukemia. 
Leuk Lymphoma. 1996;21(3-4):201-209.
46.  Shibakura M, Niiya K, Niiya M, et al. Induction of 
CXC and CC chemokines by all-trans retinoic 
acid in acute promyelocytic leukemia cells. Leuk 
Res. 2005;29(7):755-759.
47.  Dubois C, Schlageter MH, de Gentile A, et al. 
Modulation of IL-8, IL-1 beta, and G-CSF secre-
tion by all-trans retinoic acid in acute promyelo-
cytic leukemia. Leukemia. 1994;8(10):1750-1757.
48.  Burn TC, Petrovick MS, Hohaus S, Rollins BJ, 
Tenen DG. Monocyte chemoattractant pro-
tein-1 gene is expressed in activated neutrophils 
and retinoic acid-induced human myeloid cell 
lines. Blood. 1994;84(8):2776-2783.
49.  Cignetti A, Vallario A, Roato I, et al. The charac-
terization of chemokine production and 
chemokine receptor expression reveals possible 
functional cross-talks in AML blasts with mono-
cytic differentiation. Exp Hematol. 2003;31(6): 
495-503.
50.  Lanotte M, Martin-Thouvenin V, Najman S, 
Balerini P, Valensi F, Berger R. NB4, a maturation 
inducible cell line with t(15;17) marker isolated 
from a human acute promyelocytic leukemia 
(M3). Blood. 1991;77(5):1080-1086.
51.  Lo Coco F, Avvisati G, Vignetti M, et al. Front-Line 
Treatment of Acute Promyelocytic Leukemia 
with AIDA Induction Followed by Risk-Adapted 
Consolidation: Results of the AIDA-2000 Trial of 
the Italian GIMEMA Group. ASH Annual Meeting 
Abstracts. 2004;104(11):392.
52.  Chen GQ, Zhu J, Shi XG, et al. In vitro studies on 
cellular and molecular mechanisms of arsenic 
trioxide (As2O3) in the treatment of acute pro-
myelocytic leukemia: As2O3 induces NB4 cell 
apoptosis with downregulation of Bcl-2 expres-
sion and modulation of PML-RAR alpha/PML 
proteins. Blood. 1996;88(3):1052-1061.
53.  Chen GQ, Shi XG, Tang W, et al. Use of arsenic tri-
oxide (As2O3) in the treatment of acute promye-
locytic leukemia (APL): I. As2O3 exerts dose-de-
pendent dual effects on APL cells. Blood. 1997;89 
(9):3345-3353.
54.  Jing Y, Wang L, Xia L, et al. Combined effect of 
all-trans retinoic acid and arsenic trioxide in 
acute promyelocytic leukemia cells in vitro and 
in vivo. Blood. 2001;97(1):264-269.
55.  de Ridder MC, van der Plas AJ, Erpelinck-Ver-
schueren CA, Lowenberg B, Jansen JH. Dexa-
methasone does not counteract the response of 
acute promyelocytic leukaemia cells to all-trans 
retinoic acid. Br J Haematol. 1999;106(1):107-110.
5
Chapter 5
154
Supplemental data
Supplemental Table S1  CCL levels in plasma of APL patients during induction therapy
Induction therapy 
(days)
CCL1  
(pg/ml)
CCL2  
(pg/ml)
CCL4  
(pg/ml)
CCL7  
(pg/ml)
patient A Before therapy 1 1227 313 15
(without DS) 1 17 435 175 15
2 11 386 181 15
3 5 577 231 103
9 1 1337 128 58
patient B Before therapy 21 2898 168 15
(without DS) 1 30 2453 145 15
2 17 1510 89 15
15 3 1672 125 15
patient C Before therapy 12 1287 356 372
(with DS) 2 8 1286 487 555
6 17 2473 1823 1452
Induction therapy 
(days)
CCL20 
(pg/ml)
CCL22 
(pg/ml)
CCL24 
(pg/ml)
patient A Before therapy 23 513 182
(without DS) 1 14 515 411
2 5 498 397
3 13 437 830
9 10 218 244
patient B Before therapy 33 817 406
(without DS) 1 25 782 427
2 9 637 83
15 27 400 55
patient C Before therapy 45 345 434
(with DS) 2 28 331 947
6 10 203 900
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Supplemental Table S2   CC-chemokines and their receptor
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CC-chemokine receptors (CCRs)
CC
R1
CC
R2
CC
R3
CC
R4
CC
R5
CC
R6
CC
R7
CC
R8
CC
R9
CC
R1
0
I-309 CCL1 X
MCP-1 CCL2 X
MIP-1α CCL3 X X
MIP-1β CCL4 X
RANTES CCL5 X X X
Unknown CCL6
MCP-3 CCL7 X X X
MPC-2 CCL8 X X
Unknown CCL9
Unknown CCL10
Eotaxin CCL11 X
Unknown CCL12 X
MCP-4 CCL13 X X
HCC-1 CCL14 X X
HCC-2 CCL15 X X
HCC-4 CCL16 X X
TARC CCL17 X
DC-CK1 CCL18
MIP-3β CCL19 X
MIP-3α CCL20 X
SLC CCL21 X
MDC CCL22 X
MPIF-1 CCL23 X
Eotaxin2 CCL24 X
TECK CCL25 X
Eotaxin3 CCL26 X
CTACK CCL27 X
MEC CCL28 X X
X represents binding between chemokine and receptor.
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Supplemental Figure S1  WBC counts and coagulation parameters in three APL patients 
during induction therapy
Induction therapy was composed of ATRA (45 mg/m2/day, from day 1 until day 30), Idarubicine 
(IDA, 12 mg/m2/day on day 2, 4, 6, 8), and prednisone (0.5 mg/kg/day, from day 1 until day 30). 
Patient A and patient B had no signs of a DS. Patient C developed DS within 24 hours after 
initiation of induction therapy. (A)WBC counts at diagnosis and during the first two weeks of 
induction therapy. (B-D) Coagulation parameters. Platelet counts (B), fibrinogen levels (C), and 
fibrinogen degradation products (D-dimer, (D)) at diagnosis and during the first two weeks of 
induction therapy. Patients received multiple transfusions of platelets, red blood cells, and 
fresh frozen plasma during the first two weeks of induction therapy to control coagulopathy.
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Supplemental Figure S2   CCL expression in response to ATRA and ATO in NB4 cells
NB4 cells were cultured in medium in the presence or absence of ATRA (10-6M), ATO (10-6M), or 
their combination for 0, 4, 8, 24, 48, 72, and 96 hours. CCL mRNA expression was determined at 
the indicated time points by quantitative PCR. Expression, relative to GAPDH, is plotted.
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Abstract
In acute promyelocytic leukemia (APL), differentiation therapy can be complicated 
by the development of a differentiation syndrome (DS). Pulmonary infiltration of 
 differentiating leukemic cells is a key event in the development of DS. Several 
mediators have been identified that may promote the migration and extravasation of 
differentiating APL cells from the bloodstream into the tissue. Adhesion of APL cells to 
each other and to the endothelium is induced by up-regulation of the expression of 
adhesion molecules and constitutively active β2-integrins during differentiation 
therapy. The expression of chemokines and their receptors is significantly up-regulated 
as well. Pulmonary chemokine production triggers transendothelial migration of 
 differentiating APL cells from the bloodstream into the underlying tissue (initiation 
phase of DS).  Massive production of chemokines by infiltrated APL cells further 
enhances the transendothelial migration of differentiating APL cells, causing an 
uncontrollable hyperinflammatory reaction in the lung (aggravation phase of DS), 
which is not efficiently switched-off by corticosteroids.
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Introduction
Acute promyelocytic leukemia (APL) is characterized by a specific t(15;17) chromosomal 
translocation, which fuses the promyelocytic leukemia (PML) gene on chromosome 
15 to the retinoic acid receptor-alpha (RARA) gene on chromosome 17. This 
translocation results in blockage of terminal granulocytic differentiation at the 
promyelocytic stage.1;2 Treatment with high dosage of the RARA ligand all-trans 
retinoic acid (ATRA) relieves this blockage, resulting in terminal differentiation of the 
APL blasts. Presently, standard therapy for patients with newly diagnosed APL consists 
of a combination of ATRA and anthracycline-based chemotherapy which results in 
the induction of a complete remission in more than 90% of patients, and a 5-year 
overall survival rate of more than 80%.3-11 In addition, arsenic trioxide (ATO) treatment 
has been shown to be highly effective in relapsed APL patients and has also been 
used successfully as a single agent or in combination with ATRA in newly diagnosed 
APL patients.12-21 The most important complication of differentiation therapy is the 
development of a differentiation syndrome (DS), formerly known as retinoic acid 
syndrome.
The differentiation syndrome
Clinical manifestations of DS
DS is a life-threatening complication, characterized by respiratory distress, unexplained 
fever, weight gain, interstitial pulmonary infiltrates, pleural or pericardial effusions, 
hypotension and acute renal failure, as described by Frankel et al..22 DS can be 
associated with the development of hyperleukocytosis, pulmonary edema, generalized 
edema, headache, and bone pain.10;22-26 The most common manifestations are respiratory 
distress, pulmonary infiltrates and fever, which occur in about 80% of patients 
(Table 1).10;22-26 The diagnosis DS is made on clinical grounds and has proven to be 
difficult, because none of the symptoms is pathognomonic for the syndrome and can 
be due to other medical problems such as bacteremia, sepsis, pneumonia, pulmonary 
hemorrhage, or congestive heart failure. Therefore, DS may be underdiagnosed as 
well as overdiagnosed.
The incidence rates of DS in APL patients undergoing induction therapy with ATRA 
and/or ATO has been reported to range from 2.5% to 27% (Table 2). Variation in the 
incidence of DS between studies could be the result of differences in induction 
therapy and prophylactic approaches. The incidence may be lower when ATRA is 
administered concurrently with induction chemotherapy or prophylactic glucocorti-
coids.10;24;27 However, difficulties in distinguishing DS from other medical problems 
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and the use of different diagnostic criteria for DS may also explain variation in the 
incidence of DS. The criteria used to define DS vary per study and are not specifically 
defined in several reports. The seven symptoms that were originally described by 
Frankel et al. are frequently used as diagnostic criteria for DS, but there is no consensus 
regarding the stringency of these criteria.22 In a report from the Gruppo Italiano 
Malattie Ematologiche dell’ Aldulto (GIMEMA group), the diagnosis DS was made by 
the presence of 5 out of 7 symptoms. These strict criteria resulted is a low incidence of 
DS of 2.5%.5 In a report by the Programa para el Estudio y Tratamiento de las 
Hemopatias Maligna (PETHEMA) group, less strict criteria were used (≥ 2 symptoms), 
resulting in a higher DS incidence of 25%.10. When the strict criteria from the GIMEMA 
group were applied to the PETHEMA study, the incidence of DS was similar in both 
studies (2.5% versus 2.6%). Furthermore, the incidence of DS was comparable in the 
reports from the Breccia et al. (2008; single centre study GIMEMA: 14%)25 and de 
Botton et al. (1998; European APL study group: 15%)24 who both made the diagnosis 
DS in the presence of three or more symptoms. This indicates that standardization of 
the diagnostic criteria for DS is warranted. 
Management of DS
Because of the life-threatening nature of the full-blown syndrome, early recognition 
and prompt treatment with corticosteroids are critical. Currently, the standard 
approach to treat patients developing DS, is pre-emptive use of corticosteroids at the 
Table 1  Manifestations of the Differentiation Syndrome
Manifestations Patients % (range)
Dyspnoea / Respiratory distress10;22-26 88 (77-100)
Pulmonary (interstitial) infiltrates10;22-26 81 (52-100)
Fever10;22-26 79 (65-100)
Weight gain10;22;24-26 68 (38-100)
Pulmonary oedema23;25;26 54 (7-100)
Generalised/peripheral oedema10;26 52 (38-67)
Pleural effusion10;22-26 50 (13-100)
Hypotension10;22-24 28 (13-56)
Renal insufficiency10;22-26 28 (9-67)
Pericardial effusion10;22-24 21 (11-36)
Bone pain23;25 21 (14-27)
Headache23;25 21 (14-27)
Cardiac failure23;24 14 (11-17)
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earliest clinical manifestations, which has substantially reduced DS-related mortality.22-
24;28;29 The use of corticosteroid prophylaxis to prevent the development of DS is more 
controversial. At present, there is not sufficient evidence that prophylactic use of 
 corticosteroids is advantageous to reduce morbidity and mortality rates in DS.29 
When the effect of prophylactic use of corticosteroids from the start of ATRA in the 
PETHEMA LPA99 trial was retrospectively compared to the effect of pre-emptive use 
of corticosteroids in the PETHEMA LPA96 trial, a reduction in the incidence of severe 
DS was observed. However, DS-related mortality was not altered.10 The decreased 
incidence of severe DS suggest a benefit for corticosteroid prophylaxis. So far, no 
prospective randomized trials have been conducted to determine the efficacy of the 
prophylactic use of corticosteroids in the prevention of DS.
 Whether the differentiating agents should be continued or discontinued when DS 
develops is not completely clear. For most patients with DS, the administration of 
 differentiating agents can be continued. Temporary discontinuation of ATRA or ATO 
is only indicated in severe DS. Otherwise, these differentiating agents could be 
maintained unless progression to a full-blown DS or lack of response to corticosteroids 
is observed.23;29
Outcome
DS is associated with a significant morbidity and mortality, requiring mechanical 
ventilation in 15%-55% of the APL patients with DS.10;22-25;30;31 Furthermore, the development 
of DS has been associated with an increased risk of hemorrhage, higher incidence of 
thrombosis, and an increased rate of grade 3 or 4 hepatotoxicity. In addition, DS may be 
associated with a higer risk of relapse.10;25;32;33 Although corticosteroid treatment has 
substantially reduced DS-related mortality, DS is still one of the most common causes 
of mortality during induction chemotherapy in APL.33 The mortality rate of patients 
with DS ranges from 0% to 35% (Table 2).5;10;14;15;19;20;23;25-28;32 The large variation might be 
due to differences in adequate recognition and treatment of DS.22;28
Pathogenesis of DS
The pathogenesis of the syndrome is not fully understood. As DS is not observed 
during consolidation or maintenance therapy with ATRA and/or ATO in APL patients 
or during ATRA- and/or ATO-treatment in non-APL malignancies, the differentiating 
APL cells seem to play a crucial role in the development of DS.6;7;14;20;22-24;34 Occasionally, 
APL patients have shown a clinical picture resembling DS before the onset ATRA 
therapy, which significantly worsened after initiation of ATRA therapy.24 The clinical 
picture of DS resembles the acute respiratory distress syndrome (ARDS), which is 
characterized by an overactive systemic inflammatory response syndrome with 
massive infiltration of activated leukocytes in the alveolar spaces.35;36 In patients who 
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suffered from a fatal DS, extensive pulmonary infiltration of differentiating APL cells 
has been observed with marked histopathological changes in the lung (e.g. leukemic 
infiltration, pulmonary edema, intra-alveolar hemorrhage, fibrinous exudates).22;23 
The extensive pulmonary infiltration of differentiating APL cells in the lung suggests 
that these cells are directly involved in the respiratory problems in DS. In a murine 
APL-model, the infiltration of differentiating APL cells was restricted to the lung 
without specific changes in other organs.31 The pulmonary histology closely resembled the 
changes observed in DS patients post-mortem.22;23 In patients with DS, infiltration of 
other organs such as the spleen, the lymph nodes, the kidney, the liver, the skin, the 
pleura, and the pericardium has also been reported, but the lung appears to be the 
clinically most relevant target organ.22;23 Symptomatic pulmonary disease caused by 
leukemic infiltrates is uncommon in non-APL malignancies and is usually associated 
with hyperleukocytosis, although it has occasionally been reported in the absence of 
hyperleukocytosis.37-43
The migration and extravasation of differentiating APL cells from the blood into the 
lung is a key event in the pathogenesis of DS. This process is dependent on increased 
chemotaxis and adhesive interaction between APL cells and the vascular endothelial 
cell surface in the lung. The mechanism is largely comparable to normal leukocyte 
extravasation, which occurs during inflammatory and immune processes. The ability 
of circulating leukocytes to leave the bloodstream and migrate into tissue, allows 
accumulation of leukocytes at sites of inflammation. To ensure migration of leukocytes 
to the proper location, the trafficking of leukocytes is tightly regulated by an interplay 
of multiple adhesion molecules, integrins, and chemoattractants. The migration and 
extravasation of leukocytes from the circulation to the tissues occurs in several distinct 
steps, referred to as the multi-step paradigm.44 The first step comprises the rolling and 
attachment of the leukocytes on the endothelial cells (primary attachment), mediated 
by adhesion molecules. Subsequently, chemokines derived from the endothelium 
can activate β2-integrins on the surface of leukocytes. Interaction of the activated 
β2-integrins with receptors on the endothelium results in firm adherence (stable 
arrest) of the leukocytes to the endothelium. Finally, chemokines mediate the 
 transendothelial migration of leukocytes from the blood into the underlying tissue.44;45 
Transendothelial migration of leukocytes can be facilitated by the release of proteases, 
such as matrix metalloproteases (MMPs) and neutrophil elastase (NE), which can 
compromise the integrity of the endothelial vascular barrier and increase the 
permeability.46
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Induction of adhesion of APL cells to the endothelium
The role of integrins
Differentiation therapy seems to alter the balance of the expression of adhesion 
molecules and chemoattractant factors that mediate transmigration of APL cells 
across the vascular endothelium into the tissue. The effect of ATRA and/or ATO 
treatment on the adhesion of APL cells has been studied by several groups.47-52 In un-
differentiated APL cells, the primary attachment and rolling is mainly mediated by the 
interaction of α4-integrins on APL cells and VCAM-1 on endothelial cells. Undifferenti-
ated APL cells are not able to arrest stably or transmigrate due to low levels of 
β2-integrin expression.47 Differentiation induction of APL cells by ATRA causes 
alterations of the avidity state of α4-integrins, resulting in abrogation of the 
α4-integrin/VCAM-1 dependent rolling and attachment. Furthermore, differentiation 
therapy induces the expression of high-avidity β2-integrins (LFA-1,Mac-1 and p150).47-52 
Normal leukocytes require a chemokine or cytokine stimulus in order to activate 
integrins and induce firm adherence and transmigration.44 On differentiating APL 
cells, β2-integrins are expressed in an active form and do not require cytokine or 
chemokine activation to induce binding to ICAM-1 and ICAM-2, which are both 
expressed on the endothelium.31;48;51;53;54 The binding of β2-integrins to ICAM-1 and 
ICAM-2 on the endothelium mediates stable arrest (heterotypic aggregation) and 
facilitates subsequent transmigration of APL cells into the tissue. Blocking the 
expression of the β2-integrins on leukemic cells with neutralizing antibodies can 
inhibit stable arrest of APL cells, suggesting that the induction of β2-integrins indeed 
contributes to increased adhesiveness of APL cells to the endothelium.47;50;51;54 
The role of adhesion molecules
Expression of ICAM-1 in the lung can be induced by systemic ATRA treatment.31 To 
test the role of endothelial ICAM-1 expression in the pulmonary infiltration of APL 
cells, ICAM-1 (CD54) knockout mice and their wild-type controls were injected with a 
combination of ATRA and APL cells. The extent of pulmonary infiltration was 
determined by pulmonary myeloperoxidase (MPO) activity. In wild-type mice, 
injection of ATRA and APL cells resulted in a significant increase in MPO activity, 
compared with controls that received ATRA or APL cells only. However, no significant 
increase in pulmonary MPO activity was observed in ICAM-1 knockout mice.51 In 
addition, suppression of the endothelial ICAM-1 production with neutralizing 
antibodies, reduced the adhesion of APL cells to the endothelium in vitro.54 Both 
studies suggest that the expression of ICAM-1 on the pulmonary endothelium, which 
is enhanced by differentiation therapy, is important for the pulmonary infiltration of 
APL cells.
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The expression of ICAM-1 and ICAM-2 is not limited to the endothelium. APL cells 
constitutively express ICAM-2, while the expression of ICAM-1 is induced during differ-
entiation with ATRA or ATO.48;49;51 The induction of ICAM-1 on APL cells contributes to 
increased adhesion of APL cells to the extracelullar matrix, which is inhibited by 
suppression of the ICAM-1 expression on APL cells with dexamethasone or neutralizing 
antibodies.51 The simultaneous expression of β2-integrins and their counterparts 
ICAM-1 and -2 on differentiating APL cells, allows APL cells to interact with each other 
(homotypic aggregation), which may facilitate transmigration.48 Homotypic aggregation 
can be inhibited by treatment with methylprednisolone or suppression of the ICAM-2 
and β2-integrin expression on APL cells with neutralizing antibodies.48 We propose a 
model in which up-regulation of the expression of β2-integrins and adhesion molecules 
on APL cells and endothelium during differentiation therapy, induces heterotypic as 
well as homotypic aggregation, which both facilitate transmigration of APL cells into 
the underlying tissue (Figure 1). Corticosteroids can suppress the expression of ICAM-1 
and thereby reduce the adhesion of APL cells to the endothelium and to each other. 
Induction of transmigration of APL cells into the lung
Changes in the expression of chemoattractant factors play an important role in the 
transmigration of leukocytes from the bloodstream into the tissues. Circulating 
leukocytes are attracted  toward sites of inflammation by chemokines that induce 
transendothelial migration. In ARDS, the migration of activated leukocytes to the 
alveolar spaces is largely controlled by chemokines secreted from various types of 
lung cells.35 Subsequently, proteases released by activated leukocytes can compromise 
the integrity of the endothelial vascular barrier and facilitate the transendothelial 
migration.46;55 Chemokines are small chemoattractant cytokines that coordinate the 
trafficking of leukocytes during inflammatory reactions. In addition, chemokines have 
been implicated in the migration and tissue infiltration of leukemic cells.44;56 
Chemokines produce their biological effects by interacting with specific G-protein-
coupled receptors on the cell surface of their target cells.44 Most chemokines are 
able to bind several receptors and most receptors can bind multiple chemokines 
(Table 3).35;57;58 The transmigration of differentiating APL cells from the bloodstream 
into the lung may be dependent on interaction between lung epithelial cells and APL 
cells via chemokines and the release of proteases by APL cells.
Involvement of chemokines produced by the lung
The effect of differentiation therapy on chemotaxis of APL cells has been studied by 
several groups. In the lung, multiple chemokines are constitutively produced, such as 
CCL2 (MCP-1), CXCL8 (IL-8) and CXCL12 (SDF-1α).59-62 Treatment with ATRA enhances 
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Table 3  Chemokines and their receptors35;57;58
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CC-chemokine receptors (CCRs)
CC
R1
CC
R2
CC
R3
CC
R4
CC
R5
CC
R6
CC
R7
CC
R8
CC
R9
CC
R1
0
I-309 CCL1 X
MCP-1 CCL2 X
MIP-1α CCL3 X X
MIP-1β CCL4 X
RANTES CCL5 X X X
Unknown CCL6
MCP-3 CCL7 X X X
MPC-2 CCL8 X X X
Unknown CCL9
Unknown CCL10
Eotaxin CCL11 X
Unknown CCL12 X
MCP-4 CCL13 X X X
HCC-1 CCL14 X X
HCC-2 CCL15 X X
HCC-4 CCL16 X X X
TARC CCL17 X
DC-CK1 CCL18
MIP-3β CCL19 X
MIP-3α CCL20 X
SLC CCL21 X
MDC CCL22 X
MPIF-1 CCL23 X
Eotaxin2 CCL24 X
TECK CCL25 X
Eotaxin3 CCL26 X
CTACK CCL27 X
MEC CCL28 X X
X represents binding between chemokine and receptor.
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the alveolar chemokine production in vitro as well as in vivo.31;60;62 In vitro studies 
demonstrated that alveolar chemokine production induces migration of APL cells 
towards alveolar epithelial cells, which can be reduced by suppression of the alveolar 
chemokine production with dexamethasone or neutralizing antibodies. In a murine 
APL-model, differentiation therapy significantly enhanced the expression of 
chemokines in the lung, inducing accumulation of APL cells, lung edema, and marked 
congestive changes, indicative for DS. Suppression of the pulmonary chemokine 
expression by dexamethasone significantly reduced the development of lung 
edema.31 Both studies indicate that pulmonary chemokine production triggers trans-
endothelial migration of APL cells from the bloodstream into the underlying tissue. 
Involvement of chemokine receptors
Differentiation of APL cells seems to be required for their pulmonary infiltration. In a 
murine APL-model, transplantation of ATRA-treated APL cells resulted in the development 
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CXC-chemokine receptors (CXCRs)  
CX
CR
1
CX
CR
2
CX
CR
3
CX
CR
4
CX
CR
5
CX
CR
6
GROα CXCL1 X X
GROβ CXCL2 X
GROγ CXCL3 X
PF4 CXCL4
ENA-78 CXCL5 X
GCP-2 CXCL6 X X
NAP-2 CXCL7 X X
IL-8 CXCL8 X X
MIG CXCL9 X
IP-10 CXCL10 X
I-TAC CXCL11 X
SDF-1α/β CXCL12 X
BCA-1 CXCL13 X
BRAK CXCL14
Unknown CXCL15
Unknown CXCL16 X
X represents binding between chemokine and receptor.
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of DS (illustrated by accumulation of APL cells in the lung and lung edema), which was 
not observed when untreated APL cells or ATRA-resistant APL cells were given.31 
During differentiation, the expression of specific chemokine receptors (CCR1, CCR2, 
CCR3, CXCR1, CXCR2, CXCR4) is significantly up-regulated in APL cells.53;59-61 The 
induction of chemokine receptor expression on APL cells may increase their ability to 
migrate in response to chemokines. CCR2, CXCR1, CXCR2, and CXCR4 have been 
shown to play a critical role in pulmonary infiltration of leukocytes and leukemic cells. 
Interaction of CCL2 with CCR2 and CXCL8 with CXCR1/2 have been implicated in the 
pathogenesis of ARDS and multiple inflammatory diseases.63-67 In a murine 
ARDS-model, deficiency of CCR2 or treatment with a small molecule CCR2 antagonist 
both significantly suppressed the development of ARDS.68 In a rabbit ARDS-model, 
treatment with humanized anti-CXCL8 antibody could effectively prevent 
development and progression of ARDS.67  Furthermore, small molecule antagonists of 
CXCR1 and CXCR2 have been efficacious in suppression of lipopoly saccharide 
(LPS)-induced pulmonary neutrophilia in mice and rats.69;70 In addition, CXCL12-CXCR4 
interactions play an important role in the trafficking of leukemic cells.61;71 In adult 
T-cell leukemia (ATL), CXCL12 and CXCR4 have been implicated in pulmonary 
infiltration of leukemic cells. In a murine ATL-model, inhibition of CXCR4 with a specific 
CXCR4 antagonist successfully inhibited the infiltration of leukemic cells into the 
lung.71 Interactions of CCL2/CCR2, CXCL8/CXCR1-2, and CXCL12/CXCR4 have been 
proposed to play a critical role in the pulmonary infiltration of APL cells as well.53;59-61 
When the expression of CCR2, CXCR1, CXCR2, or CXCR4 on the surface of APL cells is 
blocked with neutralizing antibodies, the migration and invasion of APL cells toward 
pulmonary cells is inhibited, suggesting that expression of these chemokine receptors 
on APL cells contributes to their migration in response to pulmonary derived 
chemokines.60;61
Involvement of chemokines produced by APL cells
Apart from the induction of chemokine receptor expression, differentiation therapy 
can induce massive production of chemokines by APL cells. The expression and 
production of CCL1 (I-309), CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL7 (MCP-3), 
CCL20 (MIP-3α), CCL22 (MDC), CCL24 (Eotaxin-2), and CXCL8 (IL8) was highly induced 
after ATRA and/or ATO treatment in several studies, which may contribute to the 
development of DS.31;52;53;59-61;72-76 Furthermore, increased plasma levels of chemokines, 
including CCL2, have been observed in patients with DS.53;72 Although dexamethasone 
can effectively reduce the pulmonary chemokine production, the massive chemokine 
induction in differentiating APL cells cannot be abrogated by dexamethasone.31;53;59;60 
Differentiation therapy strongly up-regulates the expression of CCL2 and CCL24 within 
a few hours. Pre-treatment of APL cells with the protein translation inhibitor 
cycloheximide, did not influence the ATRA-induced up-regulation of CCL2 and CCL24, 
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suggesting that their expression is directly regulated by PML-RARα.53 In addition, 
Martens et al. recently showed that PML-RARα/RXR can bind to CCL2 and that this 
binding is lost upon ATRA treatment, indicating that PML-RARα directly regulates the 
expression of CCL2.77 Moreover, PML-RARα disturbs the function of PTEN, which is a 
well-known modulator of chemotaxis.78-82 Further studies regarding the role of PTEN 
in chemotaxis of APL cells might be interesting. The involvement of the PML-RARα 
fusion protein in regulation of chemokine expression might explain why DS is 
confined to APL and is not observed during differentiation therapy in non-APL 
malignancies. Furthermore, this might explain why dexamethasone can reduce the 
alveolar chemokine production, whereas the chemokine induction by APL cells is not 
influenced by dexamethasone. 
Involvement of proteases
APL cells constitutively secrete proteases, such as NE, MMP-2, and MMP-9, which may 
facilitate transmigration of APL cells from the bloodstream into the underlying tissue 
by degradation of the extracellular matrix.50;83;84 In vitro studies did not show an effect 
of differentiation therapy on the release of proteases by APL cells. 50;83 However, 
treatment with MMP inhibitors resulted in blockage of the ATRA-induced 
transmigration in vitro, suggesting that MMPs may be involved in the transmigration 
of APL cells.50;83 NE activity can effectively be blocked in APL cells in vitro by specific 
small molecule inhibitors.84 In animal models of ARDS and acute lung injury, treatment 
with Sivelestat, a small molecule inhibitor of NE, was shown to be effective, but the 
efficacy of Sivelestat for ALI patients remains controversial.85-88 So far, two cases of DS 
have been described in which treatment with Sivelestat improved the clinical 
condition of the patients, suggesting that Sivelestat treatment might be effective.89 
The role of proteases in development of DS and the role of protease inhibitors in 
treatment of DS need to be studied in more detail .
 
Two-step model for transmigration of APL cells
Chemokines play an important role in the migration and tissue infiltration of leukemic 
cells. We propose a two-step model in which the infiltration of differentiating APL 
cells into the lung is initially triggered by increased expression of adhesion molecules 
and pulmonary chemokine production (initiation phase of DS). Subsequently, 
production of massive amounts of chemokines by APL cells that have infiltrated the 
lung, enhances migration of leukemic cells from the bloodstream into the lung, which 
aggravates the hyperinflammatory reaction in the lung (aggravation phase of DS; 
Figure 1). Suppression of the adhesion molecule expression and pulmonary chemokine 
secretion by corticosteroids may eliminate the initial trigger for migration of APL cells 
toward the lung. This may explain why intervention with corticosteroids is effective in 
the initiation phase of DS. In a full-blown DS, massive chemokine production by dif-
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Figure 1  Mechanisms of pulmonary infiltration of APL cells during differentiation 
therapy
Differentiation therapy with ATRA and/or ATO alters the expression of integrins and adhesion 
molecules (left) and chemoattractant factors (right) that mediate transmigration of APL cells 
across the vascular endothelium into the tissue. Left side: Differentiation therapy induces the 
expression of constitutively active β2-integrins on the surface of APL cells and the expression of 
ICAM-1 in the lung as well as on the APL cells. Binding of β2-integrins to ICAM-1 mediates 
adhesion of APL cells to the vascular endothelium in the lung (1: heterotypic aggregation), and 
the adhesion of APL cells to each other (2: homotypic aggregation), which both facilitate 
transmigration of differentiating APL cells to the underlying pulmonary tissue. Dexamethasone 
(DEX) can suppress the expression of ICAM-1 and thereby reduce the adhesion of APL cells to 
the endothelium (1) and to each other (2). Right side: Differentiation therapy results in massive 
production of chemokines by the lung and by APL cells. Due to the up-regulation of chemokine 
receptors on the surface of differentiating APL cells, these cells can easily transmigrate in 
response to the pulmonary chemokine production (3, initiation phase of DS). Pulmonary 
infiltration of differentiating APL cells, which massively produce chemokines, further enhances 
transmigration of leukemic cells from the bloodstream into the lung, aggravating the hyperin-
flammatory reaction in the lung (4, aggravation phase of DS). Reduction of the pulmonary 
chemokine secretion by DEX may eliminate the initial trigger for migration of APL cells towards 
the lung (3). Since DEX cannot abrogate the massive chemokine production by differentiating 
APL cells, pulmonary infiltration of APL cells may induce an uncontrollable hyperinflammatory 
reaction in the lung (4).
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ferentiating APL cells that have already invaded target tissues may induce ongoing 
chemoattraction and inflammation in these tissues. Because dexamethasone cannot 
abrogate the chemokine production by differentiating APL cells, corticosteroid 
treatment may not be sufficient to reverse a full-blown DS. The therapeutic use of 
chemokine receptor antagonists may be a more efficient approach than the use of 
corticosteroids. Given that the interactions of CCL2/CCR2, CXCL8/CXCR1-2, and CXCL12/ 
CXCR4 have been proposed to play a critical role in the pulmonary infiltration of APL cells, 
targeting of these receptors with chemokine receptor antagonists may be effective in 
the treatment of DS. Currently, chemokine receptor antagonists for CCR2 are used in 
phase I clinical trials for lupus and multiple sclerosis, and phase II clinical trials for type 
II diabetes.  In addition, antagonists for CXCR2 are used in phase I clinical trials for 
chronic obstructive pulmonary disease and phase II clinical trials for colitis ulcerosa 
and cystic fibrosis. CXCR4 antagonists are in clinical development for mobilization of 
stem cells in multiple myeloma and lymphoma patients (phase I and phase II clinical 
trials). A drawback of disruption of the CXCL12/CXCR4 interaction may be the release 
of leukemic cells from the bone marrow into the blood, which may not be desirable in 
DS.65;90-92 As multiple chemokine receptors may be involved in the pathogenesis of DS, 
the use of dual-chemokine receptor antagonists, such as a CXCR1/CXCR2 antagonists 
or CCR2/CXCR2 antagonists, may be beneficial therapeutically.91;93;94
Conclusion
The differentiation syndrome (DS) is an important complication of differentiation 
therapy in APL. Pulmonary infiltration of leukemic cells is a key event in the development 
of DS, caused by alteration in the expression of adhesion molecules and chemoattrac-
tant factors in the lung as well as in APL cells, facilitating transmigration of APL cells 
across the vascular endothelium into the tissue. In the initiation phase of DS, intervention 
with corticosteroids may successfully inhibit adhesion and subsequent transmigration 
of APL cells into the lung through reduction of the expression of adhesion molecules 
and chemokines in the lung. As corticosteroids cannot abrogate the massive chemokine 
production by differentiating APL cells, pulmonary infiltration of APL cells may induce 
an uncontrollable hyperinflammatory reaction in the lung. Interventions that directly 
target the interaction of chemokines and their receptors may inhibit the hyperinflam-
mation and chemotaxis driven by the differentiating APL cells (aggravation phase of 
DS). We propose that therapeutic use of chemokine-receptor antagonists may be an 
interesting approach in the treatment of DS. 
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Summary
Thesis objective
Acute myeloid leukemia (AML) is a clinically and genetically highly heterogeneous 
disease,  characterized by the uncontrolled proliferation of immature white blood 
cells. In AML, recurrent cytogenetic and molecular aberrations are present. These 
aberrations often involve transcription factors, signal transduction molecules, and 
epigenetic regulators that play an essential role in the modulation of gene expression 
and determination of cell fate. Several cytogenetic and molecular aberrations have 
been identified that correlate with clinical outcome, resulting in better prognostic 
allocation of AML patients and development of individualized risk-adapted treatment 
strategies.1;2 The response to treatment and the outcome of patients with AML is 
heterogeneous. Prognosis is largely dependent on patient and tumor characteristics 
such as age, genetic aberrations, and response to induction therapy. Treatment 
outcome of AML patients has improved substantially with the use of risk-directed 
treatment and improved supportive care.2-4 However, with the current  multi-drug 
chemotherapy regimens, a substantial amount of AML patients die from the disease 
or treatment-related toxicity. Further intensification of chemotherapy is not feasible 
due to toxicity in healthy tissues. Therefore, other therapeutic options are needed to 
improve survival rates in AML. Underlying genetic and epigenetic aberrations can 
serve as potential therapeutic targets and therefore may result in the development of 
novel targeted therapies. One of the hallmarks of AML is deregulated gene expression. 
The objective of this thesis is to extend our knowledge on the (post-) transcriptional 
regulation of gene expression in myelopoiesis to improve prognostic classification 
and identify novel targets for therapy in AML.
MicroRNA-132 targets the hematopoietic transcription factors WT1  
and GATA2
MicroRNAs contribute to the regulation of gene expression by downregulating 
protein expression of target genes through mRNA degradation or translational 
inhibition. They play an important role in the regulation of hematopoiesis via 
interaction with crucial transcription factors, cell cycle regulators, and DNA methyl-
transferases.5-14 Although various microRNAs have been implicated in the regulation 
of normal and malignant myelopoiesis, information on relevant target genes is still 
scarce. In chapters 2 and 3, we determined the expression of microRNAs during 
myeloid differentiation using microRNA expression profiling. The aim was to identify 
differentially expressed microRNAs and determine whether these microRNAs may 
target genes involved in myeloid differentiation. We demonstrated that miR-132 is 
highly upregulated during granulocytic differentiation in myeloid cell lines as well as 
in primary myeloid cells. In chapter 2, we identified the hematopoietic transcription 
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factor Wilms’ Tumor 1 (WT1) as a direct target of miR-132. WT1 is a zinc-finger 
transcription factor which is involved in the regulation of proliferation, differentiation, 
and apoptosis of myeloid progenitors. WT1 is highly expressed in immature 
hematopoietic progenitor cells and downregulated during later stages of myeloid dif-
ferentiation.15 The mechanisms by which WT1 expression is regulated remain largely 
unclear and have mainly been studied at the transcriptional level.16-25 We demonstrate 
that miR-132 functions as a translational repressor of the WT1 oncoprotein in myeloid 
cells. During myeloid differentiation, the induction of miR-132 may contribute to the 
downregulation of WT1 protein expression. In chapter 3, we demonstrate that the 
messenger RNA (mRNA) coding for the hematopoietic transcription factor GATA2 is 
targeted by miR-132, suggesting that GATA2 is a direct target of miR-132 as well. The 
GATA2 zinc-finger transcription factor plays an essential role in the regulation of 
myeloid lineage determination and hematopoietic stem and progenitors cell 
development. The expression of GATA2 is tightly regulated in the hematopoietic 
system by several transcription factors and post-translational modifications.26 The 
direct targeting of GATA2 mRNA by miR-132 suggests that miR-132 is implicated in the 
regulation of GATA2 expression. By targeting both WT1 and GATA2, miR-132 may fulfill 
a role as a master regulator of myeloid differentiation. 
GATA2 expression is a poor prognostic factor in pediatric AML
As GATA2 plays an essential role in the regulation of myeloid differentiation, 
deregulation of GATA2 might contribute to the development of leukemia. In chapter 
4, we investigated whether deregulation of GATA2 is present in AML. In a large cohort 
of pediatric AML patients, we detected GATA2 mutations with a frequency of 2.2% 
overall and 9.8% in cytogenetically normal (CN) AML. CN-AML is a highly 
heterogeneous group of patients that lack cytogenetic aberrations and display a 
large variation in clinical outcome. The recent discovery of novel molecular markers 
with prognostic clinical significance have resulted in the identification of subsets of 
patients with differing outcomes within the CN-AML group.27;28 In CN-AML patients, 
we observed co-occurrence of GATA2 mutations with various other molecular 
aberrations, including NPM1, NRAS, CEBPA, and WT1 mutations, suggesting that these 
mutations collaborate in the development of AML. GATA2 mutations were mutually 
exclusive with FLT3-ITD. The mutual exclusiveness of GATA2 mutations and FLT3-ITD in 
CN-AML suggests that both aberrations cannot cooperate in leukemogenesis. In 
addition to the mutational analysis of GATA2, we investigated the expression of GATA2 
in pediatric AML patients in relation to outcome. At diagnosis, GATA2 is frequently 
overexpressed, whereas normalization of GATA2 expression was observed in complete 
remission. No correlation was observed between the presence of GATA2 mutations 
and the expression levels of GATA2. High GATA2 expression was shown to be a novel 
independent poor prognostic factor in pediatric AML, also after adjustment for 
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established prognostic factors including favorable cytogenetics, NPM1 mutations, 
biallelic CEBPA mutations, and FLT3-ITD. The prognostic impact of GATA2 was 
particularly high in specific morphologic and genetic AML subgroups, including 
FAB-M5 morphology, inv(16), 11q23 translocations, high WT1 expression, and FLT3-ITD 
positivity. This indicates that integrating data on different markers may contribute to 
improved risk-adapted classification in AML. 
GATA2 is not a suitable MRD-marker
Morphological response to induction chemotherapy is an important parameter for 
outcome in AML and is used to determine the intensity of subsequent therapy and to 
select candidates for allogeneic stem cell transplantation.29 Traditionally, achievement 
of complete remission is determined morphologically by the presence of less than 5% 
leukemic blasts in the bone marrow in combination with normal peripheral blood cell 
counts.29;30 The presence of submicroscopic disease is called minimal residual disease 
(MRD). In AML, no universal MRD-marker is present. Current MRD-detection methods 
in AML include real-time quantitative PCR (RQ-PCR) for abnormal fusion transcripts or 
mutated genes, and multiparameter flow cytometry to detect leukemia-associated 
aberrant immunophenotypes.31-33 Another strategy for MRD-detection is 
quantification of the expression of genes that are frequently overexpressed in AML. In 
chapter 4 we investigated whether GATA2 is a suitable MRD-marker as in the majority 
of pediatric AML patients, GATA2 is overexpressed at diagnosis. After induction and 
consolidation therapy, normalization of GATA2 expression was observed in patients 
who reached complete remission, whereas GATA2 expression levels remained high in 
patients with resistant disease, suggesting that GATA2 may be an interesting marker 
for MRD-detection. However, in a minority of patients, GATA2 was sufficiently highly 
expressed to allow detection of at least a 2-log reduction. At diagnosis and during 
chemotherapy, no differences in GATA2 expression levels were detected between 
patients who reached continuous complete remission versus patients who relapsed. 
For adequate MRD-detection, the tumor marker should be at least 100- to 1000-fold 
higher expressed in leukemic cells than in normal bone marrow cells. The 
heterogeneous expression of GATA2 in AML and the relatively high background 
expression of GATA2 in normal peripheral blood and bone marrow limits the usefulness 
of GATA2 for MRD-detection in AML. 
Chemokine induction during differentiation therapy in APL
With the current multi-drug chemotherapy regimens, a substantial amount of AML 
patients die from their disease. An important exception to this general statement are 
patients with APL, comprising 4%-13% of adult AML cases and 6%-10% of pediatric 
AML cases.34-37 Conventional treatment regimens for patients with newly diagnosed 
APL consist of a combination of all-trans retinoic acid (ATRA) and anthracycline-based 
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chemotherapy.38-46 In addition, arsenic trioxide (ATO) has been shown to be highly 
effective in newly diagnosed and relapsed APL patients as a single agent or in 
combination with conventional agents.47-57 In APL, the PML-RARα oncoprotein serves 
as a therapeutic target which is degraded by ATRA and/or ATO. The onco-fusion 
protein targeted therapy with ATRA and/or ATO has resulted in dramatic improvement 
of the outcome for patients with APL with the induction of a complete remission in 
more than 90% of the patients, and 5-year overall survival rates of more than 80%.38-46 
An important life-threatening complication of APL-treatment with ATRA and/or ATO is 
the development of a differentiation syndrome (DS), which is addressed in chapters 5 
and 6.58;59 DS is characterized by an excessive systemic inflammatory response 
resulting in massive tissue infiltration of differentiating APL cells. Pulmonary infiltration 
of differentiating leukemic cells is a key event in the development of DS. In chapter 6, 
we describe that differentiation therapy alters the expression of integrins and 
adhesion molecules in APL cells. This may contribute to increased adhesion of APL 
cells to the vascular endothelium, which is a prerequisite for transendothelial 
migration.59 In chapter 5, we studied the effect of differentiation therapy in APL using 
micro-array based gene expression profiling. We observed massive induction of the 
expression of CC-chemokines and their receptors during ATRA-induced granulocytic 
differentiation of APL cells, resulting in increased chemokine production and 
chemotaxis. Chemokine production was also induced by ATO as single agent or in 
combination with ATRA. The development of DS was associated with a significant 
increase of chemokine levels in the plasma of an APL patient. Chemokines are 
implicated in the migration and extravasation of leukemic cells from the bloodstream 
into the underlying tissues. Previous studies showed that ATRA-treatment can 
enhance the production of chemokines in the lung.60-62 We propose that the massive 
chemokine production by differentiating APL cells may contribute to the development 
of the uncontrolled hyperinflammatory reaction in DS.  
Steroids play an important role in the prevention and treatment of DS. Steroid 
prophylaxis during induction therapy has reduced the incidence of DS significantly.63 
In patients with DS, steroids are mainly effective when administered at early stages. 
When fully developed, DS is still difficult to treat.62 In chapter 5, we demonstrate that 
steroids cannot abrogate the massive induction of chemokines in differentiating APL 
cells, whereas steroids can efficiently reduce alveolar chemokine production.60-62 We 
present a model that illustrates the role of chemokines in the development of DS. 
During the initiation phase of DS, the alveolar chemokine secretion might trigger the 
migration of differentiating APL cells towards the lung. Steroids can efficiently reduce 
alveolar chemokine production and thereby might eliminate the initial trigger for 
infiltration of differentiating APL cells into the lung.60-62 Early recognition and prompt 
treatment of DS with steroids may therefore prevent the development of severe DS. 
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During the aggravation phase of DS, pulmonary infiltration of differentiating APL 
cells, which massively produce chemokines, might further enhance the migration of 
leukemic cells from the blood-stream into the lung tissue and thereby aggravate the 
inflammatory response in the lung. In a full-blown DS, differentiating APL cells have 
already invaded target tissues like the lung. The massive chemokine production by 
these leukemic cells is not responsive to steroids and thereby may induce an 
uncontrollable hyperinflammatory reaction in these tissues. Interventions that 
directly target the secreted chemokines or their receptors might inhibit the hyper-
inflammation driven by the differentiating APL cells. We suggest that the therapeutic 
use of chemokine (receptor) antagonists may be an interesting approach in the 
treatment of DS. 
General Discussion and Future Perspectives
Regulation of WT1 and GATA2 in myelopoiesis
Transcription factors play an essential role in driving the expression of lineage specific 
target-genes in the hematopoietic system. WT1 and GATA2 are hematopoietic 
transcription factors implicated in myelopoiesis. The expression and function of WT1 
and GATA2 in hematopoietic cells largely depend on their differentiation status.15;64 
Transcription factors involved in the regulation of WT1 expression include GATA1, 
GATA2, NFKB, SP1, PAX2, PAX8, and MYB.16-25 Recently, the miR-15a/16-1 cluster has been 
implicated in the regulation of WT1 protein levels, but both microRNAs did not 
directly target WT1 through microRNA-mRNA base pairing, indicating that WT1 is 
regulated by downstream targets of the miR-15a/16-1 cluster.65 In the hematopoietic 
system, the expression of GATA2 is tightly regulated by several transcription factors 
such as GATA1, NOTCH1, PU.1, EVI1, BMP4, ETS1.26 Moreover, GATA2 has a role in regulation 
of its own transcription by binding its promoter and working as an enhancer of its 
transcription.26;66 The activity of GATA2 is also modulated by post-translational 
modifications including phosphorylation, acetylation, sumoylation and ubiquitation.26 
Recently, GATA2 has been identified as a direct target of miR-24, miR-200b and miR-451 
in angiogenesis and erythroid maturation.67-70 We demonstrate that miR-132 directly 
targets WT1 and GATA2, indicating that miR-132 is involved in the regulation of both 
transcription factors.  During myeloid differentiation, upregulation of miR-132 may 
contribute to the  downregulation of WT1 and GATA2 protein levels. The biological 
relevance of miR-132 induction during myeloid differentiation needs further study. By 
the simultaneous targeting of WT1 and GATA2, miR-132 may fulfill an important 
regulatory role in myeloid differentiation. 
7
Chapter 7
188
Deregulation of GATA2 in AML
In familial AML, germ-line mutations have been detected that predispose to the 
development of AML.71  In pediatric AML, we detected somatic GATA2 mutations with 
a frequency of 2.2% overall, and 9.8% in CN-AML. In all cases, we observed 
co-occurrence of GATA2 mutations with other recurrent mutations, including NRAS, 
NPM1, CEBPA, and WT1 mutations, which is in line with recent studies on GATA2 
mutations in adult AML.72-74 GATA2 mutations are frequently detected in patients with 
biallelic CEBPA mutations, which represents a favorable prognostic subgroup in AML. 
In pediatric AML with biallelic CEBPA mutations, GATA2 mutations were present in 18% 
of the cases, whereas in adult AML the reported percentages range from 18% to 
39%.72;73 CEBPA is an important target gene of GATA2.72 Although GATA2 and CEBPA 
participate in the same hematopoietic differentiation pathway, the simultaneous 
mutations in GATA2 and CEBPA suggest an additive or synergistic effect of both 
mutations on the disturbance of hematopoietic differentiation. In intermediate-risk 
adult AML, GATA2 mutations are associated with a favorable prognosis. However, this 
effect is largely dependent on the co-occurrence of GATA2 mutations with biallelic 
CEBPA mutations.73 Analysis of a larger cohort of (CN-) AML patients will enable 
determination of the prognostic impact of GATA2 mutations in conjunction with other 
molecular markers.
In AML, GATA2 mutations are located in highly conserved residues within the critical 
functional DNA-binding domain, consisting of two zinc fingers.72-75 The GATA2 mutations 
described in this thesis are located within codon 318 of the N-terminal zinc finger domain 
(N-ZF) and codon 362 of the C-terminal zinc finger domain (C-ZF). In AML, mutations 
in the N-ZF domain cluster between codon 317 and codon 321 (figure 1A).72-74 
Homology models indicate that codon 318 is directly implicated in DNA binding.72 
Therefore, mutations in this residue will probably alter the affinity to DNA or prevent 
DNA binding and thereby influencing the capacity to transactivate GATA-responsive 
elements. Functional studies have recently shown that nonsynonymous point 
mutations in codon 318 result in reduced transactivation of GATA-responsive reporters 
compared to wild-type GATA2, suggesting a loss-of-function. In AML, mutations in the 
C-ZF domain cluster in codon 362 (figure 1A), which is highly conserved in species 
from human to zebrafish and in all six GATA binding proteins. The C-ZF domain is 
involved in DNA-binding, heterodimerisation, and interaction with the transcription 
factor PU.1. To what extent mutations in codon 362 represent loss- or gain-of-function 
mutations remains unknown. The C-ZF domain has also been targeted by somatic 
mutations in blast crisis of chronic myeloid leukemia (CML) and germ-line mutations 
in familial AML.71;76 Functional studies with GATA2 mutants located in the C-ZF domain, 
showed differential effects on DNA binding ability, transactivation of target genes, 
global gene expression, and protein-protein interactions.71;76;77 Mutations in codon 
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Figure 1  Mutations in the N-terminal and C-terminal zinc finger domains of GATA2 
in AML
(A) Acquired mutations in the N-terminal (N-ZF) and C-terminal (C-ZF) zinc-finger domain of 
GATA2 in AML. Sequence variations in pediatric AML described in the current thesis are depicted 
in black. Recently reported mutations in adult AML with FAB-M5 morphology or biallelic CEBPA 
mutations are depicted in white and dark gray, respectively.72-74 Mutations in intermediate- 
risk adult AML with wild-type CEBPA are depicted in light gray. Each symbol represents an 
independent GATA2 mutation. Numbers indicate the amino acid affected by each mutation or 
variation. The type of mutation is indicated by the symbol. (B) The amino acid sequence of the 
N-ZF and C-ZF domain of GATA2 depicted as a polypeptide chain. The amino acids targeted by 
mutations in (pediatric) AML are depicted in gray. Residue 318 and 362 are mutated in pediatric 
AML.
A
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354 (T354M) and 355 (T355del) were associated with a loss of function, whereas a gain 
of function was described for mutations in codon 359 (L359V).71;76 
We demonstrate that GATA2 is overexpressed in the majority of pediatric AML patients 
and showed that high GATA2 expression is an independent poor prognostic factor. 
The prognostic impact of GATA2 expression was particularly high in specific 
morphologic and genetic AML subgroups, including FAB-M5 morphology, inv(16), 
11q23 translocations, high WT1 expression, and FLT3-ITD positivity. High levels of 
GATA2 expression have also been associated with poor prognosis in adult AML, 
colorectal cancer, and prostate cancer.78-80 As myeloid differentiation is associated 
with downregulation of GATA2, overexpression of GATA2 in leukemic cells may reflect 
the maturation stage of the affected progenitor from which the leukemia originates.26 
Downstream targets of GATA2 include the myeloid transcription factors PU.1 and 
CEBPA, which are both involved in terminal granulocytic and monocytic differentia-
tion.81-84 In myeloid progenitors, enforced expression of GATA2 induces down-regula-
tion PU.1 and CEBPA, and inhibits the ability of PU.1 to transactivate critical myeloid 
target genes which prevents the induction of a myeloid gene expression program.81-85 
By interfering with the function of PU.1 and CEBPA, aberrant activation or 
overexpression of GATA2 may suppress normal myeloid differentiation and promote 
leukemic transformation in AML. The presence of loss-of-function GATA2 mutations in 
some patients and overexpression of GATA2 in other cases of AML seems contradictory. 
In AML, a similar paradox has been observed for WT1.86;87 Inactivating WT1 mutations 
have been detected with a frequency of 4%- 9% in adults and 8%-12% in pediatric 
patients, whereas WT1 is overexpressed in the majority of AML patients.88-90 The 
contribution of WT1 or GATA2 aberrations (e.g. mutations and overexpression) to 
malignant transformation seems to be dependent on the presence of other genetic 
aberrations and the differentiation status of the affected progenitor from which the 
leukemia originates.26;86 Differences in the leukemic cell of origin and the co-occurring 
genetic aberrations in patients carrying mutations versus patients with overexpression 
may be related to the observed paradox. In addition, overexpression of a transcription 
factor might lead to a dysbalance of the transcriptional complex in which the factor is 
involved, resulting in malfunctioning and transcriptional repression. However, this 
latter hypothesis does not seem to be supported by transcriptional activation studies, 
in which a higher dose of GATA2 and WT1 is generally associated with enhanced 
transcription of the reporter gene. 
Gene expression in risk-stratification of AML
Risk-group classification in AML plays an important role in avoiding over-treatment 
of patients with a favorable prognosis and preventing under-treatment of patients 
with a poor prognosis. Single gene expression markers may contribute to risk- 
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stratification of AML. One clear example is high expression of EVI1, which is detected 
in approximately 8% of AML cases and is associated with an extremely dismal 
prognosis.91 Other examples are high expression of BAALC, MN1 and ERG, which have 
also been associated with poor prognosis, particularly in CN-AML.92-94 The prognostic 
significance of high WT1 expression, which is present in the majority of AML cases, is 
still a matter of debate.95 Although aberrant expression of single genes has been 
associated with poor prognosis, incorporation in clinical decision making has only 
recently been done in several study protocols.1;96 We identified GATA2 expression as a 
novel independent marker for poor prognosis in pediatric AML. The interaction of 
GATA2 expression with other molecular markers and the clinical utility of GATA2 
expression as a prognostic tool to achieve better risk-group stratification and 
risk-adapted therapy, requires validation in prospective studies. 
The potential of gene expression profiling (GEP) in risk-stratification has also been 
studied extensively. Specific gene expression signatures have been identified that 
correlate with cytogenetic and molecular AML subgroups.97;98 AML with t(15;17), 
t(8;21), inv(16), and MLL-rearrangements, are associated with characteristic gene 
expression signatures.97;99;100 Moreover, AML with NPM1 mutations and biallelic CEBPA 
mutations are characterized by specific gene expression signatures. This indicates 
that unique gene expression patterns have the potential to predict specific genetic 
subgroups.97;100;101  Although GEP-based outcome prediction is largely dependent on 
the underlying genetic defects, GEP can also identify novel AML subgroups 
independent of well-established prognostic factors.98;102 Most importantly, GEP 
provides information on the genes and pathways that are deregulated by the 
underlying cytogenetic or molecular aberration.97;98 This knowledge may contribute 
to the development of more effective therapies that specifically target the deregulated 
genes and pathways in distinct AML subclasses or individual AML patients. Specific 
microRNA expression signatures have been identified that correlate with morphologic, 
cytogenetic and molecular AML-subtypes, and changes in microRNAs expression 
have been associated with clinical outcome.1;103-108 Identification of genes and 
pathways regulated by these microRNAs will provide information on the role of 
microRNAs AML.
MRD-guided therapy in AML
Response to induction chemotherapy is an important parameter for outcome in AML. 
As residual disease is the major predictor of relapse in leukemia, detection methods 
with improved sensitivity compared to morphology are essential to determine the 
residual leukemia burden after treatment.29 The presence of submicroscopic disease 
is called minimal residual disease (MRD). MRD-based risk stratification has been 
successfully incorporated in the treatment protocols of patients with APL and acute 
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lymphoblastic leukemia.109;110 In APL, quantification of PML-RARA fusion gene 
expression is used to monitor disease response. No correlation has been found 
between PML-RARA fusion gene levels and outcome during induction therapy, but 
failure to diminish the PML-RAR positive cells below the level of 1/100,000 or 
reappearance of PML-RAR positive cells during follow-up invariably led to relapse of 
the disease. Since a full-blown relapse may re-introduce the potentially lethal 
coagulation disorders typical of APL, current practice is to treat patients with minimal 
residual APL disease with re-induction strategies, which may include ATRA, arsenic 
trioxide, and/or chemotherapeutic agents.111;112 The role of WT1 expression as marker 
for MRD has been studied extensively. In AML, WT1 is sufficiently overexpressed to 
discriminate at least a 2-log reduction in transcripts in 46% and 13% of AML patients, 
compared to normal peripheral blood and bone marrow, respectively.31 In pediatric 
and adult AML, failure to normalize WT1 expression after induction or consolidation 
therapy was shown to be predictive for relapse.31;113 We show that GATA2 expression is 
not a very suitable marker for MRD-detection due to the heterogeneous expression of 
GATA2 in AML in combination with the relatively high background expression of 
GATA2 in normal peripheral blood and bone marrow. In the current AML treatment 
protocol of the medical research council (MRC AML 17 trial), the clinical value of 
disease monitoring is investigated using quantitative assessment of AML1-ETO, 
CBFB-MYH11 rearrangements, FLT3 mutations, NPM1 mutations, WT1 expression, and 
leukemia-associated aberrant immunophenotypes after each course of chemotherapy 
and during follow up.114  
Towards targeted therapy
As further intensification of the current multi-drug chemotherapy regimens is not 
feasible due to toxicity in healthy tissues, identification of agents that are more 
selective and better targeted in their action are necessary to improve survival rates in 
AML. The goal of targeted therapy is to induce a potent and specific anti-leukemic 
effect while producing minimal toxicity to non-leukemic cells. Targeted therapy is 
usually directed at leukemia driving genes or their downstream effectors. Because 
most healthy tissues are spared, these treatments tend to cause fewer and less severe 
side effects than other standard treatments. Genetic and epigenetic aberrations in 
leukemic cells may serve as potential therapeutic targets. In CML, leukemogenesis is 
driven by the BCR-ABL fusion gene. The fusion between the ABL (Abelson) tyrosine 
kinase gene at chromosome 9 and the BCR (break point cluster) gene at chromosome 
22, results in the formation of the BCR-ABL fusion gene which encodes for a 
constitutively active tyrosine kinase. In CML, the availability of bcr-abl targeting 
tyrosine kinase inhibitors (TKI) such as imatinib significantly improved the 5-year 
overall survival rates from 30% to 90%.115  Although survival rates of CML patients are 
excellent, the disease is not completely eradicated with the currently available drugs. 
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TKI-treatment has turned CML into a chronic disease for most patients, requiring 
long-term or even life-long treatment. For a definitive cure, eradication of residual 
CML initiating cells is necessary. With the development of more potent TKIs, 
investigators hope that complete disease eradication will become possible. In APL, 
oncogenic transformation originates from a chromosomal translocation t(15;17), 
fusing the retinoic acid receptor-alpha (RARA) gene on chromosome 17 with the 
promyelocytic leukemia (PML) gene on chromosome 15 in the majority of patients. 
The PML-RARα oncoprotein serves as a therapeutic target which is degraded by ATRA 
and/or ATO, resulting in dramatic improvement of the long-term survival of APL 
patients from 35% to 80%.44 Treatment with ATRA can induce transient complete 
remission, but for the induction of long-term remission, combination of ATRA with 
ATO or chemotherapy is necessary. The combination of ATRA and ATO is highly 
effective in PML-RARα degradation as both agents target the fusion protein in two 
distinct ways.51;53;116 
These example have proven that an impressive clinical benefit may be achieved when 
the disease-driving mutation is targeted efficiently. As the genetic background of 
other malignancies, including AML, is more complex, similar spectacular effects may 
be hard to achieve. In AML, a diverse spectrum of underlying genetic and epigenetic 
aberrations has been detected, including cytogenetic aberrations, somatic mutations, 
and altered expression of specific genes. The complex network of genetic and 
epigenetic aberrations makes it more difficult to develop targeted therapy. Activating 
mutations in the receptor tyrosine kinases FLT3 have emerged as a promising 
molecular target in therapy of AML using specific TKIs.117 In addition, epigenetic 
deregulation in AML can be targeted by DNA methyltransferase (DNMT) inhibitors 
and histone deacetylase (HDAC) inhibitor.118 Monotherapy will probably only be 
effective in leukemias that are mostly driven by a single genetic aberrations, such as 
CML.  The combination of different (targeted) treatment modalities will probably be 
more effective in AML than monotherapy, as illustrated by the beneficial effect of 
combination therapy with ATRA and ATO in APL. The more targeted the therapeutic 
agents become, the less side-effects may be expected. A potential draw-back of 
drugs that are extremely specific, is the development of resistance by activating 
alternative biological routes. Moreover, additional mutations can induce drug 
resistance. Mutations in the kinase domain of BCR-ABL that impair drug binding are 
the best characterized mechanism of TKI-resistance in patients with CML.115 In 
addition, the more specific the drugs are, the less capable they will be to deal with the 
genetic and epigenetic variability that may occur in tumors to a varying degree. 
Challenges in the development of targeted therapy in AML include distinguishing the 
driver mutations from passenger mutations and finding combination of drugs that 
effectively eradicate all tumor cells and prevent recurrence of disease. It may be 
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anticipated that the more complex the genetic disturbances in the cells are, the more 
we have to rely on combinations of drugs that are able to deal with the complete, 
highly heterogeneous spectrum of malignant cells that need to be eradicated.
Various investigators have suggested a role for microRNA-based therapeutic 
approaches in leukemia.119 MicroRNAs can function both as tumor suppressors by 
targeting of oncogenes, or display an oncogenic role through targeting of tumor 
suppressor genes.120;121 In general, oncogenic microRNAs may be used as therapeutic 
targets, whereas tumor-suppressive microRNAs may be used as therapeutic agents.119 
Targeting of oncogenic microRNAs with anti-microRNA molecules (such as antagomiRs 
or locked nucleic acid-anti-microRNA oligonucleotides) may induce anti-leukemic 
effects by reactivating the expression of tumor suppressor genes. In leukemic cells, 
silencing of the oncogenic miR-19 by anti-microRNA molecules was shown to 
reactivate the expression of the tumor suppressor PTEN and thereby antagonize the 
miR-19 driven leukemogenesis.122 Therapeutic agents based on tumor suppressive 
microRNAs may induce anti-leukemic effects by downregulating the expression of 
oncogenes. In this respect, miR-132 might be an interesting therapeutic tool against 
WT1 expressing leukemic cells. In vitro studies have demonstrated that targeting of 
WT1 with siRNAs can induce an anti-leukemic effect, by inhibition of proliferation and 
induction of apoptosis in leukemic cells.65;123 In addition to WT1 targeting, miR-132 
may also target GATA2 expressing leukemic cells. Simultaneous targeting of these two 
hematopoietic transcription factors by miR-132 may induce a synergistic anti-leukemic 
effect. Background expression of WT1 and GATA2 in normal peripheral blood and 
bone marrow cells may limit the specificity of this approach in leukemia treatment. An 
advantage of microRNA-based therapeutics is that one microRNA is able to target 
multiple genes and thereby might have a broad effect on gene expression. This 
advantage may however also be a complicating factor, as potentially, many off-target 
effects may be expected. In addition, in order to be effective essentially all tumor cells 
should be targeted by the micro-RNA modulating therapeutic agent, which may be 
difficult in vivo .108 
Conclusion
AML is a clinically and molecularly heterogeneous disease characterized by the 
presence of a recurrent cytogenetic and molecular aberrations. One of the hallmarks 
of AML is deregulated gene expression. The goal of this thesis was to extend our 
knowledge on the (post-) transcriptional regulation of gene expression in myelopoiesis 
to improve prognostic classification and identify novel targets for therapy in AML. 
We describe the (de)regulation of two hematopoietic transcription factors, WT1 and 
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GATA2, which are both implicated in normal and malignant myelopoiesis, and 
determine a role for miR-132 in the regulation of both transcription factors. We show 
that GATA2 is a novel independent poor prognostic factor in pediatric AML. Recent 
advances in genomic technologies have identified a diverse spectrum of genetic 
aberrations in AML. The prognostic relevance of various recently identified molecular 
markers merits further investigation as it is mostly evaluated in retrospective studies 
and the interaction with other molecular markers is not always taken  into account. To 
improve survival rates in AML, other more effective therapeutic options are needed. 
In APL, oncoprotein targeted therapy with ATRA and/or ATO has resulted in a dramatic 
improvement of the long-term survival of APL patients. Development of novel 
targeted therapeutic approaches directed at the underlying genetic aberrations in 
AML have the potential to contribute to a significant improvement of outcome while 
simultaneously decreasing therapy-related toxicity. Identification of the driver 
mutations in AML is an important step towards the development of targeted therapy. 
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Leukemie is een vorm van kanker uitgaande van de witte bloedcellen. In het menselijk 
lichaam worden dagelijks 1011–1012 nieuwe bloedcellen gemaakt in het beenmerg.  De 
bloedcellen worden onderverdeeld in rode bloedcellen (erytrocyten), witte bloedcellen 
(leukocyten) en bloedplaatjes (thrombocyten). In het beenmerg zijn stamcellen 
aanwezig die via diverse voorlopercellen uitrijpen (differentiëren) tot de verschillende 
soorten bloedcellen. Witte bloedcellen spelen een belangrijke rol in de afweer tegen 
infecties en kunnen worden onderverdeeld in lymfoïde en myeloïde cellen. De 
ontwikkeling van bloedcellen (hematopoiese) is een strikt gereguleerd proces. Bij 
leukemie is er sprake van een ongecontroleerde vermenigvuldiging (proliferatie) van 
onrijpe witte bloedcellen in het beenmerg waardoor de vorming van normale 
bloedcellen verstoord wordt en er een tekort aan rode bloedcellen, bloedplaatjes, en 
witte bloedcellen ontstaat. In Nederland wordt jaarlijks bij ongeveer 800 patiënten de 
diagnose acute leukemie gesteld, waaronder 150 kinderen. Op de kinderleeftijd is 
acute leukemie de meest voorkomende vorm van kanker. Afhankelijk van het soort 
bloedcel waaruit de ziekte ontstaat, wordt leukemie onderverdeeld in een lymphoïde 
en een myeloïde vorm. Bij myeloïde leukemie is er sprake van een verstoorde uitrijping 
myeloïde voorlopercel naar rijpe bloedcellen. 
Acute myeloïde leukemie (AML) is een heterogene ziekte die kan worden onder -
verdeeld in verschillende subgroepen afhankelijk van de voorlopercel waaruit de 
leukemie ontstaat en de onderliggende afwijkingen in het DNA van de leukemiecellen. 
Deze onderliggende genetisch afwijkingen zijn sterk geassocieerd met de respons op 
therapie en de prognose van AML patiënten. De huidige standaardbehandeling van 
AML bestaat uit intensieve chemotherapie.  Een belangrijk aspect voor de behandeling 
van AML patiënten is een goede risicostratificatie aan de hand waarvan de intensiteit 
van de behandeling bepaald wordt. Ondanks het feit dat de prognose van AML 
patiënten sterk verbeterd is door het gebruik van op de prognose aangepaste 
intensiteit van de behandeling en goede supportive care, overlijdt een aanzienlijk 
deel van de patiënten aan de gevolgen van de ziekte. Bij kinderen wordt een vijf-jaars 
overleving van 60%-70% bereikt, terwijl bij volwassenen de vijf-jaars overleving 
ongeveer 40%-50% is. Bij ouderen (> 60 jaar) is de prognose zeer slecht: na vijf jaar is 
slechts 10% van de patiënten nog in leven. Omdat de toxiciteit van de klassieke 
behandeling op gezonde weefsels limiterend is zullen, om de overleving van AML 
patiënten te verbeteren, andere therapeutische opties ontwikkeld moeten worden. 
Verbetering van de risicogroep indeling en de ontwikkeling van therapieën die 
specifiek gericht zijn op de leukemiecellen, kunnen leiden tot een verbeterde 
overleving. De huidige risicostratificatie is gebaseerd op een beperkt aantal 
genetische veranderingen in de leukemiecellen in combinatie met de respons op 
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behandeling. De laatste jaren zijn er diverse nieuwe genetische afwijkingen in de 
leukemiecellen ontdekt die eveneens een prognostische waarde hebben. De 
genetische afwijkingen in leukemie cellen leiden vaak tot verstoorde functie van 
factoren die de ontwikkeling van de myeloïde bloedcellen en de genexpressie reguleren, 
zoals transcriptiefactoren, post-transcriptionele regulatoren, en epigenetische regulatoren. 
Een van de belangrijke kenmerken van AML is verstoorde genexpressie. In dit proefschrift 
staat de (post-)transcriptionele regulatie van de genexpressie tijdens de normale en 
verstoorde uitrijping van myeloïde bloedcellen centraal. Kennis hieromtrent kan 
leiden tot het verbeteren van de prognostische classificatie en identificatie van 
nieuwe therapeutische targets in AML. 
In hoofdstuk 2 en 3, hebben wij de expressie van microRNAs tijdens de ontwikkeling 
van myeloïde bloedcellen bestudeerd. MicroRNAs spelen een belangrijke rol in de 
regulatie van genexpressie tijdens de ontwikkeling van bloedcellen. MicroRNAs 
kunnen de expressie van genen downreguleren door afbraak van het RNA of 
verminderen van de eiwit vorming. Verstoorde expressie van microRNAs leidt tot 
verstoorde expressie van specifieke target genen die de uitrijping van bloedcellen 
reguleren. In hoofdstuk 2 hebben wij aangetoond dat de expressie van microRNA-132 
sterk omhoog gaat tijdens de uitrijping van myeloïde cellen. Vervolgens hebben wij 
aangetoond dat microRNA-132 de expressie van het Wilms' Tumor 1 (WT1) gen 
reguleert. WT1 is een belangrijke transcriptiefactor die betrokken is bij regulatie van 
bloedcel vorming en de ontwikkeling van leukemie. Het onderzoek in hoofdstuk 2 
laat zien dat WT1 een direct target gen van microRNA-132 is wat resulteert in 
verminderde eiwit expressie van WT1 in myeloïde cellen. In hoofdstuk 3 wordt 
beschreven dat de transcriptie factor GATA-binding protein 2 (GATA2) eveneens een 
direct target gen van microRNA-132 is. GATA2 is betrokken bij myeloïde bloedcel 
ontwikkeling. Tevens lijkt GATA2 betrokken te zijn bij de ontwikkeling van leukemie. 
Door regulatie van de expressie van WT1 en GATA2 kan microRNA-132 een belangrijke 
rol spelen in de myeloide bloedcel vorming.  Daarnaast zou microRNA-132 een anti-
leukemisch effect kunnen hebben. 
In hoofdstuk 4 wordt deregulatie van GATA2 bij AML in kinderen beschreven. In een 
groot cohort kinder AML patiënten hebben wij expressie en mutatie screening van 
GATA2 verricht. Bij 2.2% van de patiënten is een mutatie in het GATA2 gen aangetoond. 
GATA2 mutaties worden met name gezien in AML patiënten waarbij de leukemie 
cellen geen chromosomale afwijkingen bevatten (cytogenetisch-normale AML) en 
komen samen voor met mutaties in diverse andere genen. Met behulp van microarrays 
hebben we de expressie van GATA2 in het totale cohort bestudeerd. Bij diagnose 
wordt bij de meerderheid van de patiënten (65%) hoge expressie van GATA2 
waargenomen. Indien de ziekte in remissie is, treedt normalisatie van GATA2 expressie 
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op. Hoge GATA2 expressie bij diagnose is geassocieerd met een slechte prognose, met 
name in specifieke AML-subgroepen. Expressie van GATA2 kan derhalve bijdragen aan 
een betere risico-stratificatie van kinderen met AML.
De respons op therapie is een belangrijke prognostische factor in AML. Ondanks dat 
bij de meerderheid van de AML patiënten na twee chemokuren complete remissie 
bereikt wordt, blijft slechts een deel van deze patiënten langdurig in remissie. 
Complete remissie is morfologisch gedefinieerd op basis van de aanwezigheid van 
minder dan 5% leukemische cellen in het beenmerg. Indien er sprake is van een 
morfologische complete remissie kan er echter nog een aanzienlijke hoeveelheid 
leukemische rest cellen aanwezig zijn (tot 109 cellen) die morfologische niet 
detecteerbaar zijn. Dit wordt minimale rest ziekte (minimal residual disease; MRD) 
genoemd. Recidieven worden veroorzaakt door de uitgroei van leukemische rest 
cellen. MRD kan bepaald worden aan de hand van de afwijkende immuunfenotypes 
van de leukemische cellen of de onderliggende afwijkingen in het DNA van de 
leukemiecellen zoals fusie genen en mutaties. MRD-bepaling kan bijdragen aan 
betere risico-stratificatie en vroege detectie van een aankomend recidief. In 
hoofdstuk 4 hebben wij onderzocht of GATA2 expressie een goede MRD-marker is 
omdat GATA2 in de meerderheid van de patiënten tot overexpressie komt bij diagnose. 
In de minderheid van de patiënten was er echter sprake van een 100-voudige 
overexpressie van GATA2 in vergelijking met normale bloedcellen. Door de heterogene 
expressie van GATA2 in AML en de achtergrond expressie van GATA2 in normale 
bloedcellen, lijkt de waarde van GATA2 expressie voor MRD-detectie in AML beperkt. 
Om de overleving van AML patiënten te verbeteren, is de ontwikkeling van therapieën 
die specifiek gericht zijn op de leukemiecellen ('targeted therapy') van groot belang. 
Bij acute promyelocyten leukemie (APL) wordt reeds gebruik gemaakt van 'targeted 
therapy'. In de meerderheid van de patiënten met APL is er sprake van een chromosomale 
translocatie t(15;17) waardoor het gen voor vitamine A (retinoic acid receptor alpha 
(RARA)) op chromosoom 17 gefuseerd is met het promyelocyten leukemie (PML) gen 
op chromosoom 15. Behandeling met hoge dosis vitamine A induceert uitrijping van 
de leukemie cellen en regressie van de tumor. Behandeling met vitamine A in 
combinatie met chemotherapie heeft de overleving van APL patiënten sterk verbeterd 
waardoor APL van een dodelijke ziekte in een goed behandelbare ziekte is veranderd. 
Daarnaast is behandeling met arsenicum effectief bij nieuwe APL patiënten en 
patiënten met een relapse. Tijdens de eerste fase van de behandeling (inductie fase) 
overlijdt echter 5% tot 17% van de patiënten ten gevolge van bloedingen, infecties, 
en het differentiatie syndroom (DS). Bij DS is er sprake van een overmatige systemische 
inflammatoire respons met massieve infiltratie van differentiërende APL cellen, met name 
in de longen. DS is een levensbedreigende aandoening die kan lijden tot respiratoire 
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insufficiëntie en multi-orgaan falen. In hoofdstuk 5 en 6 hebben wij onderzoek 
gedaan naar de pathogenese van DS. Wij hebben aangetoond dat de differentiatie 
van APL cellen door Vitamine A leidt tot een sterk verhoogde expressie en productie 
van chemokines waardoor migratie en infiltratie van de leukemische cellen geïnduceerd 
wordt. Daarnaast hebben wij aangetoond dat behandeling met arsenicum eveneens 
leidt tot een sterk verhoogde expressie en productie van chemokines. In hoofdstuk 6 
wordt beschreven dat de inductie van chemokine, integrines, en adhesie moleculen 
een centrale rol te speelt in de pathogenese van DS. De huidige behandeling van DS 
bestaat uit corticosteroïden waardoor de ontstekingsreactie onderdrukt kan worden. 
Profylactisch gebruik van corticosteroïden tijdens de inductie behandeling van APL 
ertoe geleid dat de incidentie van DS sterk is afgenomen. Behandeling met cortico-
steroïden lijkt echter met name effectief te zijn in de eerste fase van DS. Ondanks dat 
corticosteroïden effectief zijn voor de preventie en de vroege behandeling van DS, is 
effect van corticosteroïden bij de behandeling van ernstige DS beperkt. In hoofdstuk 
5 wordt aangetoond dat de sterk verhoogde expressie en productie van chemokines 
door APL cellen na Vitamine A behandeling niet geremd wordt door corticosteroïden 
waardoor infiltratie van APL cellen in de long kan leiden tot een oncontroleerbare 
inflammatoire reactie. Toepassing van chemokine-(receptor) antagonisten zou een 
effectieve optie kunnen zijn in de behandeling van DS. 
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je inmiddels als postdoc in Toronto werkt.  Met zijn tweetjes hebben we een mooie 
tijd gehad op het lab! Je bent een echte duizendpoot. Ik heb kunnen profiteren van al 
jouw kennis en ervaring in het lab en heb bewondering voor je enorme enthousiasme 
en gedrevenheid. Daarnaast heb ik genoten van de prachtige klassieke concerten en 
de alle zelfgemaakte taartjes. Ik ben ervan overtuigd dat je succesvolle tijd in Toronto 
zult hebben als onderzoeker en hoop dat we snel eens een wijntje op het Vrijthof 
drinken als je in Nederland bent. Juni is een mooie promotiemaand!
Jeroen Pennings en Jeannet Nigten zijn mijn voorgangers geweest die de basis gelegd 
hebben voor een deel van het werk wat in dit proefschrift staat beschreven. Het was 
fijn om met jullie data aan de slag te gaan en ik ben trots op de artikelen die hieruit 
voortgevloeid zijn. Ruth, ik ben blij dat ik je even heb mogen lenen van de “TET-groep”. 
Als analist heb je een belangrijke bijdrage geleverd aan mijn proefschrift. Thessa en 
Saskia B, ondanks dat ik niet direct met jullie heb samengewerkt, hebben jullie me toch 
regelmatig geholpen in het laboratorium. Als vast analisten zijn jullie drieën een 
geweldige bron van kennis en ervaring waar de AIOs veel profijt van hebben. Hartelijk 
dank voor jullie hulp en gezelligheid! 
Saskia L en Laurens, toen ik op het lab begon hebben jullie me met open armen 
ontvangen. Saskia, wij waren de enige twee artsen in de moleculaire research groep. 
Het was fijn om jou als voorbeeld te hebben. Je gaat een prachtige carrière als 
hematoloog tegemoet. Laurens, dank voor al je hulp en geduld. Daarnaast wil ik de 
PhD studenten uit de andere AIO-kamer van de moleculaire hematologie hartelijk 
bedanken voor de leuke tijd op het lab. Davide, you are a noisy sloddervos, but I really 
enjoyed working with you. I am sure that your thesis will be excellent and I wish you 
good luck with your postdoc at the lab in Nijmegen! Mariam, you had a really hard 
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time in the competitive field of TET2. Keep up the good spirit! Wat er ook gebeurt, 
chocola helpt.... Leilei, Leonie, Jimmy, and Pedro, good luck with your careers! 
Naast de moleculaire research groep wil ik ook graag de andere collega’s van het 
Laboratorium voor Hematologie bedanken. De dames + heer van de moleculaire 
diagnostiek wil ik bedanken voor de hulp en gezelligheid. Jullie zijn altijd bereid om 
bij te springen in de research projecten en er is geen PCR of sequencing probleem wat 
jullie niet op kunnen lossen! De kleurenprinter bij jullie was een mooi excuus om even 
binnen te lopen voor een praatje. Adrian, heel veel geluk toegewenst met je 
toekomstige man en jullie dochter. Ik hoop dat we contact blijven houden! De mensen 
van de morfologie, immuunfenotypering, BMT-unit, en de mannen van de FACS (Rob 
en Jeroen) wil ik hartelijk bedanken voor hun hulp bij mijn onderzoek. In het bijzonder 
wil ik ook de collega’s van de GVL-unit bedanken. Wieger, Kelly, Sandra, Willemijn en 
Anniek, jullie waren mijn AIO-maatjes. Ondertussen zijn jullie proefschriften al 
afgerond of gaat dat binnenkort gebeuren. Het was fijn om het AIO lief en leed met 
jullie te kunnen delen. De verhuizing van het lab naar de vierde verdieping heeft 
hiertoe zeker bijgedragen. De vrijdagmiddagen in de Aesculaef waren een goed 
begin van het weekend! 
Daarnaast wil ik graag de leden van de PhD commissie van het NCMLS bedanken. Het 
organiseren van de NCMLS PhD retraite samen met Renoud, Hanneke, Ben, en 
Willemijn was een hele leuke en gezellige uitdaging. Renoud en Hanneke, we waren 
een goed team! Naast de fijne samenwerking is er ook een mooie vriendschap 
ontstaan. Ondanks dat jullie naar het westen zijn vertrokken en ik naar het zuiden, 
hoop ik dat we contact blijven houden. 
Het laatste jaar van mijn promotieonderzoek heb ik gecombineerd met de start van 
mijn opleiding tot kinderarts in Venlo. Een pittige combinatie! Gelukkig hebben mijn 
collegaatjes aldaar mij altijd gesteund en ik vind het leuk om deze periode samen met 
jullie af te sluiten. Maaike K, jij weet als geen ander wat het combineren van opleiding 
en onderzoek betekent. Dit maakte onze carpooldates erg fijn. Heel veel succes met 
je overstap naar Nijmegen en de afronding van je proefschrift! 
Naast mijn collega’s, wil ik ook graag al mijn vrienden bedanken voor de steun en 
afleiding tijdens mijn promotie-traject. Lieve Jaap, ik ben blij dat ik jou heb leren 
kennen in Nijmegen. Je weet wat het is om te promoveren en in opleiding tot specialist 
te zijn. Zowel in voor- als tegenspoed stond je altijd voor me klaar. Helaas scheiden 
onze wegen nu. Ik wens je heel veel succes toe in Amsterdam!  Lieve meiden van de 
hockey uit Utrecht, helaas heb ik door blessures afscheid van jullie moeten nemen. 
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Gelukkig zien we elkaar nog regelmatig bij alle sociale activiteiten! Jessica, dank voor 
al je bezoekjes aan Nijmegen! Naast onze dates in Nijmegen & Utrecht heb ik ook 
genoten van onze trips naar Texel, Parijs en Istanbul. Wordt vervolgd?!? Eline, dank 
voor alle belangstelling en steun. Als dokters onder elkaar hebben we veel fijne 
gesprekken gehad. Ik wens je heel veel succes toe bij het maken van de juiste keuze 
ten aanzien van je toekomst en veel geluk met Harm Jan & the kids! Lieve jaarclub-
genootjes, wat fijn dat we na 16 jaar nog steeds samen zijn! Het is leuk om als benjamin 
van de jaarclub als eerste te kunnen promoveren. Dank voor jullie betrokkenheid en 
steun.
Natuurlijk mogen mijn paranimfen niet ontbreken in dit dankwoord. Lieve Kim, wat 
ben ik blij dat jij mijn paranimf bent! Op 1 augustus 2005 zijn we samen bij de Kinder-
geneeskunde in Nijmegen begonnen. Een mooi begin van een hele waardevolle 
vriendschap. De afgelopen jaren hebben we lief en leed gedeeld, zowel op gebied 
van promotie en opleiding, als privé. Het is fijn dat je vandaag bij de afsluiting van 
mijn promotie-traject in Nijmegen naast mij staat. Heel veel succes toegewenst met 
de laatste loodjes van je promotie en afronding van je opleiding en veel geluk met 
Maarten & the kids. Ik ga je missen in Maastricht! Lieve Jan Paul, beter een goede buur 
dan een verre vriend! Wat begonnen is als buren op de Steenweg in Utrecht, is 
uitgegroeid tot een bijzondere vriendschap. Ook al wonen we al zes jaar niet meer bij 
elkaar in de buurt, je blijft mijn favoriete buurman bij wie ik altijd terecht kan. Er is 
geen afstand die daar verandering in zal brengen! Ik heb genoten van alle 
moët-momenten samen met jou in Utrecht, Nijmegen en Enschede. Wat is het fijn dat 
je vandaag als paranimf ook mijn steun en toeverlaat bent! Ik wens je heel veel geluk 
toe samen met Femke in Enschede en hoop snel met jullie het glas te heffen in 
Maastricht.
Tot slot wil ik graag mijn familie bedanken voor alle liefde, steun en vertrouwen die ze 
mij hebben gegeven. Lieve Hylke en Chantal, jullie hebben altijd een rotsvast 
vertrouwen in mij gehad. Dank voor jullie belangstelling en steun! Lieve Yvonne, in de 
drukke promotiejaren was het fijn om uit te komen waaien op Texel. Dank voor alle 
gastvrijheid en gezelligheid. Wat een gemis dat Albert er niet meer bij kan zijn. Lieve 
Sanne, mijn grote zus, jouw huis is voor mij een tweede thuis. De weekendjes in 
Amsterdam bij jou waren een leuke en waardevolle break in de drukke promotiejaren. 
Ik hoop dat er nog veel van dergelijke weekendjes volgen in Amsterdam of Maastricht! 
Dank voor al je goede zorgen en steun. Lieve papa en mama, dank voor jullie onvoor-
waardelijke steun en liefde. Het is fijn om te zien hoe jullie genieten van de successen 
die jullie dochters behalen. Jullie gunnen ons het allerbeste. Het hoofdstuk Nijmegen 
wordt vandaag afgesloten en ik hoop jullie snel in Maastricht te mogen verwelkomen. 
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List of Abbreviations
95% CI 95% confidence interval
AML acute myeloid leukemia
APL acute promyelocytic leukemia
ARDS acute respiratory distress syndrome
ATO arsenic trioxide
ATRA all-trans retinoic acid
AU arbitrary unit
BFM study group Berlin-Frankfurt-Münster study group
BM bone marrow
C/EBP CCAAT/Enhancer binding protein
CBF core binding factor
CCL CC-chemokine
CCR CC-chemokine recpetor
CCR1 continuous first complete remission
cDNA complementary DNA
CDS coding sequence
CEBPA-DM CEBPA double mutation
CLP common lymphoid prognitor
CML chronic myeloid leukemia
CMP common myeloid progenitor
CN-AML cytogenetically normal AML
CR complete remission
Cyclohex Cyclohexamide
C-ZF C-terminal zinc finger
DCML syndrome of dendritic cell, monocyte, and B and natural killer lymphoid cell 
deficiency
DCOG Dutch Childhood Oncology Group
DEX Dexamethason
DFS disease free survival
DNA deoxyribonucleic acid
DNMT DNA methyl transferase
DS differentiation syndrome
EFS event free survival
ELISA enzyme-linked immunosorbant assay
EPLM early progenitor with lymphoid and myeloid potential
FAB classification French-American-British classification
GATA2 GATA binding protein 2
GEO gene expression omnibus
GEP gene expression profiling
GFI1 growth factor independence 1
GIMEMA Gruppo Italiano Malattie Ematologiche dell’ Adulto
GMP granulocyte-monocyte progenitor
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HDAC histone deacetylase
HR hazard ratio
HSC hematopoietic stem cell
IDA Idarubicine
LIC leukemia initiating cell
LMPP lymphoid-primed multipotent progenitor
MDS myelodysplastic syndrome
MEP megakaryocyte/erythroid progenitor
miR microRNA
MonoMAC syndrome of monocytopenia and mycobacterial infection
MPP multipotent progenitor
MRC Medical Research Council
MRD minimal residual disease
MRE microRNA recognition element
mRNA messenger RNA
N-ZF N-terminal zinc finger
OS overall survival
PB peripheral blood
PCR polymerase chain reaction
PETHEMA Programa para el Estudio y Tratamiento de las Hemopatias Maligna
PML promyelocytic leukemia gene
PRED prednisone
RAR retinoic acid receptor
RARE retinoic acid response element
RD resistant disease
RNA ribonucleic acid
RT-PCR reverse transcription polymerase chain reaction
RXR retinoid X receptor
SD standard deviation
TKI tyrosine kinase inhibitor
UTR untranslated region
VSN variance stabilization normalization
WBC white blood cell 
WHO world health organisation
wt wild type
WT1 Wilms’ Tumor 1
ZF zinc finger

